What’s new
A chronological feed of additions to PeptideSciences101: new peptide articles, FDA approvals, research entries, and source additions. Newest first. Sourced facts only — no dosage guidance.
1241 updates
October 2026
GHRP-4 is a synthetic tetrapeptide with the primary sequence D-Trp–L-Ala–L-Trp–D-Phe–NH2 (molecular weight 607.7 Da; molecular formula C34H37N7O4). It belongs to the growth hormone-releasing peptide (GHRP) family, a series of met-enkephalin analogs incorporating unnatural D-amino
Deep dive · 19 October 2026 · GHRP-4
Sermorelin is a synthetic 29-amino acid peptide constituting the biologically active N-terminal fragment of human growth hormone-releasing hormone (GHRH). Despite representing only positions 1 through 29 of the 44-residue parent molecule, this fragment retains essentially full ag
Deep dive · 19 October 2026 · Sermorelin
Sleep quality amino peptide
Peptide · 19 October 2026 · Glycine Peptide
Synthetic decapeptide identical to hypothalamic GnRH; binds pituitary receptors to trigger LH and FSH release. No approved US product remains.
Peptide · 19 October 2026 · Gonadorelin
Collagen booster
Peptide · 19 October 2026 · Palmitoyl Tripeptide-5
Melanotan II (MT-II) is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone (alpha-MSH), developed at the University of Arizona in the late 1980s (molecular formula C50H69N15O9; MW approximately 1024 g/mol; CAS 121062-08-6). MT-II acts as a non-selec
Deep dive · 19 October 2026 · Melanotan II
Glycine (aminoacetic acid) is the simplest proteinogenic amino acid and a major inhibitory neurotransmitter in the spinal cord and brainstem, acting at strychnine-sensitive glycine receptors (GlyRs). Its sleep-promoting properties, however, appear to arise through a pharmacologic
Deep dive · 19 October 2026 · Glycine Peptide
Thymosin alpha-1 (Ta1) is a 28-amino-acid peptide cleaved from its 113-residue precursor prothymosin alpha within the thymus, carrying an N-terminal acetyl group and a molecular weight of approximately 3,108 daltons. At the molecular level, Ta1 acts as a toll-like receptor (TLR)
Deep dive · 19 October 2026 · Thymosin Alpha-1
Gonadorelin is a synthetic decapeptide (molecular formula C55H75N17O13) with an amino acid sequence identical to endogenous gonadotropin-releasing hormone (GnRH), the neuropeptide secreted in intermittent pulses by the hypothalamus. It binds to GnRH receptors on gonadotroph cell
Deep dive · 19 October 2026 · Gonadorelin
Sermorelin is a synthetic 29-amino acid peptide constituting the biologically active N-terminal fragment of human growth hormone-releasing hormone (GHRH). Despite representing only positions 1 through 29 of the 44-residue parent molecule, this fragment retains essentially full ag
Deep dive · 19 October 2026 · Sermorelin
Site updates (1241)
Every published change tracked by PeptideSciences101. Each entry links to its source or the relevant article.
Showing 60 of 1241 matching updates · 1241 in the archive
| Date | Type | Title | Peptide(s) |
|---|---|---|---|
| 19 October 2026 | Deep dive | Deep-dive updated: GHRP-4 | GHRP-4 |
| GHRP-4 is a synthetic tetrapeptide with the primary sequence D-Trp–L-Ala–L-Trp–D-Phe–NH2 (molecular weight 607.7 Da; molecular formula C34H37N7O4). It belongs to the growth hormone-releasing peptide (GHRP) family, a series of met-enkephalin analogs incorporating unnatural D-amino | |||
| 19 October 2026 | Deep dive | Deep-dive updated: Sermorelin | Sermorelin |
| Sermorelin is a synthetic 29-amino acid peptide constituting the biologically active N-terminal fragment of human growth hormone-releasing hormone (GHRH). Despite representing only positions 1 through 29 of the 44-residue parent molecule, this fragment retains essentially full ag | |||
| 19 October 2026 | Peptide | Peptide updated: GHRP-4 | GHRP-4 |
| Fourth generation GHRP | |||
| 19 October 2026 | Peptide | Peptide updated: Sermorelin | Sermorelin |
| GHRH for natural GH release | |||
| 19 October 2026 | Peptide | Peptide updated: Melanotan II | Melanotan II |
| Tanning, libido | |||
| 19 October 2026 | Peptide | Peptide updated: Glycine Peptide | Glycine Peptide |
| Sleep quality amino peptide | |||
| 19 October 2026 | Peptide | Peptide updated: Gonadorelin | Gonadorelin |
| Synthetic decapeptide identical to hypothalamic GnRH; binds pituitary receptors to trigger LH and FSH release. No approved US product remains. | |||
| 19 October 2026 | Peptide | Peptide updated: Sermorelin | Sermorelin |
| GHRH for natural GH release | |||
| 19 October 2026 | Peptide | Peptide updated: Hexapeptide-11 | Hexapeptide-11 |
| Cell renewal peptide | |||
| 19 October 2026 | Peptide | Peptide updated: Palmitoyl Tripeptide-5 | Palmitoyl Tripeptide-5 |
| Collagen booster | |||
| 19 October 2026 | Peptide | Peptide updated: Syn-Coll | Syn-Coll |
| Collagen synthesis peptide | |||
| 19 October 2026 | Peptide | Peptide updated: Imunofan | Imunofan |
| Russian immune peptide | |||
| 19 October 2026 | Peptide | Peptide updated: Ovagen | Ovagen |
| Digestive system bioregulator | |||
| 19 October 2026 | Peptide | Peptide updated: Thyreogen | Thyreogen |
| Thyroid function support | |||
| 19 October 2026 | Peptide | Peptide updated: Vladonix | Vladonix |
| Thymus bioregulator complex | |||
| 19 October 2026 | Deep dive | Deep-dive updated: Melanotan II | Melanotan II |
| Melanotan II (MT-II) is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone (alpha-MSH), developed at the University of Arizona in the late 1980s (molecular formula C50H69N15O9; MW approximately 1024 g/mol; CAS 121062-08-6). MT-II acts as a non-selec | |||
| 19 October 2026 | Deep dive | Deep-dive updated: Glycine Peptide | Glycine Peptide |
| Glycine (aminoacetic acid) is the simplest proteinogenic amino acid and a major inhibitory neurotransmitter in the spinal cord and brainstem, acting at strychnine-sensitive glycine receptors (GlyRs). Its sleep-promoting properties, however, appear to arise through a pharmacologic | |||
| 19 October 2026 | Deep dive | Deep-dive updated: Thymosin Alpha-1 | Thymosin Alpha-1 |
| Thymosin alpha-1 (Ta1) is a 28-amino-acid peptide cleaved from its 113-residue precursor prothymosin alpha within the thymus, carrying an N-terminal acetyl group and a molecular weight of approximately 3,108 daltons. At the molecular level, Ta1 acts as a toll-like receptor (TLR) | |||
| 19 October 2026 | Deep dive | Deep-dive updated: Gonadorelin | Gonadorelin |
| Gonadorelin is a synthetic decapeptide (molecular formula C55H75N17O13) with an amino acid sequence identical to endogenous gonadotropin-releasing hormone (GnRH), the neuropeptide secreted in intermittent pulses by the hypothalamus. It binds to GnRH receptors on gonadotroph cell | |||
| 19 October 2026 | Deep dive | Deep-dive updated: Sermorelin | Sermorelin |
| Sermorelin is a synthetic 29-amino acid peptide constituting the biologically active N-terminal fragment of human growth hormone-releasing hormone (GHRH). Despite representing only positions 1 through 29 of the 44-residue parent molecule, this fragment retains essentially full ag | |||
| 19 October 2026 | Deep dive | Deep-dive updated: Hexapeptide-11 | Hexapeptide-11 |
| Hexapeptide-11 is a synthetic hexapeptide with the amino acid sequence phenylalanine-valine-alanine-proline-phenylalanine-proline (FVAPFP; CAS 161258-30-6; molecular formula C36H48N6O7; PubChem CID 24998056). It was originally isolated from Saccharomyces cerevisiae yeast fermenta | |||
| 19 October 2026 | Deep dive | Deep-dive updated: Palmitoyl Tripeptide-5 | Palmitoyl Tripeptide-5 |
| Palmitoyl Tripeptide-5 (INCI: Palmitoyl Tripeptide-5; trade name SYN-COLL; CAS 623172-56-5; PubChem CID 11950477) is a synthetic lipopeptide consisting of the tripeptide sequence Lys-Val-Lys covalently conjugated at its N-terminus to a palmitoyl (C16 fatty acid) chain. Molecular | |||
| 19 October 2026 | Deep dive | Deep-dive updated: Syn-Coll | Syn-Coll |
| Syn-Coll is the trade name for palmitoyl tripeptide-5, a synthetic lipopeptide with the sequence palmitoyl-Lys-Val-Lys (CAS 623172-55-4; molecular weight approximately 611.9 g/mol as free base). It was developed by Pentapharm, now part of DSM-Firmenich, and functions as a growth | |||
| 19 October 2026 | Deep dive | Deep-dive updated: Imunofan | Imunofan |
| Imunofan (RDKVYR; arginyl-alpha-aspartyl-lysyl-valyl-tyrosyl-arginine) is a synthetic hexapeptide of 836 Da modeled on positions 32-37 of thymopoietin, a 49-amino-acid hormone produced by thymic epithelial cells. The related pentapeptide thymopentin (TP-5, positions 32-36) repres | |||
| 19 October 2026 | Deep dive | Deep-dive updated: Prostatilen | Prostatilen |
| Prostatilen is a registered pharmaceutical preparation derived from the prostate glands of mature cattle. Its active substance is a complex of low-molecular-weight regulatory peptides isolated by ultrafiltration of bovine prostatic tissue. These oligopeptides are hypothesized to | |||
| 19 October 2026 | Deep dive | Deep-dive updated: Ovagen | Ovagen |
| Ovagen is a synthetic tripeptide with the sequence Glu-Asp-Leu (glutamyl-aspartyl-leucine; abbreviation EDL), commercially designated peptide complex AC-3. Its molecular formula is C15H25N3O8 (molecular weight 375.37 g/mol). The compound belongs to the class of short-peptide bior | |||
| 19 October 2026 | Deep dive | Deep-dive updated: Thyreogen | Thyreogen |
| Thyreogen (also designated Peptide Complex A-2) is an organotropic thyroid bioregulator composed of short peptide fractions — predominantly di-, tri-, and tetrapeptides — with a molecular weight below 5 kDa. The peptides are extracted from the thyroid glands of young bovine and p | |||
| 19 October 2026 | Deep dive | Deep-dive updated: Vladonix | Vladonix |
| Vladonix is a natural peptide complex derived from the thymus glands of young calves (no older than 12 months). It belongs to the "Cytomax" class of organ-specific peptide bioregulators developed at the St. Petersburg Institute of Bioregulation and Gerontology under Professor Vla | |||
| 19 October 2026 | Deep dive | Deep-dive updated: Gonadorelin | Gonadorelin |
| Gonadorelin is a synthetic decapeptide (molecular formula C55H75N17O13) with an amino acid sequence identical to endogenous gonadotropin-releasing hormone (GnRH), the neuropeptide secreted in intermittent pulses by the hypothalamus. It binds to GnRH receptors on gonadotroph cell | |||
| 19 October 2026 | Deep dive | Deep-dive updated: Glycine Peptide | Glycine Peptide |
| Glycine (aminoacetic acid) is the simplest proteinogenic amino acid and a major inhibitory neurotransmitter in the spinal cord and brainstem, acting at strychnine-sensitive glycine receptors (GlyRs). Its sleep-promoting properties, however, appear to arise through a pharmacologic | |||
| 19 October 2026 | Deep dive | Deep-dive updated: Vladonix | Vladonix |
| Vladonix is a natural peptide complex derived from the thymus glands of young calves (no older than 12 months). It belongs to the "Cytomax" class of organ-specific peptide bioregulators developed at the St. Petersburg Institute of Bioregulation and Gerontology under Professor Vla | |||
| 19 October 2026 | Deep dive | Deep-dive updated: Sermorelin | Sermorelin |
| Sermorelin is a synthetic 29-amino acid peptide constituting the biologically active N-terminal fragment of human growth hormone-releasing hormone (GHRH). Despite representing only positions 1 through 29 of the 44-residue parent molecule, this fragment retains essentially full ag | |||
| 19 October 2026 | Deep dive | Deep-dive updated: Melanotan II | Melanotan II |
| Melanotan II (MT-II) is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone (alpha-MSH), developed at the University of Arizona in the late 1980s (molecular formula C50H69N15O9; MW approximately 1024 g/mol; CAS 121062-08-6). MT-II acts as a non-selec | |||
| 19 October 2026 | Source | New source added to VladonixSevere anaphylactic reaction to thymostimulin. · pubmed.ncbi.nlm.nih.gov/2058819/ | Vladonix |
| Allergy | |||
| 19 October 2026 | Source | New source added to Glycine PeptideEffect of clozapine and adjunctive high-dose glycine in treatment-resistant schizophrenia. · pubmed.ncbi.nlm.nih.gov/9892314/ | Glycine Peptide |
| The American Journal of Psychiatry | |||
| 19 October 2026 | Source | New source added to SermorelinDrugs@FDA: NDA 020443 - GEREF (sermorelin acetate) for injection, 0.5 mg and 1 mg vials (discontinued) · accessdata.fda.gov/scripts/cder/daf/index.cfm?event… | Sermorelin |
| U.S. Food and Drug Administration, Center for Drug Evaluation and Research | |||
| 19 October 2026 | Source | New source added to Melanotan IIMelanotan II injection resulting in systemic toxicity and rhabdomyolysis. · pubmed.ncbi.nlm.nih.gov/23121206/ | Melanotan II |
| Clinical Toxicology (Philadelphia, Pa.) | |||
| 19 October 2026 | Source | New source added to SermorelinOnce daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group. · pubmed.ncbi.nlm.nih.gov/8772599/ | Sermorelin |
| The Journal of Clinical Endocrinology and Metabolism | |||
| 19 October 2026 | Source | New source added to GonadorelinDevelopment of pituitary apoplexy during TRH/GnRH test in a patient with pituitary macroadenoma. · pubmed.ncbi.nlm.nih.gov/21140103/ | Gonadorelin |
| Singapore Medical Journal | |||
| 19 October 2026 | Source | New source added to Glycine Peptide21 CFR 172.812 - Glycine, food additive permitted for direct addition to food (eCFR) · ecfr.gov/current/title-21/section-172.812 | Glycine Peptide |
| U.S. Food and Drug Administration; Electronic Code of Federal Regulations | |||
| 19 October 2026 | Source | New source added to Melanotan IIMelanotan II: a possible cause of renal infarction: review of the literature and case report. · pubmed.ncbi.nlm.nih.gov/31953620/ | Melanotan II |
| CEN Case Reports | |||
| 19 October 2026 | Source | New source added to GonadorelinPituitary apoplexy caused by luteinizing hormone-releasing hormone in prolactin-producing adenoma. · pubmed.ncbi.nlm.nih.gov/11518116/ | Gonadorelin |
| Internal Medicine (Tokyo, Japan) | |||
| 19 October 2026 | Source | New source added to Melanotan IIMelanotan and the posterior reversible encephalopathy syndrome. · pubmed.ncbi.nlm.nih.gov/23648958/ | Melanotan II |
| Annals of Internal Medicine | |||
| 19 October 2026 | Source | New source added to SermorelinDetermination That GEREF (Sermorelin Acetate) Injection, 0.5 Milligrams Base/Vial and 1.0 Milligrams Base/Vial, and GEREF (Sermorelin Acetate) Injection, 0.05 Milligrams Base/Amp, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness (Federal Register 2013-04827) · federalregister.gov/documents/2013/03/04/2013-04827/… | Sermorelin |
| U.S. Food and Drug Administration; Office of the Federal Register | |||
| 19 October 2026 | Source | New source added to Melanotan IIMelanotan-associated transverse melanonychia. · pubmed.ncbi.nlm.nih.gov/22182016/ | Melanotan II |
| Journal of the European Academy of Dermatology and Venereology | |||
| 19 October 2026 | Source | New source added to Glycine PeptideEfficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. · pubmed.ncbi.nlm.nih.gov/9892253/ | Glycine Peptide |
| Archives of General Psychiatry | |||
| 19 October 2026 | Source | New source added to Glycine PeptideMagnesium Bisglycinate Supplementation in Healthy Adults Reporting Poor Sleep: A Randomized, Placebo-Controlled Trial. · pubmed.ncbi.nlm.nih.gov/40918053/ | Glycine Peptide |
| Nature and Science of Sleep | |||
| 19 October 2026 | Source | New source added to Glycine Peptide21 CFR 170.50 - Glycine (aminoacetic acid) in food for human consumption (eCFR) · ecfr.gov/current/title-21/section-170.50 | Glycine Peptide |
| U.S. Food and Drug Administration; Electronic Code of Federal Regulations | |||
| 19 October 2026 | Source | New source added to GonadorelinImmunoglobulin-mediated hypersensitivity in response to long-term treatment with gonadorelin hydrochloride (Factrel) in a female patient. · pubmed.ncbi.nlm.nih.gov/2653043/ | Gonadorelin |
| American Journal of Obstetrics and Gynecology | |||
| 19 October 2026 | Source | New source added to GonadorelinAnaphylaxis to gonadorelin acetate in a girl with central precocious puberty. · pubmed.ncbi.nlm.nih.gov/26197466/ | Gonadorelin |
| Journal of Pediatric Endocrinology & Metabolism | |||
| 19 October 2026 | Deep dive | Deep-dive updated: Insulin | Insulin |
| Insulin is a 51-amino-acid heterodimeric peptide comprising an A-chain (21 amino acids) and a B-chain (30 amino acids) linked by two disulfide bridges. It exerts its metabolic effects through a well-characterized receptor-mediated signaling cascade. • Binds the insulin receptor | |||
| 19 October 2026 | Source | New source added to InsulinONSWIK (insulin efsitora alfa-gobe) injection Prescribing Information — DailyMed · dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6e02… | Insulin |
| U.S. National Library of Medicine / DailyMed | |||
| 19 October 2026 | Source | New source added to InsulinAWIQLI (insulin icodec-abae) injection Prescribing Information — DailyMed · dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5162… | Insulin |
| U.S. National Library of Medicine / DailyMed | |||
| 19 October 2026 | Deep dive | Deep-dive updated: Insulin | Insulin |
| Insulin is a 51-amino-acid heterodimeric peptide comprising an A-chain (21 amino acids) and a B-chain (30 amino acids) linked by two disulfide bridges. It exerts its metabolic effects through a well-characterized receptor-mediated signaling cascade. • Binds the insulin receptor | |||
| 19 October 2026 | Deep dive | Deep-dive updated: Insulin | Insulin |
| Insulin is a 51-amino-acid heterodimeric peptide comprising an A-chain (21 amino acids) and a B-chain (30 amino acids) linked by two disulfide bridges. It exerts its metabolic effects through a well-characterized receptor-mediated signaling cascade. • Binds the insulin receptor | |||
| 19 October 2026 | Peptide | Peptide updated: Insulin | Insulin |
| The foundational peptide hormone for glycemic management in type 1 and type 2 diabetes mellitus. | |||
| 19 October 2026 | Deep dive | Deep-dive updated: Semaglutide | Semaglutide |
| Semaglutide is a synthetic glucagon-like peptide-1 (GLP-1) receptor agonist sharing 94% sequence homology with endogenous human GLP-1. Three structural modifications confer its extended duration of action: alanine at position 8 is replaced with aminoisobutyric acid (Aib) to resis | |||
| 19 October 2026 | FDA approval | FDA approval updated: Metreleptinaccessdata.fda.gov/drugsatfda_docs/label/2014/125390s000lbl.pdf | Metreleptin |
| Myalept - Adjunct to diet as replacement therapy for the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy. Safety and effectiveness are not established for partial lipodystrophy or for liver disease including NASH; not indicated | |||
| 19 October 2026 | FDA approval | FDA approval updated: Pasireotide | Pasireotide |
| Signifor, Signifor LAR - Cushing's disease in adults for whom pituitary surgery is not an option or has not been curative (Signifor; Signifor LAR). Acromegaly in patients with an inadequate response to surgery or for whom surgery is not an option (Signifor LAR). | |||
| 19 October 2026 | FDA approval | FDA approval updated: Lanreotide | Lanreotide |
| Somatuline Depot - Acromegaly (long-term treatment after inadequate response to, or when not suitable for, surgery and/or radiotherapy); unresectable well- or moderately-differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adul | |||
| 19 October 2026 | FDA approval | FDA approval updated: Octreotide | Octreotide |
| Sandostatin, Sandostatin LAR Depot, Mycapssa, Bynfezia - Sandostatin injection, and Sandostatin LAR Depot in patients who have responded to the injection: acromegaly (to reduce GH and IGF-1 after inadequate response to, or when not treatable with, surgical resection, pituitary ir | |||
| 19 October 2026 | FDA approval | FDA approval updated: Desmopressin | Desmopressin |
| DDAVP, Stimate - Indications differ by formulation. Injection: central diabetes insipidus; hemophilia A and type I von Willebrand disease in patients with factor VIII levels above 5%. Tablets: central diabetes insipidus and primary nocturnal enuresis. Not effective for nephrogeni | |||
| 19 October 2026 | FDA approval | FDA approval updated: Bivalirudin | Bivalirudin |
| Angiomax - Anticoagulant in patients undergoing percutaneous coronary intervention (PCI), including patients with heparin-induced thrombocytopenia (HIT) or heparin-induced thrombocytopenia and thrombosis syndrome (HITTS). | |||
| 19 October 2026 | FDA approval | FDA approval updated: Pramlintide | Pramlintide |
| Symlin - Adjunctive treatment in patients with type 1 or type 2 diabetes who use mealtime insulin and have failed to achieve desired glycemic control despite optimal insulin therapy. Drugs@FDA lists every Symlin presentation as discontinued (NDA 021332; checked 2026-10-18). | |||
| 19 October 2026 | FDA approval | FDA approval updated: Abaloparatide | Abaloparatide |
| Tymlos - Postmenopausal women with osteoporosis at high risk for fracture, or who have failed or are intolerant to other osteoporosis therapy (reduces the risk of vertebral and nonvertebral fractures); and to increase bone density in men with osteoporosis at high risk for fractur | |||
| 19 October 2026 | FDA approval | FDA approval updated: Teriparatide | Teriparatide |
| Forteo - Osteoporosis at high risk for fracture, or after failure of or intolerance to other osteoporosis therapy, in: postmenopausal women (reduces the risk of vertebral and nonvertebral fractures); men with primary or hypogonadal osteoporosis (to increase bone mass); and men an | |||
| 19 October 2026 | FDA approval | FDA approval updated: Calcitonin | Calcitonin |
| Miacalcin, Fortical - Miacalcin injection: symptomatic Paget's disease of bone and postmenopausal osteoporosis, each when alternative treatments are not suitable (fracture-reduction efficacy has not been demonstrated), and hypercalcemia. Because of a possible association with mal | |||
| 19 October 2026 | FDA approval | FDA approval updated: Insulin | Insulin |
| Humulin, Novolin, Humalog, NovoLog, Lantus, Tresiba, Awiqli, Onswik, many others - Umbrella record for human insulin and insulin analogs: to improve glycemic control in patients with diabetes mellitus, with the covered age range and diabetes type set by each product's label (for | |||
| 19 October 2026 | FDA approval | FDA approval updated: Oxytocin | Oxytocin |
| Pitocin - Antepartum: induction of labor in patients with a medical indication, stimulation or reinforcement of labor in selected cases of uterine inertia, and adjunctive therapy in incomplete or inevitable abortion. Postpartum: to produce uterine contractions during the third st | |||
| 19 October 2026 | FDA approval | FDA approval updated: Gonadorelin | Gonadorelin |
| Factrel, Lutrepulse - Drugs@FDA lists every Factrel and Lutrepulse (gonadorelin) presentation as discontinued (NDA 018123, NDA 019687; checked 2026-10-18). No current FDA label is available, so the originally labeled indications are not restated here. | |||
| 19 October 2026 | FDA approval | FDA approval updated: Sermorelin | Sermorelin |
| Geref - Drugs@FDA lists every Geref (sermorelin acetate) presentation as discontinued (NDA 019863, NDA 020443; checked 2026-10-18). No current FDA label is available, so the originally labeled indication is not restated here. | |||
| 19 October 2026 | FDA approval | FDA approval updated: Exenatide | Exenatide |
| Byetta, Bydureon - Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus (Byetta). Drugs@FDA lists the extended-release products Bydureon and Bydureon BCise as discontinued (checked 2026-10-18). | |||
| 19 October 2026 | FDA approval | FDA approval updated: Tesamorelin | Tesamorelin |
| Egrifta SV, Egrifta WR - Reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. Not indicated for weight loss; long-term cardiovascular safety has not been established. | |||
| 19 October 2026 | Deep dive | Deep-dive updated: MOTS-c | MOTS-c |
| MOTS-c is a 16-amino-acid peptide (sequence MRWQEMGYIFYPRKLR) encoded by an open reading frame within the mitochondrial 12S rRNA gene (MT-RNR1). It was characterized by Lee and colleagues in 2015 as the founding member of a class of mitochondria-encoded signaling molecules, somet | |||
| 19 October 2026 | Deep dive | Deep-dive updated: MOTS-c | MOTS-c |
| MOTS-c is a 16-amino-acid peptide (sequence MRWQEMGYIFYPRKLR) encoded by an open reading frame within the mitochondrial 12S rRNA gene (MT-RNR1). It was characterized by Lee and colleagues in 2015 as the founding member of a class of mitochondria-encoded signaling molecules, somet | |||
| 19 October 2026 | Source | New source added to MOTS-cA Phase 2a, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Pharmacodynamics of MOTS-c in Adults With Prediabetes and Overweight/Obesity (NCT07505745) · clinicaltrials.gov/study/NCT07505745 | MOTS-c |
| ClinicalTrials.gov, U.S. National Library of Medicine (sponsor: Hudson Biotech) | |||
| 19 October 2026 | Source | New source added to MOTS-cA Phase 1a/1b Study of Safety, Tolerability, and Pharmacokinetics of CB4211 in Healthy Non-obese Subjects and Subjects With Nonalcoholic Fatty Liver Disease (NCT03998514) · clinicaltrials.gov/study/NCT03998514 | MOTS-c |
| ClinicalTrials.gov, U.S. National Library of Medicine (sponsor: CohBar, Inc.) | |||
| 19 October 2026 | Deep dive | Deep-dive updated: DHEA Peptide | DHEA Peptide |
| Dehydroepiandrosterone (DHEA) is a C19 steroid hormone, not a peptide, synthesized primarily in the zona reticularis of the adrenal cortex with minor contributions from the gonads and brain. It is catalogued here under the hormone category as the body's most abundant circulating | |||
| 19 October 2026 | Deep dive | Deep-dive updated: Gonadorelin | Gonadorelin |
| Gonadorelin is a synthetic decapeptide (molecular formula C55H75N17O13) with an amino acid sequence identical to endogenous gonadotropin-releasing hormone (GnRH), the neuropeptide secreted in intermittent pulses by the hypothalamus. It binds to GnRH receptors on gonadotroph cell | |||
| 19 October 2026 | Deep dive | Deep-dive updated: Sermorelin | Sermorelin |
| Sermorelin is a synthetic 29-amino acid peptide constituting the biologically active N-terminal fragment of human growth hormone-releasing hormone (GHRH). Despite representing only positions 1 through 29 of the 44-residue parent molecule, this fragment retains essentially full ag | |||
| 19 October 2026 | Deep dive | Deep-dive updated: Leptin | Leptin |
| Leptin is a 16-kilodalton adipokine secreted by adipocytes in proportion to total fat mass. It serves as a long-range energy-status signal to the hypothalamus, binding primarily to the long isoform of the leptin receptor (LepRb) in the arcuate nucleus and ventromedial hypothalamu | |||
| 19 October 2026 | Deep dive | Deep-dive updated: Pramlintide | Pramlintide |
| Pramlintide is a 37-amino acid synthetic analog of human amylin (islet amyloid polypeptide, IAPP), a neurohormone co-secreted with insulin by pancreatic beta cells following nutrient ingestion. In type 1 diabetes, amylin secretion is virtually absent alongside the loss of insulin | |||
| 19 October 2026 | Deep dive | Deep-dive updated: Pentosan Polysulfate | Pentosan Polysulfate |
| Pentosan polysulfate sodium (PPS) is a semi-synthetic sulfated polysaccharide derived from beechwood hemicellulose (xylan). Its heavily sulfated anionic structure allows it to mimic heparan sulfate proteoglycans found on cell surfaces and in the extracellular matrix, enabling int | |||
| 19 October 2026 | Source | New source added to GonadorelinDrugs@FDA: NDA 018123 - FACTREL (gonadorelin hydrochloride) injection (discontinued) · accessdata.fda.gov/scripts/cder/daf/index.cfm?event… | Gonadorelin |
| U.S. Food and Drug Administration, Center for Drug Evaluation and Research | |||
| 19 October 2026 | Source | New source added to SermorelinDrugs@FDA: NDA 019863 - GEREF (sermorelin acetate) injection (discontinued) · accessdata.fda.gov/scripts/cder/daf/index.cfm?event… | Sermorelin |
| U.S. Food and Drug Administration, Center for Drug Evaluation and Research | |||
| 19 October 2026 | Source | New source added to DHEA PeptideINTRAROSA (prasterone) vaginal insert - FDA prescribing information (DailyMed) · dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ada6… | DHEA Peptide |
| Millicent US, Inc.; U.S. National Library of Medicine, DailyMed | |||
| 19 October 2026 | Source | New source added to Pentosan PolysulfateELMIRON (pentosan polysulfate sodium) capsules - FDA prescribing information (DailyMed) · dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f0ba… | Pentosan Polysulfate |
| Janssen Pharmaceuticals, Inc.; U.S. National Library of Medicine, DailyMed | |||
| 19 October 2026 | Source | New source added to LeptinMYALEPT (metreleptin) for injection - FDA prescribing information (DailyMed) · dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d3b5… | Leptin |
| Chiesi USA, Inc.; U.S. National Library of Medicine, DailyMed | |||
| 19 October 2026 | Source | New source added to PramlintideSymlinPen (pramlintide acetate) injection — FDA prescribing information · dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4aea… | Pramlintide |
| AstraZeneca Pharmaceuticals LP | |||
| 19 October 2026 | Peptide | Peptide updated: Actovegin | Actovegin |
| Hypoxic pain and healing | |||
| 19 October 2026 | Peptide | Peptide updated: Groprinosin | Groprinosin |
| Inosine pranobex, a synthetic immunomodulator studied in viral infection. Randomized trials exist; it is not approved in the United States. | |||
| 19 October 2026 | Peptide | Peptide updated: Thymosin Alpha-1 | Thymosin Alpha-1 |
| Immune system support | |||
| 19 October 2026 | Deep dive | Deep-dive updated: Pentosan Polysulfate | Pentosan Polysulfate |
| Pentosan polysulfate sodium (PPS) is a semi-synthetic sulfated polysaccharide derived from beechwood hemicellulose (xylan). Its heavily sulfated anionic structure allows it to mimic heparan sulfate proteoglycans found on cell surfaces and in the extracellular matrix, enabling int | |||
| 19 October 2026 | Peptide | Peptide updated: Pentosan Polysulfate | Pentosan Polysulfate |
| FDA-approved oral drug (ELMIRON) for bladder pain of interstitial cystitis; joint uses are investigational | |||
| 19 October 2026 | FDA approval | FDA approval updated: Liraglutide | Liraglutide |
| Victoza, Saxenda - Victoza: adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes; and to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction | |||
| 19 October 2026 | FDA approval | New FDA-approved peptide: Palopegteriparatidedailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a1fa23fd-c434-443e-9… | Palopegteriparatide |
| Yorvipath - Hypoparathyroidism in adults. Not studied for acute post-surgical hypoparathyroidism. | |||
| 19 October 2026 | FDA approval | New FDA-approved peptide: Zilucoplandailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9f1d53d6-e495-4a3a-8… | Zilucoplan |
| Zilbrysq - Generalized myasthenia gravis in adults who are anti-acetylcholine receptor (AChR) antibody positive. | |||
| 19 October 2026 | FDA approval | New FDA-approved peptide: Motixafortidedailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e704b2db-f119-40ba-9… | Motixafortide |
| Aphexda - In combination with filgrastim (G-CSF), to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma. | |||
| 19 October 2026 | FDA approval | New FDA-approved peptide: Trofinetidedailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=67e6f2d9-21f6-466f-9… | Trofinetide |
| Daybue, Daybue Stix - Treatment of Rett syndrome in adults and pediatric patients 2 years of age and older. | |||
| 19 October 2026 | FDA approval | New FDA-approved peptide: Terlipressindailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3a35b86c-f451-4fac-8… | Terlipressin |
| Terlivaz - To improve kidney function in adults with hepatorenal syndrome with rapid reduction in kidney function. Patients with serum creatinine above 5 mg/dL are unlikely to benefit. | |||
| 19 October 2026 | FDA approval | New FDA-approved peptide: Lutetium Lu 177 vipivotide tetraxetandailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14908037-2892-4d98-a… | Lutetium Lu 177 vipivotide tetraxetan |
| Pluvicto - Adults with prostate-specific membrane antigen (PSMA)-positive metastatic prostate cancer: in combination with an androgen receptor pathway inhibitor for androgen pathway modulation-naive or -sensitive disease; or for androgen pathway modulation-resistant disease after | |||
| 19 October 2026 | FDA approval | New FDA-approved peptide: Vosoritidedailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=228e8560-04a4-4bb1-a… | Vosoritide |
| Voxzogo - To increase linear growth in pediatric patients with achondroplasia with open epiphyses. Accelerated approval based on improvement in annualized growth velocity; continued approval may be contingent upon verification and description of clinical benefit in confirmatory t | |||
| 19 October 2026 | FDA approval | New FDA-approved peptide: Difelikefalindailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0c7b81f2-0fd3-47cb-8… | Difelikefalin |
| Korsuva - Moderate-to-severe pruritus associated with chronic kidney disease (CKD-aP) in adults undergoing hemodialysis. Not studied in, and not recommended for, patients on peritoneal dialysis. | |||
| 19 October 2026 | FDA approval | New FDA-approved peptide: Pegcetacoplandailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c23d89e9-b00b-4520-e… | Pegcetacoplan |
| Empaveli, Syfovre - Empaveli (subcutaneous): paroxysmal nocturnal hemoglobinuria (PNH) in adults; and C3 glomerulopathy or primary immune-complex membranoproliferative glomerulonephritis in patients 12 years and older, to reduce proteinuria and the loss of kidney function. Syfovr | |||
| 19 October 2026 | FDA approval | New FDA-approved peptide: Dasiglucagondailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14704879-872c-4967-8… | Dasiglucagon |
| Zegalogue - Treatment of severe hypoglycemia in pediatric and adult patients with diabetes aged 6 years and above. | |||
| 19 October 2026 | FDA approval | New FDA-approved peptide: Setmelanotidedailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=70c3ccf7-4df0-4c75-b… | Setmelanotide |
| Imcivree - To reduce excess body weight and maintain weight reduction long term in patients 4 years and older with acquired hypothalamic obesity, and in patients 2 years and older with Bardet-Biedl syndrome or with POMC, PCSK1 or LEPR deficiency confirmed by genetic testing (vari | |||
| 19 October 2026 | FDA approval | New FDA-approved peptide: Afamelanotidedailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=94f53286-11dd-7fbb-e… | Afamelanotide |
| Scenesse - To increase pain-free light exposure in adults with a history of phototoxic reactions from erythropoietic protoporphyria (EPP). | |||
| 19 October 2026 | FDA approval | New FDA-approved peptide: Lutetium Lu 177 dotatatedailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=72d1a024-00b7-418a-b… | Lutetium Lu 177 dotatate |
| Lutathera, Bexlutry, Bravnetsa - Somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut and hindgut neuroendocrine tumors: Lutathera (NDA 208700, approved 2018-01-26) in adults and pediatric patients 12 years and older. T | |||
| 19 October 2026 | FDA approval | New FDA-approved peptide: Angiotensin IIdailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c265d69a-3efe-4107-9… | Angiotensin II |
| Giapreza - To increase blood pressure in adults with septic or other distributive shock. | |||
| 19 October 2026 | FDA approval | New FDA-approved peptide: Etelcalcetidedailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cd270093-c6a8-4596-a… | Etelcalcetide |
| Parsabiv - Secondary hyperparathyroidism in adults with chronic kidney disease on hemodialysis. Not studied in, and not recommended for, parathyroid carcinoma, primary hyperparathyroidism, or chronic kidney disease without hemodialysis. | |||
| 19 October 2026 | FDA approval | New FDA-approved peptide: Plecanatidedailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fe2895bf-71a6-493a-b… | Plecanatide |
| Trulance - In adults: chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C). | |||
| 19 October 2026 | FDA approval | New FDA-approved peptide: Lixisenatidedailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4bba538b-cf7c-4310-a… | Lixisenatide |
| Adlyxin, Soliqua 100/33 - Type 2 diabetes. First approved in 2016 as single-ingredient Adlyxin, for which no current label is published on DailyMed (checked 2026-10-18). Lixisenatide is currently labeled in Soliqua 100/33 (insulin glargine and lixisenatide), indicated as an adjun | |||
| 19 October 2026 | FDA approval | New FDA-approved peptide: Somatropinaccessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.proces… | Somatropin |
| Genotropin, Humatrope, Norditropin, Nutropin AQ, Omnitrope, Saizen, Serostim, Zomacton, Zorbtive - Umbrella record for separately approved somatropin products; the date shown is the earliest somatropin approval in Drugs@FDA (Humatrope, BLA 019640). Labeled indications differ by p | |||
| 19 October 2026 | FDA approval | New FDA-approved peptide: Enlicitidedailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=100ec543-fbd0-44fc-b… | Enlicitide |
| Lipfendra - Adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH). The label notes that cardiovascular outcome benefit from LDL-C lowering has been demons | |||
| 19 October 2026 | Deep dive | Deep-dive updated: Retatrutide | Retatrutide |
| Retatrutide (LY3437943) is a 31-aa acylated peptide triagonist with C18 fatty-diacid chain via mini-PEG linker enabling once-weekly dosing. Three receptor pathways: (1) GIP receptor agonism -- augments glucose-dependent insulin secretion, reduces food intake via hypothalamic GIPR | |||
| 19 October 2026 | Deep dive | Deep-dive updated: Retatrutide | Retatrutide |
| Retatrutide (LY3437943) is a 31-aa acylated peptide triagonist with C18 fatty-diacid chain via mini-PEG linker enabling once-weekly dosing. Three receptor pathways: (1) GIP receptor agonism -- augments glucose-dependent insulin secretion, reduces food intake via hypothalamic GIPR | |||
| 19 October 2026 | Deep dive | Deep-dive updated: Pramlintide | Pramlintide |
| Pramlintide is a 37-amino acid synthetic analog of human amylin (islet amyloid polypeptide, IAPP), a neurohormone co-secreted with insulin by pancreatic beta cells following nutrient ingestion. In type 1 diabetes, amylin secretion is virtually absent alongside the loss of insulin | |||
| 19 October 2026 | Peptide | Peptide updated: Pramlintide | Pramlintide |
| Amylin analog for diabetes | |||
| 19 October 2026 | Deep dive | Deep-dive updated: Exenatide | Exenatide |
| Exenatide is a synthetic analog of exendin-4, a 39-amino-acid peptide originally isolated from the salivary secretions of the Gila monster (Heloderma suspectum). It shares 53% amino acid sequence homology with native human glucagon-like peptide-1 (GLP-1) and functions as a full a | |||
| 19 October 2026 | Peptide | Peptide updated: Exenatide | Exenatide |
| FDA-approved GLP-1 receptor agonist for type 2 diabetes; the first incretin mimetic approved in the US. | |||
| 19 October 2026 | Peptide | Peptide updated: GLOW Stack | GLOW Stack |
| Trending injectable research blend of GHK-Cu, BPC-157 and TB-500, marketed for skin rejuvenation and tissue recovery. Not FDA-approved; sold as a research chemical. | |||
| 19 October 2026 | Peptide | Peptide updated: Dihexa | Dihexa |
| Potent cognitive enhancer | |||
| 19 October 2026 | Peptide | Peptide updated: LL-37 | LL-37 |
| Antimicrobial defense peptide | |||
| 19 October 2026 | Peptide | Peptide updated: Melanotan II | Melanotan II |
| Tanning, libido | |||
| 19 October 2026 | Peptide | Peptide updated: GHK-Cu | GHK-Cu |
| Wound healing, skin regeneration | |||
| 19 October 2026 | Peptide | Peptide updated: Epitalon | Epitalon |
| Longevity, telomere support | |||
| 19 October 2026 | Peptide | Peptide updated: Thymosin Beta-4 | Thymosin Beta-4 |
| Comprehensive tissue pain relief | |||
| 19 October 2026 | Peptide | Peptide updated: NA-Semax-Amidate | NA-Semax-Amidate |
| Triple modified Semax | |||
| 19 October 2026 | Peptide | Peptide updated: MOTS-c | MOTS-c |
| Mitochondrial optimization | |||
| 19 October 2026 | Peptide | Peptide updated: TB-500 | TB-500 |
| Tissue repair, flexibility, inflammation | |||
| 19 October 2026 | Peptide | Peptide updated: KPV | KPV |
| Anti-inflammatory immune peptide | |||
| 19 October 2026 | Peptide | Peptide updated: BPC-157 | BPC-157 |
| Healing & recovery, gut health | |||
| 19 October 2026 | Peptide | Peptide updated: Semax-Amidate | Semax-Amidate |
| Extended release Semax | |||
| 19 October 2026 | Peptide | Peptide updated: Semax Low Dose | Semax Low Dose |
| Evening cognitive calming | |||
| 19 October 2026 | Peptide | Peptide updated: Semax | Semax |
| Cognitive enhancement, focus, memory | |||
| 19 October 2026 | Peptide | Peptide updated: DSIP | DSIP |
| Delta sleep-inducing peptide | |||
| 19 October 2026 | Peptide | Peptide updated: Epitalon | Epitalon |
| Longevity, telomere support | |||
| 19 October 2026 | Research | Research updated: FDA Novel Drug Approval: Foundayo (Orforglipron) — First Oral Small-Molecule GLP-1 Agonistfda.gov/drugs/novel-drug-approvals-fda/novel-drug-approv… | Orforglipron |
| FDA approved Foundayo (orforglipron) April 1, 2026. First oral small-molecule (non-peptide) GLP-1 receptor agonist for weight management in adults with obesity or overweight; oral semaglutide, a peptide, was approved earlier (Rybelsus 2019; Wegovy tablets December 2025). Eli Lill | |||
| 19 October 2026 | Research | Research updated: Retatrutide TRIUMPH-1 Phase 3: 28.3% Weight Loss at 80 Weeks (Eli Lilly, May 2026)investor.lilly.com/news-releases/news-release-details/lillys-triple… | Retatrutide, Tirzepatide, CagriSema |
| Phase 3 TRIUMPH-1 (Eli Lilly press release May 21, 2026): Retatrutide 12 mg produced 28.3% body weight loss (70.3 lb) over 80 weeks in adults with obesity without T2D. 9 mg: 25.9% (64.4 lb). 4 mg: 19.0% (47.2 lb). All doses met primary and key secondary endpoints. 45.3% of 12 mg | |||
| 19 October 2026 | Deep dive | Deep-dive updated: Retatrutide | Retatrutide |
| Retatrutide (LY3437943) is a 31-aa acylated peptide triagonist with C18 fatty-diacid chain via mini-PEG linker enabling once-weekly dosing. Three receptor pathways: (1) GIP receptor agonism -- augments glucose-dependent insulin secretion, reduces food intake via hypothalamic GIPR | |||
| 19 October 2026 | Peptide | Peptide updated: Retatrutide | Retatrutide |
| Investigational triple agonist (GIP/GLP-1/glucagon). TRIUMPH-1 Phase 3 (May 2026): 28.3% body weight loss at 80 weeks. FDA submission anticipated Q3–Q4 2026. | |||
| 19 October 2026 | Research | Research updated: Enlicitide Decanoate (Oral Macrocyclic Peptide PCSK9 Inhibitor) Reduced LDL-C 55.8% in Phase 3 CORALreef Lipids (Merck, AHA 2025)merck.com/news/mercks-enlicitide-decanoate-an-investigatio… | Enlicitide decanoate (MK-0616) |
| Once-daily ORAL macrocyclic peptide PCSK9 inhibitor (Merck/MSD; MK-0616). Late-breaking Phase 3 CORALreef Lipids results presented at AHA Scientific Sessions 2025 (announced 8 Nov 2025): in adults with or at risk for atherosclerotic cardiovascular disease on background lipid-lowe | |||
| 18 October 2026 | Research | New research: Regulator Tests “Retatrutide” Vial: Finds No Retatrutide and Undeclared High-Dose Semaglutidetga.gov.au/safety/safety-monitoring-and-information/safety-… | Retatrutide, Semaglutide |
| Australia's Therapeutic Goods Administration issued a safety alert after investigating a serious adverse-event report involving a product sold as retatrutide. TGA obtained a sample from the product's original unmarked vial and reported that laboratory testing found no retatrutide | |||
| 18 October 2026 | Research | New research: Can Stalk-Derived Peptides Restore Polycystin-1 Signaling? What the ADPKD Research Showselifesciences.org/articles/95992 | Polycystin-1 stalk-derived peptide agonists (p9, p17, p21) |
| In a peer-reviewed 2024 eLife study, Pawnikar and colleagues investigated whether soluble peptides derived from the endogenous polycystin-1 (PC1) stalk can reactivate signaling in a laboratory model. Polycystin-1 is encoded by PKD1, a gene associated with autosomal dominant polyc | |||
| 29 September 2026 | Deep dive | Deep-dive updated: Vladonix | Vladonix |
| Vladonix is a natural peptide complex derived from the thymus glands of young calves (no older than 12 months). It belongs to the "Cytomax" class of organ-specific peptide bioregulators developed at the St. Petersburg Institute of Bioregulation and Gerontology under Professor Vla | |||
| 29 September 2026 | Deep dive | Deep-dive updated: Syn-Coll | Syn-Coll |
| Syn-Coll is the trade name for palmitoyl tripeptide-5, a synthetic lipopeptide with the sequence palmitoyl-Lys-Val-Lys (CAS 623172-55-4; molecular weight approximately 611.9 g/mol as free base). It was developed by Pentapharm, now part of DSM-Firmenich, and functions as a growth | |||
| 29 September 2026 | Deep dive | Deep-dive updated: GHRP-4 | GHRP-4 |
| GHRP-4 is a synthetic tetrapeptide with the primary sequence D-Trp–L-Ala–L-Trp–D-Phe–NH2 (molecular weight 607.7 Da; molecular formula C34H37N7O4). It belongs to the growth hormone-releasing peptide (GHRP) family, a series of met-enkephalin analogs incorporating unnatural D-amino | |||
| 29 September 2026 | Deep dive | Deep-dive updated: Dihexa | Dihexa |
| Dihexa (systematic name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide; also designated PNB-0408) is a synthetic, metabolically stabilized small peptide derived from angiotensin IV (AngIV), the hexapeptide fragment of angiotensin II. Its Tyr-Ile dipeptide core is flanked by an N-term | |||
| 29 September 2026 | Deep dive | Deep-dive updated: Semax-Amidate | Semax-Amidate |
| Semax-Amidate, formally N-Acetyl Semax Amidate (Ac-Met-Glu-His-Phe-Pro-Gly-Pro-NH2, MW ~855 Da), is a dual-modified synthetic heptapeptide derived from Semax, which is itself an analogue of the adrenocorticotropic hormone (ACTH) fragment 4–10. The N-terminal methionine carries an | |||
| 29 September 2026 | Deep dive | Deep-dive updated: Thyreogen | Thyreogen |
| Thyreogen (also designated Peptide Complex A-2) is an organotropic thyroid bioregulator composed of short peptide fractions — predominantly di-, tri-, and tetrapeptides — with a molecular weight below 5 kDa. The peptides are extracted from the thyroid glands of young bovine and p | |||
| 29 September 2026 | Deep dive | Deep-dive updated: Epithalon + Follistatin Stack | Epithalon + Follistatin Stack |
| Epithalon (designation AEDG, reflecting its amino acid sequence Ala-Glu-Asp-Gly) is a synthetic tetrapeptide modeled on Epithalamin, a bovine pineal gland extract. Its best-characterized proposed mechanism is activation of telomerase, the ribonucleoprotein enzyme that synthesizes | |||
| 29 September 2026 | Deep dive | Deep-dive updated: Selank-Amidate | Selank-Amidate |
| Selank-Amidate is a chemically stabilized derivative of Selank, a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro; TKPRPGP) patterned on tuftsin, a naturally occurring immunomodulatory tetrapeptide derived enzymatically from IgG. C-terminal amidation replaces the free carboxy | |||
| 29 September 2026 | Deep dive | Deep-dive updated: Matrixyl 3000 | Matrixyl 3000 |
| Matrixyl 3000 is a commercial matrikine peptide blend developed by Sederma (now a Croda brand) comprising two lipopeptides: palmitoyl tripeptide-1 (Pal-GHK) and palmitoyl tetrapeptide-7 (Pal-GQPR). Both peptides carry a C16 palmitic acid chain that increases lipophilicity and fac | |||
| 29 September 2026 | Deep dive | Deep-dive updated: Ovagen | Ovagen |
| Ovagen is a synthetic tripeptide with the sequence Glu-Asp-Leu (glutamyl-aspartyl-leucine; abbreviation EDL), commercially designated peptide complex AC-3. Its molecular formula is C15H25N3O8 (molecular weight 375.37 g/mol). The compound belongs to the class of short-peptide bior | |||
| 29 September 2026 | Deep dive | Deep-dive updated: NA-Semax-Amidate | NA-Semax-Amidate |
| NA-Semax-Amidate (Ac-Met-Glu-His-Phe-Pro-Gly-Pro-NH2) is a synthetic heptapeptide analog of the adrenocorticotropic hormone fragment ACTH(4-10), extended by a C-terminal Pro-Gly-Pro tripeptide that abolishes hormonal melanocortin receptor binding. It differs from its parent compo | |||
| 29 September 2026 | Source | Source updated in Palmitoyl Tripeptide-5Activation of latent TGF-beta by thrombospondin-1: mechanisms and physiology · pubmed.ncbi.nlm.nih.gov/10708953/ | Palmitoyl Tripeptide-5 |
| Cytokine & Growth Factor Reviews (Elsevier) | |||
| 29 September 2026 | Deep dive | Deep-dive updated: Thymalin | Thymalin |
| Thymalin is a polypeptide complex of low molecular weight (up to 10 kDa) isolated from the thymus glands of calves. Its active pharmaceutical constituents include a mixture of short peptide fragments, among which the dipeptides KE (Lys-Glu) and EW (Glu-Trp) have been most extensi | |||
| 29 September 2026 | Deep dive | Deep-dive updated: Vladonix | Vladonix |
| Vladonix is a natural peptide complex derived from the thymus glands of young calves (no older than 12 months). It belongs to the "Cytomax" class of organ-specific peptide bioregulators developed at the St. Petersburg Institute of Bioregulation and Gerontology under Professor Vla | |||
| 29 September 2026 | Deep dive | Deep-dive updated: Sermorelin | Sermorelin |
| Sermorelin is a synthetic 29-amino acid peptide constituting the biologically active N-terminal fragment of human growth hormone-releasing hormone (GHRH). Despite representing only positions 1 through 29 of the 44-residue parent molecule, this fragment retains essentially full ag | |||
| 29 September 2026 | Deep dive | Deep-dive updated: Pegzilarginase-nbln | Pegzilarginase-nbln |
| Arginase 1 deficiency (ARG1-D) is caused by biallelic mutations in the ARG1 gene, which encodes the hepatic enzyme catalyzing the final step of the urea cycle: hydrolysis of L-arginine to L-ornithine and urea. Loss of this activity causes pathological accumulation of plasma argin | |||
| 29 September 2026 | Deep dive | Deep-dive updated: P21 (Adamax) | P21 (Adamax) |
| P21 (P021) is a synthetic pentapeptide (Ac-DGGLAG-NH2; MW 578.3 g/mol) derived from amino acid residues 148-151 of ciliary neurotrophic factor (CNTF). Full-length CNTF fails as a therapeutic due to poor blood-brain barrier penetration and systemic side effects including anorexia | |||
| 29 September 2026 | Deep dive | Deep-dive updated: Fragment 176-191 | Fragment 176-191 |
| Fragment 176-191 is the C-terminal amino acid sequence spanning residues 176 through 191 of human growth hormone (hGH). This region of the hGH molecule was identified in early research as containing the domain responsible for the hormone's lipolytic activity, functionally separab | |||
| 29 September 2026 | Deep dive | Deep-dive updated: Hexarelin | Hexarelin |
| Hexarelin (INN: examorelin; sequence His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2) is a synthetic hexapeptide derived from GHRP-6 by substitution of 2-methyl-D-tryptophan at the second position. Its primary mechanism is potent agonism at the growth hormone secretagogue receptor subty | |||
| 29 September 2026 | Deep dive | Deep-dive updated: Epitalon | Epitalon |
| Epitalon (also written Epithalon; sequence Ala-Glu-Asp-Gly, abbreviated AEDG) is a synthetic tetrapeptide with molecular formula C14H22N4O9 and molecular weight 390.35 g/mol. It was designed to replicate the bioactive core of epithalamin, a peptide fraction isolated from bovine p | |||
| 29 September 2026 | Deep dive | Deep-dive updated: Cortagen | Cortagen |
| Cortagen (Ala-Glu-Asp-Pro; AEDP) is a synthetic tetrapeptide with the molecular formula C17H26N4O9 (molar mass 430.4 g/mol). It was derived by directed chemical synthesis from the amino acid composition of cortexin, a natural polypeptide extract of cattle cerebral cortex in clini | |||
| 29 September 2026 | Deep dive | Deep-dive updated: TB4-FRAG | TB4-FRAG |
| TB4-FRAG designates the biologically active fragments derived from thymosin beta-4 (Tβ4), a ubiquitous 43-amino acid G-actin-sequestering protein encoded by TMSB4X on the X chromosome. Two fragments are principally studied in research and performance contexts. The heptapeptide A | |||
| 29 September 2026 | Deep dive | Deep-dive updated: Semax-Amidate | Semax-Amidate |
| Semax-Amidate, formally N-Acetyl Semax Amidate (Ac-Met-Glu-His-Phe-Pro-Gly-Pro-NH2, MW ~855 Da), is a dual-modified synthetic heptapeptide derived from Semax, which is itself an analogue of the adrenocorticotropic hormone (ACTH) fragment 4–10. The N-terminal methionine carries an | |||
| 29 September 2026 | Deep dive | Deep-dive updated: Bulevirtide | Bulevirtide |
| Bulevirtide is a synthetic 47-amino acid lipopeptide derived from the preS1 domain of the large hepatitis B virus (HBV) surface protein, modified with an N-terminal myristic acid (C13 fatty acid) group. It acts as a competitive entry inhibitor targeting the sodium taurocholate co | |||
| 29 September 2026 | Deep dive | Deep-dive updated: Thyreogen | Thyreogen |
| Thyreogen (also designated Peptide Complex A-2) is an organotropic thyroid bioregulator composed of short peptide fractions — predominantly di-, tri-, and tetrapeptides — with a molecular weight below 5 kDa. The peptides are extracted from the thyroid glands of young bovine and p | |||
| 29 September 2026 | Deep dive | Deep-dive updated: YK-11 | YK-11 |
| YK-11 (CAS 1370003-76-1; molecular formula C₂₅H₃₄O₆; molar mass 430.5 g/mol) is a synthetic steroidal compound first characterized by Kanno et al. in 2011 as a partial agonist of the androgen receptor (AR). Unlike full AR agonists such as dihydrotestosterone (DHT), YK-11 does not | |||
| 29 September 2026 | Deep dive | Deep-dive updated: Semax Low Dose | Semax Low Dose |
| Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a synthetic heptapeptide derived from the 4-10 fragment of adrenocorticotropic hormone (ACTH). Unlike intact ACTH, it lacks corticotropic activity and does not stimulate cortisol or adrenal hormone secretion. Its best-replicated molecular a | |||
| 29 September 2026 | Deep dive | Deep-dive updated: Melanotan II | Melanotan II |
| Melanotan II (MT-II) is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone (alpha-MSH), developed at the University of Arizona in the late 1980s (molecular formula C50H69N15O9; MW approximately 1024 g/mol; CAS 121062-08-6). MT-II acts as a non-selec | |||
| 29 September 2026 | Deep dive | Deep-dive updated: Selank-Amidate | Selank-Amidate |
| Selank-Amidate is a chemically stabilized derivative of Selank, a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro; TKPRPGP) patterned on tuftsin, a naturally occurring immunomodulatory tetrapeptide derived enzymatically from IgG. C-terminal amidation replaces the free carboxy | |||
| 29 September 2026 | Deep dive | Deep-dive updated: Pinealon | Pinealon |
| Pinealon (systematic name Glu-Asp-Arg, also designated EDR) is a synthetic tripeptide isolated from Cortexin, a polypeptide extract derived from the cerebral cortex that has been used clinically in Russia as a neuroprotective agent. Its molecular formula is C15H26N6O8, with a mol | |||
| 29 September 2026 | Deep dive | Deep-dive updated: Ovagen | Ovagen |
| Ovagen is a synthetic tripeptide with the sequence Glu-Asp-Leu (glutamyl-aspartyl-leucine; abbreviation EDL), commercially designated peptide complex AC-3. Its molecular formula is C15H25N3O8 (molecular weight 375.37 g/mol). The compound belongs to the class of short-peptide bior | |||
| 29 September 2026 | Deep dive | Deep-dive updated: Gonadorelin | Gonadorelin |
| Gonadorelin is a synthetic decapeptide (molecular formula C55H75N17O13) with an amino acid sequence identical to endogenous gonadotropin-releasing hormone (GnRH), the neuropeptide secreted in intermittent pulses by the hypothalamus. It binds to GnRH receptors on gonadotroph cell | |||
| 29 September 2026 | Deep dive | Deep-dive updated: Ipamorelin | Ipamorelin |
| Ipamorelin (Aib-His-D-2-Nal-D-Phe-Lys-NH2; MW 711.87 Da) is a synthetic pentapeptide that acts as a selective agonist of the ghrelin receptor, also designated the growth hormone secretagogue receptor type 1a (GHS-R1a). Developed by Novo Nordisk and first characterized by Raun et | |||
| 29 September 2026 | Deep dive | Deep-dive updated: CJC-1295 | CJC-1295 |
| CJC-1295 is a synthetic 30-amino acid analog of growth hormone-releasing hormone (GHRH), derived from the biologically active GHRH(1-29) fragment. The DAC (Drug Affinity Complex) formulation incorporates a maleimidopropionic acid moiety that covalently binds to cysteine-34 on cir | |||
| 29 September 2026 | Deep dive | Deep-dive updated: KPV | KPV |
| KPV (Lys-Pro-Val) is the C-terminal tripeptide corresponding to residues 11 through 13 of alpha-melanocyte-stimulating hormone (alpha-MSH), a neuropeptide with broad anti-inflammatory and immunomodulatory activity. KPV retains most of the anti-inflammatory capacity of the full ho | |||
| 29 September 2026 | Deep dive | Deep-dive updated: Matrixyl (Palmitoyl Pentapeptide) | Matrixyl (Palmitoyl Pentapeptide) |
| Palmitoyl pentapeptide-4 (trade name Matrixyl, developed by Sederma SAS, France) is a synthetic lipopeptide consisting of the pentapeptide KTTKS (Lys-Thr-Thr-Lys-Ser) coupled to a 16-carbon palmitoyl fatty acid chain. It functions as a matrikine — a bioactive signaling fragment t | |||
| 29 September 2026 | Deep dive | Deep-dive updated: Matrixyl 3000 | Matrixyl 3000 |
| Matrixyl 3000 is a commercial matrikine peptide blend developed by Sederma (now a Croda brand) comprising two lipopeptides: palmitoyl tripeptide-1 (Pal-GHK) and palmitoyl tetrapeptide-7 (Pal-GQPR). Both peptides carry a C16 palmitic acid chain that increases lipophilicity and fac | |||
| 28 September 2026 | Peptide | Peptide updated: Pinealon | Pinealon |
| Glu-Asp-Arg (EDR), a synthetic tripeptide from the Khavinson bioregulator programme. No completed randomized human trials have been published. | |||
| 28 September 2026 | Peptide | Peptide updated: Matrixyl (Palmitoyl Pentapeptide) | Matrixyl (Palmitoyl Pentapeptide) |
| Palmitoyl pentapeptide-4 (pal-KTTKS), a cosmetic matrikine studied for dermal collagen renewal in a 12-week split-face randomized trial. | |||
| 28 September 2026 | Peptide | Peptide updated: Groprinosin | Groprinosin |
| Inosine pranobex, a synthetic immunomodulator studied in viral infection. Randomized trials exist; it is not approved in the United States. | |||
| 28 September 2026 | Peptide | Peptide updated: Gonadorelin | Gonadorelin |
| Synthetic decapeptide identical to hypothalamic GnRH; binds pituitary receptors to trigger LH and FSH release. No approved US product remains. | |||
| 28 September 2026 | Peptide | Epitalon — FDA advisory committee recommendation (24 Jul 2026) | Epitalon |
| On 24 July 2026 the FDA Pharmacy Compounding Advisory Committee voted to recommend Epitalon for the 503A Bulks List (reported 7-5, one abstention). Advisory only — not a final FDA decision; Epitalon is not yet on the 503A list and still requires a prescription. | |||
| 28 September 2026 | Peptide | Peptide updated: Epitalon | Epitalon |
| Longevity, telomere support | |||
| 14 September 2026 | Peptide | Peptide updated: Epithalon + Follistatin Stack | Epithalon + Follistatin Stack |
| Anti-aging performance combo | |||
| 14 September 2026 | Peptide | Peptide updated: Thymosin Beta-4 | Thymosin Beta-4 |
| Comprehensive tissue pain relief | |||
| 14 September 2026 | Peptide | Peptide updated: NA-Semax-Amidate | NA-Semax-Amidate |
| Triple modified Semax | |||
| 14 September 2026 | Peptide | Peptide updated: Semax-Amidate | Semax-Amidate |
| Extended release Semax | |||
| 14 September 2026 | Peptide | Peptide updated: Epitalon | Epitalon |
| Longevity, telomere support | |||
| 14 September 2026 | Peptide | Peptide updated: Semax Low Dose | Semax Low Dose |
| Evening cognitive calming | |||
| 14 September 2026 | Peptide | Peptide updated: DSIP | DSIP |
| Delta sleep-inducing peptide | |||
| 14 September 2026 | Peptide | Peptide updated: MOTS-c | MOTS-c |
| Mitochondrial optimization | |||
| 14 September 2026 | Peptide | Peptide updated: TB-500 | TB-500 |
| Tissue repair, flexibility, inflammation | |||
| 14 September 2026 | Peptide | Peptide updated: KPV | KPV |
| Anti-inflammatory immune peptide | |||
| 14 September 2026 | Peptide | Peptide updated: BPC-157 | BPC-157 |
| Healing & recovery, gut health | |||
| 14 September 2026 | Peptide | Peptide updated: Semax | Semax |
| Cognitive enhancement, focus, memory | |||
| 7 September 2026 | FDA approval | New FDA-approved peptide: Rusfertidedailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=101aff01-31ed-4841-a… | Rusfertide |
| MIMRYLO - Treatment of erythrocytosis in adults with polycythemia vera. Approved as an addition to standard-of-care therapy (phlebotomy and/or cytoreductive agents), based on the Phase 3 VERIFY trial. This is a narrow hematology-oncology indication; the approval does not extend t | |||
| 7 September 2026 | Deep dive | Deep-dive published: Rusfertide | Rusfertide |
| Rusfertide is a synthetic peptide mimetic of hepcidin, the body's principal hormonal regulator of systemic iron availability. It binds ferroportin, the sole known cellular iron exporter, and induces its internalization and degradation. By blocking ferroportin-mediated iron export | |||
| 5 September 2026 | Source | New source added to RusfertideProtagonist Therapeutics Announces U.S. FDA Approval of Hepcidin Mimetic Peptide MIMRYLO (rusfertide) for Polycythemia Vera · biospace.com/press-releases/protagonist-thera… | Rusfertide |
| Protagonist Therapeutics, Inc. | |||
| 5 September 2026 | Source | New source added to RusfertideFDA Approves MIMRYLO (rusfertide) for Polycythemia Vera · takeda.com/en-us/newsroom/news-releases/202… | Rusfertide |
| Takeda Pharmaceutical Company Limited | |||
| 5 September 2026 | Source | New source added to RusfertideA Phase 3 Study of the Hepcidin Mimetic Rusfertide (PTG-300) in Patients With Polycythemia Vera (VERIFY) · clinicaltrials.gov/study/NCT05210790 | Rusfertide |
| ClinicalTrials.gov / Protagonist Therapeutics | |||
| 5 September 2026 | Source | New source added to RusfertideMIMRYLO (rusfertide) for injection, for subcutaneous use — prescribing information · dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=101a… | Rusfertide |
| U.S. National Library of Medicine (DailyMed) / Takeda Pharmaceuticals America, Inc. | |||
| 5 September 2026 | Peptide | New peptide added: Rusfertide | Rusfertide |
| A once-weekly injectable hepcidin-mimetic peptide FDA-approved to treat erythrocytosis in adults with polycythemia vera. | |||
| 5 September 2026 | Deep dive | Deep-dive updated: Tirzepatide | Tirzepatide |
| Tirzepatide (LY3298176) is a synthetic 39-amino acid peptide engineered as a dual agonist at the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R). It is acylated at lysine-20 with a C20 fatty diacid chain via a linker, | |||
| 5 September 2026 | Peptide | Peptide updated: Orforglipron | Orforglipron |
| Oral GLP-1 | |||
| 5 September 2026 | FDA approval | FDA approval updated: Dulaglutide | Dulaglutide |
| Trulicity - Type 2 diabetes (Trulicity). Reduction of major adverse cardiovascular events in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors (Trulicity), approved 2020-02-21, based on the REWIND trial. | |||
| 5 September 2026 | FDA approval | FDA approval updated: Tirzepatide | Tirzepatide |
| Mounjaro, Zepbound - Type 2 diabetes (Mounjaro). Chronic weight management (Zepbound). Moderate-to-severe obstructive sleep apnea in adults with obesity (Zepbound), approved 2024-12-20, based on the SURMOUNT-OSA trials. Reduction of major adverse cardiovascular events (cardiovasc | |||
| 5 September 2026 | FDA approval | FDA approval updated: Semaglutide | Semaglutide |
| Ozempic, Wegovy, Rybelsus - Type 2 diabetes (Ozempic). Chronic weight management (Wegovy). Cardiovascular risk reduction in adults with known cardiovascular disease and obesity or overweight (Wegovy), approved 2024-03-08, based on the SELECT trial. Reduction of the risk of kidney | |||
| 4 September 2026 | Research | New research: FDA Approves Trulicity (Dulaglutide) to Reduce Cardiovascular Events in Type 2 Diabetesprnewswire.com/news-releases/trulicity-dulaglutide-is-the-first… | Dulaglutide |
| FDA approved Trulicity (dulaglutide) for reduction of major adverse cardiovascular events (MACE) — nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death — in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk | |||
| 4 September 2026 | Research | New research: FDA Approves Zepbound (Tirzepatide) as First Prescription Medicine for Obstructive Sleep Apneaprnewswire.com/news-releases/fda-approves-zepbound-tirzepatide-… | Tirzepatide |
| FDA approved Zepbound (tirzepatide) as the first and only prescription medicine for moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity, based on the SURMOUNT-OSA trials. Reported results: reductions of roughly 25-29 apnea-hypopnea events per hour versus about | |||
| 4 September 2026 | Research | New research: FDA Approves Mounjaro (Tirzepatide) to Reduce Cardiovascular Risk in Adults With Type 2 Diabetesprnewswire.com/news-releases/fda-approves-lillys-mounjaro-tirze… | Tirzepatide |
| FDA approved Mounjaro (tirzepatide) to reduce the risk of major adverse cardiovascular events (MACE) — cardiovascular death, non-fatal heart attack, or non-fatal stroke — in adults with type 2 diabetes who are at high risk for these events, based on the SURPASS-CVOT trial (13,299 | |||
| 4 September 2026 | Research | New research: FDA Approves Ozempic (Semaglutide) to Reduce Chronic Kidney Disease Progressionprnewswire.com/news-releases/fda-approves-ozempic-semaglutide-a… | Semaglutide |
| FDA approved Ozempic (semaglutide) for a third indication: to reduce the risk of kidney disease worsening, kidney failure (end-stage kidney disease), and death due to cardiovascular disease in adults with type 2 diabetes and chronic kidney disease, based on the FLOW trial. This i | |||
| 4 September 2026 | Research | New research: FDA Approves Wegovy (Semaglutide) for Cardiovascular Risk Reductionprnewswire.com/news-releases/wegovy-receives-fda-approval-for-c… | Semaglutide |
| FDA approved Wegovy (semaglutide) 2.4 mg for an additional indication: to reduce the risk of major cardiovascular events (cardiovascular death, non-fatal heart attack, or non-fatal stroke) in adults with known cardiovascular disease and either obesity or overweight, based on the | |||
| 4 September 2026 | Research | New research: FDA Grants Accelerated Approval to Wegovy (Semaglutide) for MASH With Liver Fibrosisprnewswire.com/news-releases/wegovy-approved-by-fda-for-the-tre… | Semaglutide |
| FDA granted Wegovy (semaglutide) 2.4 mg accelerated approval to treat adults with metabolic dysfunction-associated steatohepatitis (MASH) with moderate-to-advanced liver fibrosis, but not cirrhosis, alongside a reduced-calorie diet and increased physical activity. The approval is | |||
| 4 September 2026 | Research | New research: FDA Approves Wegovy (Semaglutide) Tablets, the First Oral GLP-1 for Weight Managementprnewswire.com/news-releases/fda-approves-novo-nordisks-wegovy-… | Semaglutide |
| FDA approved Wegovy (semaglutide) tablets, an oral once-daily 25 mg formulation, for chronic weight management in adults with obesity or overweight and at least one weight-related condition, and for reduction of major adverse cardiovascular events in adults with overweight or obe | |||
| 4 September 2026 | Research | New research: FDA Approves Higher-Dose Wegovy HD (Semaglutide 7.2 mg) Under National Priority Voucher Programfda.gov/news-events/press-announcements/fda-approves-fou… | Semaglutide |
| FDA approved Wegovy HD (semaglutide injection, 7.2 mg), a higher-dose formulation, to reduce excess body weight and maintain weight reduction long-term in adults with obesity, or overweight with at least one weight-related condition. This was the fourth approval granted under the | |||
| 4 September 2026 | Research | New research: GLP-1 Microdosing: We Finally Have Published Data. Here's What It Actually Showsacademic.oup.com/biomethods/advance-article/doi/10.1093/biomethod… | Semaglutide, Tirzepatide |
| A peer-reviewed retrospective electronic-health-record study compared patients with sustained prescriptions at the lowest marketed initiation doses of semaglutide (0.25 mg) and tirzepatide (2.5 mg). Using a federated EHR system covering 29 million patients, the authors identified | |||
| 4 September 2026 | Research | New research: FDA Warning Letter: “Research Use Only” Labeling Did Not Override Evidence of Intended Human Drug Usefda.gov/inspections-compliance-enforcement-and-criminal-… | Tirzepatide, Semaglutide, Retatrutide, SS-31 (Elamipretide), PT-141, Tesamorelin, Ipamorelin |
| FDA issued a warning letter to Royal Peptides LLC after reviewing its website in July 2026. FDA identified products marketed as tirzepatide, semaglutide, retatrutide, SS-31 (elamipretide), PT-141, tesamorelin and a tesamorelin/ipamorelin blend (BIMORELIN) as unapproved new drugs | |||
| 26 August 2026 | Research | New research: FDA Pharmacy Compounding Advisory Committee Final Summary Minutes (October 29, 2024): Committee Voted Against Adding Ipamorelin, Ibutamoren Mesylate and Kisspeptin-10 to the 503A Bulks Listfda.gov/advisory-committees/advisory-committee-calendar/… | Ipamorelin, MK-677 (Ibutamoren), Kisspeptin |
| Final Summary Minutes of the FDA Pharmacy Compounding Advisory Committee (PCAC) meeting held October 29, 2024 at the FDA White Oak Campus; minutes approved January 15, 2025. The Committee discussed bulk drug substances being considered for inclusion on the 503A Bulks List. FDA pr | |||
| 23 August 2026 | Research | New research: FDA Early Announcement: Pharmacy Compounding Advisory Committee to Consider LL-37, GHK-Cu, Dihexa Acetate, Melanotan II and PEG-MGF for the 503A Bulks List Before the End of February 2027fda.gov/advisory-committees/pharmacy-compounding-advisor… | LL-37, GHK-Cu, Dihexa, Melanotan II |
| FDA early announcement page for a meeting of the Pharmacy Compounding Advisory Committee (PCAC), Center for Drug Evaluation and Research; page content current as of 04/15/2026. FDA states that it "will host an advisory committee meeting before the end of February 2027". Under Age | |||
| 20 August 2026 | Research | New research: FDA Requests Removal of Suicidal Behavior and Ideation Warning from Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Medicationsfda.gov/drugs/drug-safety-communications/fda-requests-re… | Semaglutide, Tirzepatide, Liraglutide |
| FDA Drug Safety Communication dated 01-13-2026, updating FDA's communication of January 30, 2024. FDA is requesting that drug application holders remove information regarding the risk of suicidal ideation and behavior (SI/B) from the labeling of GLP-1 receptor agonist medications | |||
| 13 August 2026 | Deep dive | Deep-dive updated: MOTS-c | MOTS-c |
| MOTS-c is a 16-amino-acid peptide (sequence MRWQEMGYIFYPRKLR) encoded by an open reading frame within the mitochondrial 12S rRNA gene (MT-RNR1). It was characterized by Lee and colleagues in 2015 as the founding member of a class of mitochondria-encoded signaling molecules, somet | |||
| 13 August 2026 | Source | New source added to MOTS-cFDA Briefing Document — Pharmacy Compounding Advisory Committee meeting, July 23-24, 2026: Evaluation of MOTS-c-related Bulk Drug Substances (MOTS-c (free base) and MOTS-c acetate) for Inclusion on the 503A Bulk Drug Substances List · fda.gov/media/193347/download | MOTS-c |
| U.S. Food and Drug Administration, Center for Drug Evaluation and Research | |||
| 12 August 2026 | Deep dive | Deep-dive updated: TB-500 | TB-500 |
| TB-500 is a synthetic heptapeptide (Ac-LKKTETQ), corresponding to residues 17–23 of thymosin beta-4 (Tβ4), the principal actin-sequestering molecule in eukaryotic cells. Its primary molecular action is high-affinity binding to G-actin (globular, monomeric actin), which modulates | |||
| 12 August 2026 | Source | New source added to TB-500FDA Briefing Document — Pharmacy Compounding Advisory Committee meeting, July 23-24, 2026: Evaluation of TB-500-related Bulk Drug Substances (TB-500 (free base) and TB-500 acetate) for Inclusion on the 503A Bulk Drug Substances List · fda.gov/media/193349/download | TB-500 |
| U.S. Food and Drug Administration, Center for Drug Evaluation and Research | |||
| 11 August 2026 | Deep dive | Deep-dive updated: KPV | KPV |
| KPV (Lys-Pro-Val) is the C-terminal tripeptide corresponding to residues 11 through 13 of alpha-melanocyte-stimulating hormone (alpha-MSH), a neuropeptide with broad anti-inflammatory and immunomodulatory activity. KPV retains most of the anti-inflammatory capacity of the full ho | |||
| 11 August 2026 | Source | New source added to KPVFDA Briefing Document — Pharmacy Compounding Advisory Committee meeting, July 23-24, 2026: Evaluation of KPV-related Bulk Drug Substances (KPV (free base) and KPV acetate) for Inclusion on the 503A Bulk Drug Substances List · fda.gov/media/193346/download | KPV |
| U.S. Food and Drug Administration, Center for Drug Evaluation and Research | |||
| 10 August 2026 | Deep dive | Deep-dive updated: BPC-157 | BPC-157 |
| BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from a protective protein found in gastric juice. It promotes healing through multiple mechanisms: • Angiogenesis: Stimulates formation of new blood vessels via VEGF pathway, improving blood flow to i | |||
| 10 August 2026 | Source | New source added to BPC-157FDA Briefing Document — Pharmacy Compounding Advisory Committee meeting, July 23-24, 2026: bulk drug substances nominated for the 503A Bulks List (introduction and points to consider) · fda.gov/media/193342/download | BPC-157 |
| U.S. Food and Drug Administration, Center for Drug Evaluation and Research | |||
| 4 August 2026 | FDA approval | New FDA-approved peptide: Elamipretideaccessdata.fda.gov/drugsatfda_docs/label/2025/215244s000lbl.pdf | Elamipretide |
| Forzinity - Accelerated approval — Barth syndrome only. Indicated to improve muscle strength in adult and pediatric patients with Barth syndrome weighing at least 30 kg. Continued approval for this indication may be contingent upon verification and description of clinical benefit | |||
| 3 August 2026 | Research | New research: FDA Publishes 17 Revised Draft Product-Specific Guidances for Generic Peptide Products, and Withdraws the 2021 Synthetic Peptide ANDA Guidancefda.gov/drugs/drug-alerts-and-statements/fda-publishes-r… | Semaglutide, Tirzepatide, Liraglutide, Teriparatide, Calcitonin |
| FDA Drug Alert dated 7/28/2026. FDA published 17 revised draft product-specific guidances (PSGs) for peptide products. The listed products include calcitonin salmon (CALCIMAR NDA 017769; MIACALCIN NDA 017808), dasiglucagon hydrochloride (ZEGALOGUE NDA 214231), glucagon (BAQSIMI N | |||
| 1 August 2026 | Deep dive | Deep-dive published: Somatropin | Somatropin |
| Somatropin is recombinant human growth hormone: a 191-amino-acid polypeptide of molecular weight 22,124 daltons, expressed in Escherichia coli, with an amino acid sequence identical to growth hormone of human pituitary origin. It replaces endogenous growth hormone rather than sti | |||
| 31 July 2026 | Source | Source updated in SomatropinGuidelines for Growth Hormone and Insulin-Like Growth Factor-I Treatment in Children and Adolescents: Growth Hormone Deficiency, Idiopathic Short Stature, and Primary Insulin-Like Growth Factor-I Deficiency · pubmed.ncbi.nlm.nih.gov/27884013/ | Somatropin |
| Hormone Research in Paediatrics | |||
| 31 July 2026 | Source | Source updated in SomatropinEvaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline · pubmed.ncbi.nlm.nih.gov/21602453/ | Somatropin |
| The Journal of Clinical Endocrinology & Metabolism | |||
| 31 July 2026 | Source | New source added to Somatropin21 U.S. Code 333(e) - Prohibited distribution of human growth hormone · law.cornell.edu/uscode/text/21/333 | Somatropin |
| Legal Information Institute, Cornell Law School | |||
| 31 July 2026 | Source | New source added to SomatropinThe effect of treatment with recombinant human growth hormone (rhGH) on linear growth and adult height in children with idiopathic short stature (ISS): a systematic review and meta-analysis · pubmed.ncbi.nlm.nih.gov/33035189/ | Somatropin |
| Journal of Pediatric Endocrinology & Metabolism | |||
| 31 July 2026 | Source | New source added to SomatropinAssociation Between Recombinant Growth Hormone Therapy and All-Cause Mortality and Cancer Risk in Childhood: Systematic Review and Meta-Analysis · pubmed.ncbi.nlm.nih.gov/35529328/ | Somatropin |
| Frontiers in Pediatrics | |||
| 31 July 2026 | Source | New source added to SomatropinLong-term mortality after childhood growth hormone treatment: the SAGhE cohort study · pubmed.ncbi.nlm.nih.gov/32707116/ | Somatropin |
| The Lancet Diabetes & Endocrinology | |||
| 31 July 2026 | Source | New source added to SomatropinGuidelines for Growth Hormone and Insulin-Like Growth Factor-I Treatment in Children and Adolescents: Growth Hormone Deficiency, Idiopathic Short Stature, and Primary Insulin-Like Growth Factor-I Deficiency · pubmed.ncbi.nlm.nih.gov/27884013/ | Somatropin |
| Hormone Research in Paediatrics | |||
| 31 July 2026 | Source | New source added to SomatropinEvaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline · pubmed.ncbi.nlm.nih.gov/21602453/ | Somatropin |
| The Journal of Clinical Endocrinology & Metabolism | |||
| 31 July 2026 | Source | New source added to SomatropinGENOTROPIN (somatropin) for injection - full prescribing information · dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ffeb… | Somatropin |
| U.S. National Library of Medicine, DailyMed (Pfizer Laboratories Div Pfizer Inc) | |||
| 31 July 2026 | Peptide | New peptide added: Somatropin | Somatropin |
| Recombinant human growth hormone, FDA-approved for growth failure in children and growth hormone deficiency in adults. | |||
| 26 July 2026 | Peptide | Peptide updated: Gonadorelin | Gonadorelin |
| GnRH for fertility | |||
| 26 July 2026 | Peptide | Peptide updated: Sermorelin | Sermorelin |
| GHRH for natural GH release | |||
| 26 July 2026 | Peptide | Peptide updated: Oxytocin | Oxytocin |
| Bonding and relaxation hormone | |||
| 26 July 2026 | Peptide | Peptide updated: Pramlintide | Pramlintide |
| Amylin analog for diabetes | |||
| 17 July 2026 | Peptide | Peptide updated: Epitalon | Epitalon |
| Longevity, telomere support | |||
| 1 July 2026 | Peptide | Peptide updated: Tesamorelin | Tesamorelin |
| GHRH for visceral fat | |||
| 1 July 2026 | Peptide | Peptide updated: Dulaglutide | Dulaglutide |
| Weekly GLP-1 (Trulicity) | |||
| 1 July 2026 | Peptide | Peptide updated: Calcitonin | Calcitonin |
| FDA-approved bone resorption inhibitor | |||
| 1 July 2026 | Peptide | Peptide updated: Abaloparatide | Abaloparatide |
| Advanced bone anabolic | |||
| 1 July 2026 | Peptide | Peptide updated: Teriparatide | Teriparatide |
| FDA-approved bone builder | |||
| 18 June 2026 | Peptide | Peptide updated: Insulin | Insulin |
| The foundational peptide hormone for glycemic management in type 1 and type 2 diabetes mellitus. | |||
| 18 June 2026 | Peptide | Peptide updated: Bivalirudin | Bivalirudin |
| FDA-approved synthetic peptide direct thrombin inhibitor used for anticoagulation during PCI, including in HIT patients. | |||
| 18 June 2026 | Peptide | Peptide updated: Exenatide | Exenatide |
| FDA-approved GLP-1 receptor agonist for type 2 diabetes; the first incretin mimetic approved in the US. | |||
| 18 June 2026 | Peptide | Peptide updated: Desmopressin | Desmopressin |
| Synthetic ADH analog (DDAVP) FDA-approved for diabetes insipidus, nocturnal enuresis, and bleeding disorders | |||
| 18 June 2026 | Peptide | Peptide updated: Pasireotide | Pasireotide |
| Multi-receptor somatostatin analog (Signifor/Signifor LAR) FDA-approved for Cushing's disease and acromegaly. | |||
| 18 June 2026 | Peptide | Peptide updated: Lanreotide | Lanreotide |
| FDA-approved long-acting somatostatin analog for acromegaly, GEP-NETs, and carcinoid syndrome | |||
| 18 June 2026 | Peptide | Peptide updated: Octreotide | Octreotide |
| FDA-approved somatostatin analog for acromegaly, carcinoid syndrome, and VIPomas since 1988 | |||
| 18 June 2026 | Peptide | Peptide updated: GLOW Stack | GLOW Stack |
| Trending injectable research blend of GHK-Cu, BPC-157 and TB-500, marketed for skin rejuvenation and tissue recovery. Not FDA-approved; sold as a research chemical. | |||
| 18 June 2026 | Peptide | Peptide updated: Bulevirtide | Bulevirtide |
| First/only FDA-approved treatment for chronic hepatitis delta virus (HDV). FDA accelerated approval May 22, 2026. Brand: Hepcludex (Gilead). | |||
| 18 June 2026 | Peptide | Peptide updated: Pegzilarginase-nbln | Pegzilarginase-nbln |
| PEGylated recombinant arginase enzyme for Arginase 1 Deficiency. FDA approved February 23, 2026. | |||
| 18 June 2026 | Peptide | Peptide updated: Navepegritide | Navepegritide |
| PEGylated CNP analog for achondroplasia. FDA approved February 27, 2026. | |||
| 18 June 2026 | Peptide | Peptide updated: Icotrokinra | Icotrokinra |
| Oral macrocyclic peptide. First-in-class IL-23 receptor antagonist. FDA approved March 17, 2026 for plaque psoriasis. | |||
| 18 June 2026 | Peptide | Peptide updated: NMN (Nicotinamide Mononucleotide) | NMN (Nicotinamide Mononucleotide) |
| NAD+ direct precursor nucleotide; key longevity compound. | |||
| 18 June 2026 | Peptide | Peptide updated: Collagen Peptides | Collagen Peptides |
| Structural bone and joint support | |||
| 18 June 2026 | Peptide | Peptide updated: Calcitonin | Calcitonin |
| FDA-approved bone resorption inhibitor | |||
| 18 June 2026 | Peptide | Peptide updated: Abaloparatide | Abaloparatide |
| Advanced bone anabolic | |||
| 18 June 2026 | Peptide | Peptide updated: Teriparatide | Teriparatide |
| FDA-approved bone builder | |||
| 18 June 2026 | Peptide | Peptide updated: Prostatilen | Prostatilen |
| Prostate and male hormone support | |||
| 18 June 2026 | Peptide | Peptide updated: Thyreogen | Thyreogen |
| Thyroid function support | |||
| 18 June 2026 | Peptide | Peptide updated: DHEA Peptide | DHEA Peptide |
| Hormone precursor support | |||
| 18 June 2026 | Peptide | Peptide updated: Oxytocin | Oxytocin |
| Bonding and relaxation hormone | |||
| 18 June 2026 | Peptide | Peptide updated: PT-141 | PT-141 |
| Sexual function peptide | |||
| 18 June 2026 | Peptide | Peptide updated: HCG (Human Chorionic Gonadotropin) | HCG (Human Chorionic Gonadotropin) |
| Testosterone production support | |||
| 18 June 2026 | Peptide | Peptide updated: Gonadorelin | Gonadorelin |
| GnRH for fertility | |||
| 18 June 2026 | Peptide | Peptide updated: Kisspeptin | Kisspeptin |
| Reproductive hormone regulator | |||
| 18 June 2026 | Peptide | Peptide updated: Thymosin Beta-4 | Thymosin Beta-4 |
| Comprehensive tissue pain relief | |||
| 18 June 2026 | Peptide | Peptide updated: Actovegin | Actovegin |
| Hypoxic pain and healing | |||
| 18 June 2026 | Peptide | Peptide updated: PEA (Palmitoylethanolamide) | PEA (Palmitoylethanolamide) |
| Natural pain modulator | |||
| 18 June 2026 | Peptide | Peptide updated: ARA-290 | ARA-290 |
| Neuropathic pain specialist | |||
| 18 June 2026 | Peptide | Peptide updated: Semax Low Dose | Semax Low Dose |
| Evening cognitive calming | |||
| 18 June 2026 | Peptide | Peptide updated: Glycine Peptide | Glycine Peptide |
| Sleep quality amino peptide | |||
| 18 June 2026 | Peptide | Peptide updated: Pinealon | Pinealon |
| Pineal gland bioregulator | |||
| 18 June 2026 | Peptide | Peptide updated: Melatonin Peptide Complex | Melatonin Peptide Complex |
| Enhanced melatonin delivery | |||
| 18 June 2026 | Peptide | Peptide updated: Epithalon | Epithalon |
| Circadian rhythm regulator | |||
| 18 June 2026 | Peptide | Peptide updated: DSIP | DSIP |
| Delta sleep-inducing peptide | |||
| 18 June 2026 | Peptide | Peptide updated: AMP-K | AMP-K |
| Metabolic immune support | |||
| 18 June 2026 | Peptide | Peptide updated: KPV | KPV |
| Anti-inflammatory immune peptide | |||
| 18 June 2026 | Peptide | Peptide updated: Splenopentin | Splenopentin |
| Spleen-derived immune peptide | |||
| 18 June 2026 | Peptide | Peptide updated: Beta-Glucan Peptide | Beta-Glucan Peptide |
| Immune activating complex | |||
| 18 June 2026 | Peptide | Peptide updated: Groprinosin | Groprinosin |
| Antiviral immune booster | |||
| 18 June 2026 | Peptide | Peptide updated: Imunofan | Imunofan |
| Russian immune peptide | |||
| 18 June 2026 | Peptide | Peptide updated: Vilon | Vilon |
| Simple immune dipeptide | |||
| 18 June 2026 | Peptide | Peptide updated: Vladonix | Vladonix |
| Thymus bioregulator complex | |||
| 18 June 2026 | Peptide | Peptide updated: Thymalin | Thymalin |
| Thymus restoration peptide | |||
| 18 June 2026 | Peptide | Peptide updated: LL-37 | LL-37 |
| Antimicrobial defense peptide | |||
| 18 June 2026 | Peptide | Peptide updated: Hexapeptide-11 | Hexapeptide-11 |
| Cell renewal peptide | |||
| 18 June 2026 | Peptide | Peptide updated: Palmitoyl Tripeptide-5 | Palmitoyl Tripeptide-5 |
| Collagen booster | |||
| 18 June 2026 | Peptide | Peptide updated: Copper Peptide GHK-Cu | Copper Peptide GHK-Cu |
| Multi-functional skin peptide | |||
| 18 June 2026 | Peptide | Peptide updated: Snap-8 | Snap-8 |
| Enhanced Argireline | |||
| 18 June 2026 | Peptide | Peptide updated: Syn-Coll | Syn-Coll |
| Collagen synthesis peptide | |||
| 18 June 2026 | Peptide | Peptide updated: Matrixyl 3000 | Matrixyl 3000 |
| Advanced collagen booster | |||
| 18 June 2026 | Peptide | Peptide updated: Argireline (Acetyl Hexapeptide-8) | Argireline (Acetyl Hexapeptide-8) |
| Botox-like peptide | |||
| 18 June 2026 | Peptide | Peptide updated: Urolithin A | Urolithin A |
| Mitochondrial health compound | |||
| 18 June 2026 | Peptide | Peptide updated: Ovagen | Ovagen |
| Digestive system bioregulator | |||
| 18 June 2026 | Peptide | Peptide updated: Cortagen | Cortagen |
| Brain bioregulator | |||
| 18 June 2026 | Peptide | Peptide updated: Memantine | Memantine |
| NMDA antagonist | |||
| 18 June 2026 | Peptide | Peptide updated: RG3 (Rhodiola) | RG3 (Rhodiola) |
| Adaptogenic peptide | |||
| 18 June 2026 | Peptide | Peptide updated: FGL (Fibroblast Growth Loop) | FGL (Fibroblast Growth Loop) |
| NCAM mimetic | |||
| 18 June 2026 | Peptide | Peptide updated: Cortexin | Cortexin |
| Neuropeptide complex | |||
| 18 June 2026 | Peptide | Peptide updated: P21 (Adamax) | P21 (Adamax) |
| Neurogenic peptide | |||
| 18 June 2026 | Peptide | Peptide updated: NA-Semax-Amidate | NA-Semax-Amidate |
| Triple modified Semax | |||
| 18 June 2026 | Peptide | Peptide updated: Selank-Amidate | Selank-Amidate |
| Extended release Selank | |||
| 18 June 2026 | Peptide | Peptide updated: Semax-Amidate | Semax-Amidate |
| Extended release Semax | |||
| 18 June 2026 | Peptide | Peptide updated: HGH Fragment 176-191 | HGH Fragment 176-191 |
| Fat loss without GH effects | |||
| 18 June 2026 | Peptide | Peptide updated: Epithalon + Follistatin Stack | Epithalon + Follistatin Stack |
| Anti-aging performance combo | |||
| 18 June 2026 | Peptide | Peptide updated: YK-11 | YK-11 |
| Myostatin inhibitor | |||
| 18 June 2026 | Peptide | Peptide updated: ACE-031 | ACE-031 |
| Myostatin inhibitor | |||
| 18 June 2026 | Peptide | Peptide updated: TB4-FRAG | TB4-FRAG |
| TB-500 fragment | |||
| 18 June 2026 | Peptide | Peptide updated: GHRP-4 | GHRP-4 |
| Fourth generation GHRP | |||
| 18 June 2026 | Peptide | Peptide updated: Tesamorelin | Tesamorelin |
| GHRH for visceral fat | |||
| 18 June 2026 | Peptide | Peptide updated: Sermorelin | Sermorelin |
| GHRH for natural GH release | |||
| 18 June 2026 | Peptide | Peptide updated: Fragment 176-191 | Fragment 176-191 |
| HGH fragment for fat loss | |||
| 18 June 2026 | Peptide | Peptide updated: Leptin | Leptin |
| Satiety hormone | |||
| 18 June 2026 | Peptide | Peptide updated: Pramlintide | Pramlintide |
| Amylin analog for diabetes | |||
| 18 June 2026 | Peptide | Peptide updated: CagriSema | CagriSema |
| Combination therapy | |||
| 18 June 2026 | Peptide | Peptide updated: Retatrutide | Retatrutide |
| Investigational triple agonist (GIP/GLP-1/glucagon). TRIUMPH-1 Phase 3 (May 2026): 28.3% body weight loss at 80 weeks. FDA submission anticipated Q3–Q4 2026. | |||
| 18 June 2026 | Peptide | Peptide updated: Orforglipron | Orforglipron |
| Oral GLP-1 | |||
| 18 June 2026 | Peptide | Peptide updated: Dulaglutide | Dulaglutide |
| Weekly GLP-1 (Trulicity) | |||
| 18 June 2026 | Peptide | Peptide updated: Liraglutide | Liraglutide |
| FDA-approved GLP-1 for weight loss | |||
| 18 June 2026 | Peptide | Peptide updated: Ghrelinomimetic | Ghrelinomimetic |
| Appetite and healing support | |||
| 18 June 2026 | Peptide | Peptide updated: BPC-157 Stable | BPC-157 Stable |
| Stabilized BPC variant | |||
| 18 June 2026 | Peptide | Peptide updated: Pentosan Polysulfate | Pentosan Polysulfate |
| Joint and bladder support | |||
| 18 June 2026 | Peptide | Peptide updated: Larazotide | Larazotide |
| Gut permeability regulator | |||
| 18 June 2026 | Peptide | Peptide updated: Melanotan II | Melanotan II |
| Tanning, libido | |||
| 18 June 2026 | Peptide | Peptide updated: Copper Peptides | Copper Peptides |
| Skin regeneration | |||
| 18 June 2026 | Peptide | Peptide updated: Matrixyl (Palmitoyl Pentapeptide) | Matrixyl (Palmitoyl Pentapeptide) |
| Anti-aging skincare | |||
| 18 June 2026 | Peptide | Peptide updated: SS-31 (Elamipretide) | SS-31 (Elamipretide) |
| Mitochondrial optimization | |||
| 18 June 2026 | Peptide | Peptide updated: Humanin | Humanin |
| Mitochondrial protection, longevity | |||
| 18 June 2026 | Peptide | Peptide updated: Epitalon | Epitalon |
| Longevity, telomere support | |||
| 18 June 2026 | Peptide | Peptide updated: Cerebrolysin | Cerebrolysin |
| Neuroprotection, recovery | |||
| 18 June 2026 | Peptide | Peptide updated: NSI-189 | NSI-189 |
| Neurogenesis, depression | |||
| 18 June 2026 | Peptide | Peptide updated: Dihexa | Dihexa |
| Potent cognitive enhancer | |||
| 18 June 2026 | Peptide | Peptide updated: Selank | Selank |
| Anxiety reduction, focus | |||
| 18 June 2026 | Peptide | Peptide updated: Semax | Semax |
| Cognitive enhancement, focus, memory | |||
| 18 June 2026 | Peptide | Peptide updated: Hexarelin | Hexarelin |
| Potent GH releaser | |||
| 18 June 2026 | Peptide | Peptide updated: MK-677 (Ibutamoren) | MK-677 (Ibutamoren) |
| Oral GH secretagogue | |||
| 18 June 2026 | Peptide | Peptide updated: Ipamorelin | Ipamorelin |
| GH secretagogue, anti-aging | |||
| 18 June 2026 | Peptide | Peptide updated: CJC-1295 | CJC-1295 |
| Growth hormone, muscle mass, fat loss | |||
| 18 June 2026 | Peptide | Peptide updated: MOTS-c | MOTS-c |
| Mitochondrial optimization | |||
| 18 June 2026 | Peptide | Peptide updated: AOD-9604 | AOD-9604 |
| Fat loss, metabolic enhancement | |||
| 18 June 2026 | Peptide | Peptide updated: Tirzepatide | Tirzepatide |
| Dual GIP/GLP-1 agonist for weight loss | |||
| 18 June 2026 | Peptide | Peptide updated: Semaglutide | Semaglutide |
| Weight loss, blood sugar control | |||
| 18 June 2026 | Peptide | Peptide updated: Thymosin Alpha-1 | Thymosin Alpha-1 |
| Immune system support | |||
| 18 June 2026 | Peptide | Peptide updated: GHK-Cu | GHK-Cu |
| Wound healing, skin regeneration | |||
| 18 June 2026 | Peptide | Peptide updated: TB-500 | TB-500 |
| Tissue repair, flexibility, inflammation | |||
| 18 June 2026 | Peptide | Peptide updated: BPC-157 | BPC-157 |
| Healing & recovery, gut health | |||
| 15 June 2026 | Source | Source updated in InsulinIntensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) · pubmed.ncbi.nlm.nih.gov/9742976/ | Insulin |
| The Lancet | |||
| 15 June 2026 | Source | New source added to InsulinUKPDS 33 Study Summary — Wiki Journal Club · wikijournalclub.org/wiki/UKPDS_33 | Insulin |
| Wiki Journal Club | |||
| 15 June 2026 | Source | New source added to InsulinIntensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) — The Lancet 1998 · thelancet.com/journals/lancet/article/PIIS0140… | Insulin |
| The Lancet | |||
| 15 June 2026 | Source | New source added to InsulinBlood Glucose Control Studies for Type 1 Diabetes: DCCT and EDIC — NIDDK · niddk.nih.gov/about-niddk/research-areas/diabe… | Insulin |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | |||
| 15 June 2026 | Source | New source added to InsulinInsulin: Pharmacology, Therapeutic Regimens and Principles of Intensive Insulin Therapy — Endotext (NCBI Bookshelf NBK278938) · ncbi.nlm.nih.gov/books/NBK278938/ | Insulin |
| MDText.com / NCBI Bookshelf | |||
| 15 June 2026 | Source | New source added to InsulinLantus (insulin glargine injection) Prescribing Information — FDA accessdata · accessdata.fda.gov/drugsatfda_docs/label/2019/02108… | Insulin |
| U.S. Food and Drug Administration / Sanofi | |||
| 15 June 2026 | Source | New source added to InsulinHUMULIN R (insulin human) Prescribing Information — DailyMed · dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b519… | Insulin |
| U.S. National Library of Medicine / DailyMed | |||
| 15 June 2026 | Peptide | New peptide added: Insulin | Insulin |
| The foundational peptide hormone for glycemic management in type 1 and type 2 diabetes mellitus. | |||
| 15 June 2026 | Source | Source updated in BivalirudinBivalirudin during primary PCI in acute myocardial infarction (HORIZONS-AMI) · pubmed.ncbi.nlm.nih.gov/18499566/ | Bivalirudin |
| New England Journal of Medicine | |||
| 15 June 2026 | Source | New source added to BivalirudinSafety and Efficacy of Bivalirudin with Glycoprotein IIb/IIIa for High-Risk Percutaneous Coronary Intervention (Deshpande et al., Indian Heart Journal 2012) · pmc.ncbi.nlm.nih.gov/articles/PMC3860907/ | Bivalirudin |
| Indian Heart Journal / PMC | |||
| 15 June 2026 | Source | New source added to BivalirudinBivalirudin Versus Heparin During PCI in NSTEMI: Individual Patient Data Meta-Analysis of Large Randomized Trials · ahajournals.org/doi/10.1161/CIRCULATIONAHA.123.0… | Bivalirudin |
| Circulation (American Heart Association) | |||
| 15 June 2026 | Source | New source added to BivalirudinBivalirudin — Wikidoc (chemical structure, pharmacokinetics, approval history) · wikidoc.org/index.php/Bivalirudin | Bivalirudin |
| Wikidoc | |||
| 15 June 2026 | Source | New source added to BivalirudinBivalirudin or Unfractionated Heparin in Acute Coronary Syndromes — MATRIX Trial (Valgimigli et al., NEJM 2015) · nejm.org/doi/full/10.1056/NEJMoa1507854 | Bivalirudin |
| New England Journal of Medicine | |||
| 15 June 2026 | Source | New source added to BivalirudinBivalirudin for Patients with Acute Coronary Syndromes — ACUITY Trial (Stone et al., NEJM 2006) · nejm.org/doi/full/10.1056/NEJMoa062437 | Bivalirudin |
| New England Journal of Medicine | |||
| 15 June 2026 | Source | New source added to BivalirudinHORIZONS-AMI Trial Summary — Wiki Journal Club (Stone et al., NEJM 2008; PMID 18499566) · wikijournalclub.org/wiki/HORIZONS-AMI | Bivalirudin |
| Wiki Journal Club | |||
| 15 June 2026 | Source | New source added to BivalirudinBivalirudin and Provisional Glycoprotein IIb/IIIa Blockade Compared With Heparin and Planned Glycoprotein IIb/IIIa Blockade During Percutaneous Coronary Intervention: REPLACE-2 Randomized Trial (Lincoff et al., JAMA 2003) · jamanetwork.com/journals/jama/fullarticle/195991 | Bivalirudin |
| JAMA (American Medical Association) | |||
| 15 June 2026 | Source | New source added to BivalirudinDailyMed: ANGIOMAX (bivalirudin) for injection — FDA Prescribing Information · dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5f13… | Bivalirudin |
| U.S. National Library of Medicine / FDA | |||
| 15 June 2026 | Peptide | New peptide added: Bivalirudin | Bivalirudin |
| FDA-approved synthetic peptide direct thrombin inhibitor used for anticoagulation during PCI, including in HIT patients. | |||
| 15 June 2026 | Source | New source added to ExenatideExenatide once weekly: clinical outcomes and patient satisfaction (DURATION-1 data) · pmc.ncbi.nlm.nih.gov/articles/PMC2943223/ | Exenatide |
| Drug Design, Development and Therapy | |||
| 15 June 2026 | Source | New source added to ExenatideExenatide once weekly improved glycaemic control, cardiometabolic risk factors and a composite index of an HbA1c < 7%, without weight gain or hypoglycaemia, over 52 weeks · pmc.ncbi.nlm.nih.gov/articles/PMC3593159/ | Exenatide |
| Diabetes, Obesity and Metabolism | |||
| 15 June 2026 | Source | New source added to ExenatideEvolution of Exenatide as a Diabetes Therapeutic · pmc.ncbi.nlm.nih.gov/articles/PMC3664512/ | Exenatide |
| BioMed Research International | |||
| 15 June 2026 | Source | New source added to ExenatideExenatide Once-Weekly Clinical Development: Safety and Efficacy Across a Range of Background Therapies (DURATION program review) · pmc.ncbi.nlm.nih.gov/articles/PMC3303092/ | Exenatide |
| Clinical Therapeutics | |||
| 15 June 2026 | Source | New source added to ExenatideEXSCEL Trial Summary — American College of Cardiology · acc.org/Latest-in-Cardiology/Clinical-Tr… | Exenatide |
| American College of Cardiology | |||
| 15 June 2026 | Source | New source added to ExenatideEffects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes (EXSCEL trial) · nejm.org/doi/full/10.1056/NEJMoa1612917 | Exenatide |
| New England Journal of Medicine | |||
| 15 June 2026 | Source | New source added to ExenatideHighlights of Prescribing Information — BYDUREON BCise (exenatide extended-release), NDA 022200 (2024 label) · accessdata.fda.gov/drugsatfda_docs/label/2024/02220… | Exenatide |
| U.S. Food and Drug Administration | |||
| 15 June 2026 | Source | New source added to ExenatideBYETTA (exenatide) Prescribing Information — FDA/accessdata (2020 label, NDA 021773) · accessdata.fda.gov/drugsatfda_docs/label/2020/02177… | Exenatide |
| U.S. Food and Drug Administration | |||
| 15 June 2026 | Peptide | New peptide added: Exenatide | Exenatide |
| FDA-approved GLP-1 receptor agonist for type 2 diabetes; the first incretin mimetic approved in the US. | |||
| 15 June 2026 | Source | New source added to DesmopressinDesmopressin for nocturnal enuresis in children (Cochrane Review) · pubmed.ncbi.nlm.nih.gov/12137645/ | Desmopressin |
| Cochrane Database of Systematic Reviews / PubMed | |||
| 15 June 2026 | Source | New source added to DesmopressinModern Approach in Treatment of Diabetes Insipidus · pmc.ncbi.nlm.nih.gov/articles/PMC7214070/ | Desmopressin |
| PMC / NLM | |||
| 15 June 2026 | Source | New source added to DesmopressinDesmopressin in combination with anticholinergic agents in the treatment of nocturnal enuresis: a systematic review and meta-analysis · pmc.ncbi.nlm.nih.gov/articles/PMC10620680/ | Desmopressin |
| PMC / NLM | |||
| 15 June 2026 | Source | New source added to DesmopressinA Review of Desmopressin Use in Bleeding Disorders: An Unsung Hero? · pmc.ncbi.nlm.nih.gov/articles/PMC12292229/ | Desmopressin |
| MDPI Biomolecules | |||
| 15 June 2026 | Source | New source added to DesmopressinDDAVP (desmopressin acetate) Tablets — Prescribing Information · dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6d55… | Desmopressin |
| U.S. National Library of Medicine / DailyMed | |||
| 15 June 2026 | Source | New source added to DesmopressinDDAVP (desmopressin acetate) Injection — Full Prescribing Information · dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?seti… | Desmopressin |
| U.S. National Library of Medicine / DailyMed | |||
| 15 June 2026 | Peptide | New peptide added: Desmopressin | Desmopressin |
| Synthetic ADH analog (DDAVP) FDA-approved for diabetes insipidus, nocturnal enuresis, and bleeding disorders | |||
| 15 June 2026 | Source | New source added to PasireotidePasireotide, a multi-somatostatin receptor ligand with potential efficacy for treatment of pituitary and neuroendocrine tumors · pubmed.ncbi.nlm.nih.gov/23462624/ | Pasireotide |
| Drugs Today (Barcelona) | |||
| 15 June 2026 | Source | New source added to PasireotideHyperglycemia induced by pasireotide in patients with Cushing's disease or acromegaly · pmc.ncbi.nlm.nih.gov/articles/PMC4996868/ | Pasireotide |
| PubMed Central | |||
| 15 June 2026 | Source | New source added to PasireotideClinical use of pasireotide for Cushing's disease in adults · pmc.ncbi.nlm.nih.gov/articles/PMC4370333/ | Pasireotide |
| PubMed Central | |||
| 15 June 2026 | Source | New source added to PasireotidePasireotide — a novel somatostatin receptor ligand after 20 years of use · pmc.ncbi.nlm.nih.gov/articles/PMC9156514/ | Pasireotide |
| PubMed Central | |||
| 15 June 2026 | Source | New source added to PasireotidePasireotide versus octreotide or lanreotide in inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial · thelancet.com/journals/landia/article/PIIS2213… | Pasireotide |
| Lancet Diabetes and Endocrinology | |||
| 15 June 2026 | Source | New source added to PasireotideA 12-Month Phase 3 Study of Pasireotide in Cushing's Disease (B2305) · nejm.org/doi/full/10.1056/NEJMoa1105743 | Pasireotide |
| New England Journal of Medicine | |||
| 15 June 2026 | Source | New source added to PasireotideDailyMed: SIGNIFOR (pasireotide diaspartate) injection — Full Prescribing Information · dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a09a… | Pasireotide |
| U.S. National Library of Medicine / FDA | |||
| 15 June 2026 | Source | New source added to PasireotideDailyMed: SIGNIFOR LAR (pasireotide) for injectable suspension — Full Prescribing Information · dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a0aa… | Pasireotide |
| U.S. National Library of Medicine / FDA | |||
| 15 June 2026 | Peptide | New peptide added: Pasireotide | Pasireotide |
| Multi-receptor somatostatin analog (Signifor/Signifor LAR) FDA-approved for Cushing's disease and acromegaly. | |||
| 15 June 2026 | Source | New source added to LanreotideTreatment of neuroendocrine tumors: new recommendations based on the CLARINET study · pmc.ncbi.nlm.nih.gov/articles/PMC4709401/ | Lanreotide |
| Cancer Treatment Reviews | |||
| 15 June 2026 | Source | New source added to LanreotideEfficacy of lanreotide Autogel administered every 4-8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: a phase III trial · pubmed.ncbi.nlm.nih.gov/16918950/ | Lanreotide |
| Clinical Endocrinology (Oxford) | |||
| 15 June 2026 | Source | New source added to LanreotideEvaluation of Lanreotide Depot/Autogel Efficacy and Safety as a Carcinoid Syndrome Treatment (ELECT): A Randomized, Double-Blind, Placebo-Controlled Trial · pubmed.ncbi.nlm.nih.gov/27214300/ | Lanreotide |
| Endocrine Practice | |||
| 15 June 2026 | Source | New source added to LanreotideLanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study · pubmed.ncbi.nlm.nih.gov/33052555/ | Lanreotide |
| Endocrine | |||
| 15 June 2026 | Source | New source added to LanreotideLanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors (CLARINET trial) · pubmed.ncbi.nlm.nih.gov/25014687/ | Lanreotide |
| New England Journal of Medicine | |||
| 15 June 2026 | Source | New source added to LanreotideSOMATULINE DEPOT (lanreotide acetate) - Full Prescribing Information, DailyMed · dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?seti… | Lanreotide |
| Ipsen Biopharmaceuticals / U.S. National Library of Medicine | |||
| 15 June 2026 | Peptide | New peptide added: Lanreotide | Lanreotide |
| FDA-approved long-acting somatostatin analog for acromegaly, GEP-NETs, and carcinoid syndrome | |||
| 15 June 2026 | Source | New source added to OctreotideOctreotide Long-Acting Repeatable in the Treatment of Neuroendocrine Tumors: Patient Selection and Perspectives · pmc.ncbi.nlm.nih.gov/articles/PMC5723116/ | Octreotide |
| OncoTargets and Therapy | |||
| 15 June 2026 | Source | New source added to OctreotideEfficacy of Octreotide Long-Acting Repeatable in Neuroendocrine Tumors: RADIANT-2 Placebo Arm Post Hoc Analysis · pmc.ncbi.nlm.nih.gov/articles/PMC4609826/ | Octreotide |
| Oncologist | |||
| 15 June 2026 | Source | New source added to OctreotideA Prospective Multicentre Study to Investigate the Efficacy, Safety and Tolerability of Octreotide LAR in the Primary Therapy of Patients with Acromegaly · pmc.ncbi.nlm.nih.gov/articles/PMC1974838/ | Octreotide |
| European Journal of Endocrinology | |||
| 15 June 2026 | Source | New source added to OctreotidePhase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors (NETTER-1) · pmc.ncbi.nlm.nih.gov/articles/PMC5895095/ | Octreotide |
| New England Journal of Medicine | |||
| 15 June 2026 | Source | New source added to OctreotidePlacebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients with Metastatic Neuroendocrine Midgut Tumors (PROMID): Results of Long-Term Survival · pubmed.ncbi.nlm.nih.gov/26731483/ | Octreotide |
| Neuroendocrinology / Karger | |||
| 15 June 2026 | Source | New source added to OctreotideDailyMed: Octreotide Acetate for Injectable Suspension (Sandostatin LAR Depot) — Full Prescribing Information · dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d973… | Octreotide |
| NLM / FDA | |||
| 15 June 2026 | Source | New source added to OctreotideDailyMed: Octreotide Acetate Injection, Solution (Sandostatin) — Full Prescribing Information · dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7ce2… | Octreotide |
| NLM / FDA | |||
| 15 June 2026 | Peptide | New peptide added: Octreotide | Octreotide |
| FDA-approved somatostatin analog for acromegaly, carcinoid syndrome, and VIPomas since 1988 | |||
| 14 June 2026 | FDA approval | New FDA-approved peptide: Bremelanotidefda.gov/news-events/press-announcements/fda-approves-new… | Bremelanotide |
| Vyleesi — Acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women | |||
| 14 June 2026 | Peptide | Peptide updated: PT-141 | PT-141 |
| Sexual function peptide | |||
| 14 June 2026 | Source | New source added to RetatrutideA Master Protocol to Investigate the Efficacy and Safety of LY3437943 (Retatrutide) Once Weekly in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight · clinicaltrials.gov/study/NCT05929079 | Retatrutide |
| ClinicalTrials.gov | |||
| 14 June 2026 | Source | New source added to RetatrutideA Phase 3 Event-Driven Study of Retatrutide on Major Adverse Cardiovascular and Kidney Events in Participants With BMI >=27 and Established Cardiovascular or Kidney Disease · clinicaltrials.gov/study/NCT06383390 | Retatrutide |
| ClinicalTrials.gov | |||
| 14 June 2026 | Source | New source added to RetatrutideA Master Protocol to Investigate the Efficacy and Safety of LY3437943 (Retatrutide) Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Overweight (TRIUMPH-1) · clinicaltrials.gov/study/NCT05929066 | Retatrutide |
| ClinicalTrials.gov | |||
| 14 June 2026 | Source | New source added to RetatrutideLY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial · pubmed.ncbi.nlm.nih.gov/36354040/ | Retatrutide |
| The Lancet | |||
| 14 June 2026 | Source | New source added to RetatrutideLY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept · pubmed.ncbi.nlm.nih.gov/35985340/ | Retatrutide |
| Cell Metabolism | |||
| 14 June 2026 | Source | New source added to RetatrutideTriple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial · pubmed.ncbi.nlm.nih.gov/38858523/ | Retatrutide |
| Nature Medicine | |||
| 14 June 2026 | Source | New source added to RetatrutideRetatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial · pubmed.ncbi.nlm.nih.gov/37385280/ | Retatrutide |
| The Lancet | |||
| 14 June 2026 | Source | New source added to RetatrutideTriple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial · pubmed.ncbi.nlm.nih.gov/37366315/ | Retatrutide |
| New England Journal of Medicine | |||
| 13 June 2026 | Source | New source added to VladonixDetailed Results of a Clinical Study of Vladonix · qisupplements.com/blogs/news/detailed-results-of-a… | Vladonix |
| Qi Supplements | |||
| 13 June 2026 | Source | New source added to VladonixVladonix A-6 Thymus Natural Peptide Bioregulator (product page) · vita-stream.com/a-6-thymus-peptide-bioregulator-… | Vladonix |
| Vita-Stream | |||
| 13 June 2026 | Source | New source added to VladonixThymus Extract — Uses, Dosage, Side Effects, Interactions · rxlist.com/thymus_extract/supplements.htm | Vladonix |
| RxList / WebMD | |||
| 13 June 2026 | Source | New source added to VladonixPeptide bioregulators: A new class of geroprotectors, report 2. The results of clinical trials · link.springer.com/article/10.1134/S207905701404012… | Vladonix |
| Advances in Gerontology / Springer | |||
| 13 June 2026 | Source | New source added to VladonixPeptides of pineal gland and thymus prolong human life (NeL.edu abstract) · nel.edu/peptides-of-pineal-gland-and-thy… | Vladonix |
| Neuro Endocrinology Letters | |||
| 13 June 2026 | Source | New source added to VladonixPeptides of pineal gland and thymus prolong human life · pubmed.ncbi.nlm.nih.gov/14523363/ | Vladonix |
| Neuro Endocrinology Letters | |||
| 13 June 2026 | Source | New source added to VilonPeptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line · pubmed.ncbi.nlm.nih.gov/35408963/ | Vilon |
| International Journal of Molecular Sciences | |||
| 13 June 2026 | Source | New source added to VilonEffect of vilon on the immunity status and coagulation hemostasis in patients of different age with diabetes mellitus · pubmed.ncbi.nlm.nih.gov/18306698/ | Vilon |
| Advances in Gerontology | |||
| 13 June 2026 | Source | New source added to VilonThe effect of vilon (Lys-Glu) on 1,2-dimethylhydrazine-induced neoplasia · pubmed.ncbi.nlm.nih.gov/16308980/ | Vilon |
| Voprosy Onkologii | |||
| 13 June 2026 | Source | New source added to VilonStudies of the effects of Vilon and Epithalon on gene expression in mouse heart using DNA-microarray technology · pubmed.ncbi.nlm.nih.gov/12360356/ | Vilon |
| Bulletin of Experimental Biology and Medicine | |||
| 13 June 2026 | Source | New source added to VilonInhibitory effect of peptide vilon on the development of induced rat urinary bladder tumors in rats · pubmed.ncbi.nlm.nih.gov/11586406/ | Vilon |
| Bulletin of Experimental Biology and Medicine | |||
| 13 June 2026 | Source | New source added to VilonEffect of peptide Lys-Glu on interleukin-2 gene expression in lymphocytes · pubmed.ncbi.nlm.nih.gov/11177276/ | Vilon |
| Bulletin of Experimental Biology and Medicine | |||
| 13 June 2026 | Source | New source added to VilonA synthetic dipeptide vilon (L-Lys-L-Glu) inhibits growth of spontaneous tumors and increases life span of mice · pubmed.ncbi.nlm.nih.gov/10944717/ | Vilon |
| Doklady Biological Sciences | |||
| 13 June 2026 | Source | New source added to VilonEffect of vilon on biological age and lifespan in mice · pubmed.ncbi.nlm.nih.gov/11140587/ | Vilon |
| Bulletin of Experimental Biology and Medicine | |||
| 13 June 2026 | Source | New source added to Urolithin AUrolithin A and nicotinamide riboside differentially regulate innate immune defenses and metabolism in human microglial cells · pmc.ncbi.nlm.nih.gov/articles/PMC11631940/ | Urolithin A |
| Frontiers in Aging Neuroscience | |||
| 13 June 2026 | Source | New source added to Urolithin ADirect supplementation with Urolithin A overcomes limitations of dietary exposure and gut microbiome variability in healthy adults to achieve consistent levels across the population · pmc.ncbi.nlm.nih.gov/articles/PMC8821002/ | Urolithin A |
| European Journal of Clinical Nutrition | |||
| 13 June 2026 | Source | New source added to Urolithin AEffect of the mitophagy inducer urolithin A on age-related immune decline: a randomized, placebo-controlled trial · nature.com/articles/s43587-025-00996-x | Urolithin A |
| Nature Aging | |||
| 13 June 2026 | Source | New source added to Urolithin ATargeting aging with urolithin A in humans: A systematic review · pubmed.ncbi.nlm.nih.gov/39002645/ | Urolithin A |
| Ageing Research Reviews | |||
| 13 June 2026 | Source | New source added to Urolithin AUrolithin A improves muscle strength, exercise performance, and biomarkers of mitochondrial health in a randomized trial in middle-aged adults · cell.com/cell-reports-medicine/fulltext/S… | Urolithin A |
| Cell Reports Medicine | |||
| 13 June 2026 | Source | New source added to Urolithin AEffect of Urolithin A Supplementation on Muscle Endurance and Mitochondrial Health in Older Adults: A Randomized Clinical Trial · jamanetwork.com/journals/jamanetworkopen/fullart… | Urolithin A |
| JAMA Network Open | |||
| 13 June 2026 | Source | New source added to Urolithin AThe mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans · nature.com/articles/s42255-019-0073-4 | Urolithin A |
| Nature Metabolism | |||
| 13 June 2026 | Source | New source added to ThyreogenThyreogen Peptide: Thyroid Bioregulator for Endocrine Support · bioregulatorpeptides.co.uk/thyreogen/ | Thyreogen |
| 13 June 2026 | Source | New source added to ThyreogenPeptide bioregulators: A new class of geroprotectors, report 2. The results of clinical trials · link.springer.com/article/10.1134/S207905701404012… | Thyreogen |
| Advances in Gerontology | |||
| 13 June 2026 | Source | New source added to ThyreogenSafety of Natural Peptide Bioregulators · antiaging-nutrition.com/articles/safety-of-natural-pepti… | Thyreogen |
| 13 June 2026 | Source | New source added to ThyreogenPeptide bioregulation of aging: results and prospects · pubmed.ncbi.nlm.nih.gov/19830585/ | Thyreogen |
| Biogerontology | |||
| 13 June 2026 | Source | New source added to ThyreogenPeptide bioregulator efficacy in the correction of reduced thyroid gland function in the residents of Magadan Region · pubmed.ncbi.nlm.nih.gov/16075681/ | Thyreogen |
| Advances in Gerontology | |||
| 13 June 2026 | Source | New source added to Thymosin Beta-4Efficacy and Safety Study of Thymosin Beta 4 in Patients With Acute Myocardial Infarction (NCT05984134) · clinicaltrials.gov/study/NCT05984134 | Thymosin Beta-4 |
| 13 June 2026 | Source | New source added to Thymosin Beta-4Thymosin β4 inhibits TNF-α-induced NF-κB activation, IL-8 expression, and the sensitizing effects by its partners PINCH-1 and ILK · pmc.ncbi.nlm.nih.gov/articles/PMC3101037/ | Thymosin Beta-4 |
| PLoS ONE / PMC | |||
| 13 June 2026 | Source | New source added to Thymosin Beta-4Thymosin β4 Promotes Dermal Healing · pubmed.ncbi.nlm.nih.gov/27450738/ | Thymosin Beta-4 |
| Vitamins and Hormones / Elsevier | |||
| 13 June 2026 | Source | New source added to Thymosin Beta-4Thymosin beta-4 and venous ulcers: clinical remarks on a European prospective, randomized study on safety, tolerability, and enhancement on healing · pubmed.ncbi.nlm.nih.gov/17495250/ | Thymosin Beta-4 |
| 13 June 2026 | Source | New source added to Thymosin Beta-4Progress on the Function and Application of Thymosin β4 · pmc.ncbi.nlm.nih.gov/articles/PMC8724243/ | Thymosin Beta-4 |
| Frontiers in Endocrinology | |||
| 13 June 2026 | Source | New source added to Thymosin Beta-4A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteers · pubmed.ncbi.nlm.nih.gov/34346165/ | Thymosin Beta-4 |
| British Journal of Clinical Pharmacology | |||
| 13 June 2026 | Source | New source added to Thymosin Beta-4Thymosin beta4 accelerates wound healing · pubmed.ncbi.nlm.nih.gov/10469335/ | Thymosin Beta-4 |
| Journal of Investigative Dermatology | |||
| 13 June 2026 | Source | New source added to Thymosin Beta-4Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues · pubmed.ncbi.nlm.nih.gov/16099219/ | Thymosin Beta-4 |
| Trends in Molecular Medicine / Elsevier | |||
| 13 June 2026 | Source | New source added to Syn-CollSafety Assessment of Palmitoyl Oligopeptides Ingredients as Used in Cosmetics · cir-safety.org/panelbook/safety-assessment-palm… | Syn-Coll |
| Cosmetic Ingredient Review (CIR) | |||
| 13 June 2026 | Source | New source added to Syn-CollPalmitoyl Tripeptide-5: What Can It Do for Your Skin? · thedermreview.com/palmitoyl-tripeptide-5/ | Syn-Coll |
| The Dermatology Review | |||
| 13 June 2026 | Source | New source added to Syn-CollPalmitoyl Tripeptide-5 Ingredient Profile · incidecoder.com/ingredients/palmitoyl-tripeptide… | Syn-Coll |
| INCIDecoder | |||
| 13 June 2026 | Source | New source added to Syn-CollPalmitoyl Tripeptide-5: Collagen Booster Profile · peptidejournal.org/peptides/palmitoyl-tripeptide-5-… | Syn-Coll |
| PeptideJournal.org | |||
| 13 June 2026 | Source | New source added to SS-31 (Elamipretide)The mitochondria-targeted peptide SS-31 binds lipid bilayers and modulates surface electrostatics as a key component of its mechanism of action · pmc.ncbi.nlm.nih.gov/articles/PMC7247319/ | SS-31 (Elamipretide) |
| Journal of Biological Chemistry | |||
| 13 June 2026 | Source | New source added to SS-31 (Elamipretide)A Trial to Evaluate Safety, Tolerability and Efficacy of Elamipretide in Subjects With Barth Syndrome (TAZPOWER) — NCT03098797 · clinicaltrials.gov/study/NCT03098797 | SS-31 (Elamipretide) |
| ClinicalTrials.gov | |||
| 13 June 2026 | Source | New source added to SS-31 (Elamipretide)Elamipretide: The first cardiolipin-directed mitochondrial therapeutic for Barth syndrome approved under accelerated approval · pubmed.ncbi.nlm.nih.gov/41260682/ | SS-31 (Elamipretide) |
| Drug Discovery and Therapeutics | |||
| 13 June 2026 | Source | New source added to SS-31 (Elamipretide)Long-term treatment with Elamipretide enhances healthy aging phenotypes in mice · pmc.ncbi.nlm.nih.gov/articles/PMC9562127/ | SS-31 (Elamipretide) |
| Aging Pathobiology and Therapeutics | |||
| 13 June 2026 | Source | New source added to SS-31 (Elamipretide)SS-31 and NMN: Two paths to improve metabolism and function in aged hearts · pmc.ncbi.nlm.nih.gov/articles/PMC7576234/ | SS-31 (Elamipretide) |
| Aging Cell | |||
| 13 June 2026 | Source | New source added to SS-31 (Elamipretide)Novel Mitochondria-Targeting Peptide in Heart Failure Treatment: A Randomized, Placebo-Controlled Trial of Elamipretide · pubmed.ncbi.nlm.nih.gov/29217757/ | SS-31 (Elamipretide) |
| Circulation: Heart Failure | |||
| 13 June 2026 | Source | New source added to SS-31 (Elamipretide)FORZINITY (elamipretide hydrochloride) Prescribing Information · dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=146bf3… | SS-31 (Elamipretide) |
| U.S. National Library of Medicine / Stealth BioTherapeutics | |||
| 13 June 2026 | Source | New source added to SS-31 (Elamipretide)Elamipretide: A Review of Its Structure, Mechanism of Action, and Therapeutic Potential · pmc.ncbi.nlm.nih.gov/articles/PMC11816484/ | SS-31 (Elamipretide) |
| International Journal of Molecular Sciences | |||
| 13 June 2026 | Source | New source added to SplenopentinFunctional effects of splenin32-34 on antibody formation in immunosuppressed mice · pubmed.ncbi.nlm.nih.gov/3551932/ | Splenopentin |
| Biomedica Biochimica Acta | |||
| 13 June 2026 | Source | New source added to SplenopentinThymopentin and splenopentin as immunomodulators. Current status · pubmed.ncbi.nlm.nih.gov/9638477/ | Splenopentin |
| Immunologic Research | |||
| 13 June 2026 | Source | New source added to SplenopentinSplenopentin (DAc-SP5)--influence on engraftment and graft-vs-host reaction after non-H-2 bone marrow transplantation in mice · pubmed.ncbi.nlm.nih.gov/2083570/ | Splenopentin |
| Experimental and Clinical Endocrinology | |||
| 13 June 2026 | Source | New source added to SplenopentinDiacetyl-splenopentin (BCH 069) did not affect the concentrations of various hormones in men · pubmed.ncbi.nlm.nih.gov/2083571/ | Splenopentin |
| Experimental and Clinical Endocrinology | |||
| 13 June 2026 | Source | New source added to SplenopentinClinical, biochemical and immunological effectiveness of diacetyl-splenopentin (BCH 069) in hay fever · pubmed.ncbi.nlm.nih.gov/2251976/ | Splenopentin |
| Allergologia et Immunopathologia | |||
| 13 June 2026 | Source | New source added to SplenopentinThe effect of splenopentin (DA SP-5) on in vitro myelopoiesis and on AZT-induced bone marrow toxicity · pubmed.ncbi.nlm.nih.gov/8505137/ | Splenopentin |
| International Journal of Immunopharmacology | |||
| 13 June 2026 | Source | New source added to SplenopentinSplenopentin (DAc-SP-5) accelerates the restoration of myelopoietic and immune systems after sublethal radiation in mice · pubmed.ncbi.nlm.nih.gov/2292457/ | Splenopentin |
| International Journal of Immunopharmacology | |||
| 13 June 2026 | Source | New source added to SplenopentinContrasting biological activities of thymopoietin and splenin, two closely related polypeptide products of thymus and spleen · pmc.ncbi.nlm.nih.gov/articles/PMC345168/ | Splenopentin |
| Proceedings of the National Academy of Sciences USA | |||
| 13 June 2026 | Source | New source added to Snap-8Method development for acetyl octapeptide-3 analysis by liquid chromatography-tandem mass spectrometry · link.springer.com/article/10.1186/s40543-020-00232… | Snap-8 |
| Journal of Analytical Science and Technology | |||
| 13 June 2026 | Source | New source added to Snap-8A peptide that mimics the C-terminal sequence of SNAP-25 inhibits secretory vesicle docking in chromaffin cells · pubmed.ncbi.nlm.nih.gov/9006897/ | Snap-8 |
| Journal of Biological Chemistry | |||
| 13 June 2026 | Source | New source added to Snap-8The anti-wrinkle efficacy of argireline, a synthetic hexapeptide, in Chinese subjects: a randomized, placebo-controlled study · pubmed.ncbi.nlm.nih.gov/23417317/ | Snap-8 |
| American Journal of Clinical Dermatology | |||
| 13 June 2026 | Source | New source added to Snap-8An Open Label Clinical Trial of a Peptide Treatment Serum and Supporting Regimen Designed to Improve the Appearance of Aging Facial Skin · jddonline.com/articles/an-open-label-clinical-… | Snap-8 |
| Journal of Drugs in Dermatology | |||
| 13 June 2026 | Source | New source added to Snap-8Peptide-pro complex serum: Investigating effects on aged skin · pmc.ncbi.nlm.nih.gov/articles/PMC10084013/ | Snap-8 |
| 13 June 2026 | Source | New source added to Snap-8Peptides: Emerging Candidates for the Prevention and Treatment of Skin Senescence: A Review · pmc.ncbi.nlm.nih.gov/articles/PMC11762834/ | Snap-8 |
| MDPI | |||
| 13 June 2026 | Source | New source added to Snap-8Cosmeceutical Peptides in the Framework of Sustainable Wellness Economy · pmc.ncbi.nlm.nih.gov/articles/PMC7662462/ | Snap-8 |
| Frontiers in Chemistry | |||
| 13 June 2026 | Source | New source added to SermorelinWhat Should Athletes Know About Sermorelin? · usada.org/spirit-of-sport/athletes-know-se… | Sermorelin |
| United States Anti-Doping Agency (USADA) | |||
| 13 June 2026 | Source | New source added to SermorelinSermorelin Acetate: Prescribing Information · rxlist.com/sermorelin-acetate-drug.htm | Sermorelin |
| RxList / WebMD | |||
| 13 June 2026 | Source | New source added to SermorelinGrowth Hormone and Aging - Endotext · ncbi.nlm.nih.gov/books/NBK279163/ | Sermorelin |
| NCBI Bookshelf (Endotext / MDText.com) | |||
| 13 June 2026 | Source | New source added to SermorelinTreating age-related changes in somatotrophic hormones, sleep, and cognition · pmc.ncbi.nlm.nih.gov/articles/PMC3181657/ | Sermorelin |
| Dialogues in Clinical Neuroscience | |||
| 13 June 2026 | Source | New source added to SermorelinBeyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males · pmc.ncbi.nlm.nih.gov/articles/PMC7108996/ | Sermorelin |
| Translational Andrology and Urology | |||
| 13 June 2026 | Source | New source added to SermorelinEndocrine and Metabolic Effects of Long-Term Administration of [Nle27]Growth Hormone-Releasing Hormone-(1-29)-NH2 in Age-Advanced Men and Women · academic.oup.com/jcem/article/82/5/1472/2823341 | Sermorelin |
| Journal of Clinical Endocrinology and Metabolism | |||
| 13 June 2026 | Source | New source added to Thymosin Alpha-1Zadaxin (Thymalfasin): Side Effects, Uses, Dosage, Interactions, Warnings · rxlist.com/zadaxin-drug.htm | Thymosin Alpha-1 |
| 13 June 2026 | Source | New source added to Thymosin Alpha-1Thymosin alpha 1 reduces the mortality of severe COVID-19 by restoration of lymphocytopenia and reversion of exhausted T cells · pmc.ncbi.nlm.nih.gov/articles/PMC7314217/ | Thymosin Alpha-1 |
| 13 June 2026 | Source | New source added to Thymosin Alpha-1Immune Modulation with Thymosin Alpha 1 Treatment · pubmed.ncbi.nlm.nih.gov/27450734/ | Thymosin Alpha-1 |
| 13 June 2026 | Source | New source added to Thymosin Alpha-1Clinical efficacy and safety of synthetic thymic peptides with chemotherapy for non-small cell lung cancer: A systematic review and meta-analysis of 27 randomized controlled trials · pubmed.ncbi.nlm.nih.gov/31326719/ | Thymosin Alpha-1 |
| PubMed / NCBI | |||
| 13 June 2026 | Source | New source added to Thymosin Alpha-1Thymosin alpha1 treatment of chronic hepatitis B: results of a phase III multicentre, randomized, double-blind and placebo-controlled study · pubmed.ncbi.nlm.nih.gov/10607256/ | Thymosin Alpha-1 |
| 13 June 2026 | Source | New source added to Thymosin Alpha-1Thymosin-alpha1 for Sepsis Management: A Systematic Review and Meta-Analysis of 1972 Patients · pmc.ncbi.nlm.nih.gov/articles/PMC12792209/ | Thymosin Alpha-1 |
| 13 June 2026 | Source | New source added to Thymosin Alpha-1Thymosin alpha 1: A comprehensive review of the literature · pmc.ncbi.nlm.nih.gov/articles/PMC7747025/ | Thymosin Alpha-1 |
| Vitamins and Hormones, Academic Press | |||
| 13 June 2026 | Source | New source added to ThymalinNatural and synthetic thymic peptides as therapeutics for immune dysfunction · sciencedirect.com/science/article/abs/pii/S0192056… | Thymalin |
| International Journal of Immunopharmacology | |||
| 13 June 2026 | Source | New source added to ThymalinPeptide bioregulators: A new class of geroprotectors, report 2. The results of clinical trials · link.springer.com/article/10.1134/S207905701404012… | Thymalin |
| Advances in Gerontology (Springer Nature) | |||
| 13 June 2026 | Source | New source added to ThymalinPeptide Drug Thymalin Regulates Immune Status in Severe COVID-19 Older Patients · link.springer.com/article/10.1134/S207905702104006… | Thymalin |
| Advances in Gerontology (Springer Nature) | |||
| 13 June 2026 | Source | New source added to ThymalinThe Influence of KE and EW Dipeptides in the Composition of the Thymalin Drug on Gene Expression and Protein Synthesis Involved in the Pathogenesis of COVID-19 · pmc.ncbi.nlm.nih.gov/articles/PMC10488166/ | Thymalin |
| International Journal of Molecular Sciences | |||
| 13 June 2026 | Source | New source added to ThymalinResults and Prospects of Using Activator of Hematopoietic Stem Cell Differentiation in Complex Therapy for Patients with COVID-19 · pmc.ncbi.nlm.nih.gov/articles/PMC7877506/ | Thymalin |
| Stem Cell Reviews and Reports | |||
| 13 June 2026 | Source | New source added to ThymalinPeptides of pineal gland and thymus prolong human life · pubmed.ncbi.nlm.nih.gov/14523363/ | Thymalin |
| Neuro Endocrinology Letters | |||
| 13 June 2026 | Source | New source added to TeriparatideFORTEO (teriparatide) Prescribing Information — DailyMed · dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?seti… | Teriparatide |
| U.S. National Library of Medicine / FDA | |||
| 13 June 2026 | Source | New source added to TeriparatideTeriparatide - StatPearls · ncbi.nlm.nih.gov/books/NBK559248/ | Teriparatide |
| NCBI Bookshelf / StatPearls | |||
| 13 June 2026 | Source | New source added to TeriparatideThe why and how of sequential and combination therapy in osteoporosis: a review of the current evidence · pmc.ncbi.nlm.nih.gov/articles/PMC10118820/ | Teriparatide |
| 13 June 2026 | Source | New source added to TeriparatideTeriparatide (recombinant human parathyroid hormone 1-34) in postmenopausal women with osteoporosis: systematic review · pmc.ncbi.nlm.nih.gov/articles/PMC11026046/ | Teriparatide |
| 13 June 2026 | Source | New source added to TeriparatideTeriparatide and Osteosarcoma Risk: History, Science, Elimination of Boxed Warning, and Other Label Updates · pmc.ncbi.nlm.nih.gov/articles/PMC9465003/ | Teriparatide |
| 13 June 2026 | Source | New source added to TeriparatideTeriparatide or Alendronate in Glucocorticoid-Induced Osteoporosis · pubmed.ncbi.nlm.nih.gov/18003959/ | Teriparatide |
| New England Journal of Medicine | |||
| 13 June 2026 | Source | New source added to TeriparatideEffects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial · pubmed.ncbi.nlm.nih.gov/29129436/ | Teriparatide |
| The Lancet | |||
| 13 June 2026 | Source | New source added to TeriparatideEffect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis (Fracture Prevention Trial) · pubmed.ncbi.nlm.nih.gov/11346808/ | Teriparatide |
| New England Journal of Medicine | |||
| 13 June 2026 | Source | New source added to TB4-FRAGThymosin β4 and its degradation product, Ac-SDKP, are novel reparative factors in renal fibrosis · pubmed.ncbi.nlm.nih.gov/23739235/ | TB4-FRAG |
| Kidney International | |||
| 13 June 2026 | Source | New source added to TB4-FRAGA Dose Response Study of Thymosin β4 for the Treatment of Acute Stroke · pmc.ncbi.nlm.nih.gov/articles/PMC4177939/ | TB4-FRAG |
| Journal of Neurological Sciences | |||
| 13 June 2026 | Source | New source added to TB4-FRAGRGN-259 (thymosin β4) improves clinically important dry eye efficacies in comparison with prescription drugs in a dry eye model · pmc.ncbi.nlm.nih.gov/articles/PMC6043477/ | TB4-FRAG |
| Scientific Reports | |||
| 13 June 2026 | Source | New source added to TB4-FRAGPreventive and therapeutic effects of thymosin β4 N-terminal fragment Ac-SDKP in the bleomycin model of pulmonary fibrosis · pmc.ncbi.nlm.nih.gov/articles/PMC5085123/ | TB4-FRAG |
| Oncotarget | |||
| 13 June 2026 | Source | New source added to TB-500A Study of the Safety and Efficacy of Injectable Thymosin Beta 4 for Treating Acute Myocardial Infarction (NCT01311518) · clinicaltrials.gov/study/NCT01311518 | TB-500 |
| ClinicalTrials.gov | |||
| 13 June 2026 | Source | New source added to TB-500Progress on the Function and Application of Thymosin β4 · pmc.ncbi.nlm.nih.gov/articles/PMC8724243/ | TB-500 |
| Frontiers in Endocrinology | |||
| 13 June 2026 | Source | New source added to TB-500Thymosin β4 Promotes Dermal Healing · pubmed.ncbi.nlm.nih.gov/27450738/ | TB-500 |
| Vitamins and Hormones | |||
| 13 June 2026 | Source | New source added to TB-500Thymosin beta-4 and venous ulcers: clinical remarks on a European prospective, randomized study on safety, tolerability, and enhancement on healing · pubmed.ncbi.nlm.nih.gov/17495250/ | TB-500 |
| Annals of the New York Academy of Sciences | |||
| 13 June 2026 | Source | New source added to TB-5000.1% RGN-259 (Thymosin β4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic Keratopathy Patients in a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical Trial · pmc.ncbi.nlm.nih.gov/articles/PMC9820614/ | TB-500 |
| International Journal of Molecular Sciences | |||
| 13 June 2026 | Source | New source added to TB-500Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications · pubmed.ncbi.nlm.nih.gov/22074294/ | TB-500 |
| Expert Opinion on Biological Therapy | |||
| 13 June 2026 | Source | New source added to TB-500Biological activities of thymosin beta4 defined by active sites in short peptide sequences · pubmed.ncbi.nlm.nih.gov/20179146/ | TB-500 |
| FASEB Journal | |||
| 13 June 2026 | Source | New source added to TB-500The actin binding site on thymosin beta4 promotes angiogenesis · pubmed.ncbi.nlm.nih.gov/14500546/ | TB-500 |
| FASEB Journal | |||
| 13 June 2026 | Source | New source added to YK-11Detection of selective androgen receptor modulator YK-11 in a doping control sample (Sobolevsky et al., 2024) · pubmed.ncbi.nlm.nih.gov/37946705/ | YK-11 |
| Drug Testing and Analysis | |||
| 13 June 2026 | Source | New source added to YK-11Studies on the in vivo metabolism of the SARM YK11: identification and characterization of metabolites potentially useful for doping controls (Piper et al., 2018) · pubmed.ncbi.nlm.nih.gov/30379415/ | YK-11 |
| Drug Testing and Analysis | |||
| 13 June 2026 | Source | New source added to YK-11YK11 promotes osteogenic differentiation of BMSCs and repair of bone defects (Wang et al., 2025) · pubmed.ncbi.nlm.nih.gov/39660819/ | YK-11 |
| Journal of Molecular Endocrinology | |||
| 13 June 2026 | Source | New source added to YK-11Myostatin inhibitor YK11 as a preventative health supplement for bacterial sepsis (Lee et al., 2021) · pubmed.ncbi.nlm.nih.gov/33588136/ | YK-11 |
| Biochemical and Biophysical Research Communications | |||
| 13 June 2026 | Source | New source added to YK-11Selective androgen receptor modulator YK11 regulates myogenic differentiation of C2C12 myoblasts by follistatin expression (Kanno et al., 2013) · pubmed.ncbi.nlm.nih.gov/23995658/ | YK-11 |
| Biological and Pharmaceutical Bulletin | |||
| 13 June 2026 | Source | New source added to YK-11YK11 is a partial agonist of the androgen receptor (Kanno et al., 2011) · pubmed.ncbi.nlm.nih.gov/21372378/ | YK-11 |
| Biological and Pharmaceutical Bulletin | |||
| 13 June 2026 | Source | New source added to Pentosan PolysulfateNCT06917404 – A Study to Investigate the Treatment Effect of Subcutaneous Injections of Pentosan Polysulfate Sodium in Knee Osteoarthritis Pain · clinicaltrials.gov/study/NCT06917404 | Pentosan Polysulfate |
| 13 June 2026 | Source | New source added to Pentosan PolysulfatePentosan Polysulfate: Mechanism, Adverse Effects, Contraindications, and Dosage · urology-textbook.com/pps.html | Pentosan Polysulfate |
| 13 June 2026 | Source | New source added to Pentosan PolysulfatePentosan Polysulfate Maculopathy - StatPearls · ncbi.nlm.nih.gov/books/NBK589706/ | Pentosan Polysulfate |
| NCBI Bookshelf / StatPearls | |||
| 13 June 2026 | Source | New source added to Pentosan PolysulfatePentosan Polysulfate Affords Pleotropic Protection to Multiple Cells and Tissues · pmc.ncbi.nlm.nih.gov/articles/PMC10132487/ | Pentosan Polysulfate |
| 13 June 2026 | Source | New source added to Pentosan PolysulfateEfficacy and safety of pentosan polysulfate sodium in people with symptomatic knee osteoarthritis and dyslipidaemia: protocol of the MaRVeL trial · pubmed.ncbi.nlm.nih.gov/38777590/ | Pentosan Polysulfate |
| 13 June 2026 | Source | New source added to Pentosan PolysulfateThe effect of pentosan polysulfate sodium for improving dyslipidaemia and knee pain in people with knee osteoarthritis: A pilot study · pubmed.ncbi.nlm.nih.gov/36879559/ | Pentosan Polysulfate |
| 13 June 2026 | Source | New source added to Pentosan PolysulfateSafety and efficacy of pentosan polysulfate in patients with bladder pain syndrome/interstitial cystitis: a multicenter, double-blind, placebo-controlled, randomized study · pubmed.ncbi.nlm.nih.gov/34336239/ | Pentosan Polysulfate |
| 13 June 2026 | Source | New source added to Pentosan PolysulfateEfficacy of pentosan polysulfate for the treatment of interstitial cystitis/bladder pain syndrome: results of a systematic review of randomized controlled trials · pubmed.ncbi.nlm.nih.gov/30849922/ | Pentosan Polysulfate |
| Current Medical Research and Opinion | |||
| 13 June 2026 | Source | New source added to Pegzilarginase-nblnPegzilarginase for Arginase-1 deficiency — NIHR Evidence Scan · io.nihr.ac.uk/wp-content/uploads/2022/01/22745… | Pegzilarginase-nbln |
| National Institute for Health Research (NIHR) | |||
| 13 June 2026 | Source | New source added to Pegzilarginase-nblnFDA Grants Accelerated Approval to Pegzilarginase for Arginase 1 Deficiency · pharmacytimes.com/view/fda-grants-accelerated-appr… | Pegzilarginase-nbln |
| Pharmacy Times | |||
| 13 June 2026 | Source | New source added to Pegzilarginase-nblnArginase 1 deficiency: a treatable form of spastic paraplegia · pmc.ncbi.nlm.nih.gov/articles/PMC12394256/ | Pegzilarginase-nbln |
| 13 June 2026 | Source | New source added to Pegzilarginase-nblnU.S. FDA has granted accelerated approval of Loargys (pegzilarginase-nbln) for the treatment of hyperargininemia in patients 2 years and older with Arginase 1 Deficiency (ARG1-D) · prnewswire.com/news-releases/us-fda-has-granted… | Pegzilarginase-nbln |
| Immedica Pharma via PR Newswire | |||
| 13 June 2026 | Source | New source added to Pegzilarginase-nblnLOARGYS (pegzilarginase-nbln) injection — DailyMed Prescribing Label · dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d5ceab… | Pegzilarginase-nbln |
| 13 June 2026 | Source | New source added to Pegzilarginase-nblnEfficacy and safety of pegzilarginase in arginase 1 deficiency (PEACE): a phase 3, randomized, double-blind, placebo-controlled, multi-centre trial · pmc.ncbi.nlm.nih.gov/articles/PMC10825663/ | Pegzilarginase-nbln |
| eClinicalMedicine (The Lancet) | |||
| 13 June 2026 | Source | New source added to PEA (Palmitoylethanolamide)Palmitoylethanolamide: A Multifunctional Molecule for Neuroprotection, Chronic Pain, and Immune Modulation · pmc.ncbi.nlm.nih.gov/articles/PMC12189779/ | PEA (Palmitoylethanolamide) |
| Biomedicines (MDPI) | |||
| 13 June 2026 | Source | New source added to PEA (Palmitoylethanolamide)Effectiveness of Palmitoylethanolamide (Levagen+) Compared to a Placebo for Reducing Pain, Duration, and Medication Use during Migraines in Otherwise Healthy Participants: A Double-Blind Randomised Controlled Study · pmc.ncbi.nlm.nih.gov/articles/PMC10892859/ | PEA (Palmitoylethanolamide) |
| Nutrients (MDPI) | |||
| 13 June 2026 | Source | New source added to PEA (Palmitoylethanolamide)Safety of micronized palmitoylethanolamide (microPEA): lack of toxicity and genotoxic potential · pmc.ncbi.nlm.nih.gov/articles/PMC5332261/ | PEA (Palmitoylethanolamide) |
| Food Science and Nutrition | |||
| 13 June 2026 | Source | New source added to PEA (Palmitoylethanolamide)Palmitoylethanolamide: A Natural Compound for Health Management · pmc.ncbi.nlm.nih.gov/articles/PMC8157570/ | PEA (Palmitoylethanolamide) |
| International Journal of Molecular Sciences | |||
| 13 June 2026 | Source | New source added to PEA (Palmitoylethanolamide)Palmitoylethanolamide Is a Disease-Modifying Agent in Peripheral Neuropathy: Pain Relief and Neuroprotection Share a PPAR-Alpha-Mediated Mechanism · pmc.ncbi.nlm.nih.gov/articles/PMC3596927/ | PEA (Palmitoylethanolamide) |
| Mediators of Inflammation | |||
| 13 June 2026 | Source | New source added to PEA (Palmitoylethanolamide)Ultramicronized palmitoylethanolamide in spinal cord injury neuropathic pain: a randomized, double-blind, placebo-controlled trial · pubmed.ncbi.nlm.nih.gov/27227691/ | PEA (Palmitoylethanolamide) |
| Pain | |||
| 13 June 2026 | Source | New source added to PEA (Palmitoylethanolamide)A randomized controlled trial assessing the safety and efficacy of palmitoylethanolamide for treating diabetic-related peripheral neuropathic pain · pmc.ncbi.nlm.nih.gov/articles/PMC9700575/ | PEA (Palmitoylethanolamide) |
| Pain and Therapy | |||
| 13 June 2026 | Source | New source added to PEA (Palmitoylethanolamide)Palmitoylethanolamide in the Treatment of Chronic Pain: A Systematic Review and Meta-Analysis of Double-Blind Randomized Controlled Trials · pmc.ncbi.nlm.nih.gov/articles/PMC10053226/ | PEA (Palmitoylethanolamide) |
| Nutrients (MDPI) | |||
| 13 June 2026 | Source | New source added to Palmitoyl Tripeptide-5Syn-Coll (Palmitoyl Tripeptide-5) — Active Ingredient Safety Data · rootsbybenda.com/ingredients/syn-coll-palmitoyl-t… | Palmitoyl Tripeptide-5 |
| Roots by Benda | |||
| 13 June 2026 | Source | New source added to Palmitoyl Tripeptide-5Palmitoyl Tripeptide-5 (Explained + Products) · incidecoder.com/ingredients/palmitoyl-tripeptide… | Palmitoyl Tripeptide-5 |
| INCIDecoder | |||
| 13 June 2026 | Source | New source added to Palmitoyl Tripeptide-5Safety Assessment of Palmitoyl Oligopeptides as Used in Cosmetics · cir-safety.org/sites/default/files/palmit072012… | Palmitoyl Tripeptide-5 |
| Cosmetic Ingredient Review (CIR) | |||
| 13 June 2026 | Source | New source added to Palmitoyl Tripeptide-5Function of Palmitoyl Tripeptide-5 · creative-peptides.com/article/palmitoyl-tripeptide-5-1… | Palmitoyl Tripeptide-5 |
| Creative Peptides | |||
| 13 June 2026 | Source | New source added to Palmitoyl Tripeptide-5Activation of latent transforming growth factor-beta by thrombospondin-1: mechanisms and physiology · corepeptides.com/palmitoyl-tripeptide-5-syn-coll-… | Palmitoyl Tripeptide-5 |
| Core Peptides (cites Murphy-Ullrich & Poczatek 2000, DOI 10.1016/s1359-6101(99)00029-5) | |||
| 13 June 2026 | Source | New source added to Palmitoyl Tripeptide-5Immediate and Long-term Clinical Benefits of a Topical Treatment for Facial Lines and Wrinkles · jcadonline.com/immediate-and-long-term-clinical… | Palmitoyl Tripeptide-5 |
| Journal of Clinical and Aesthetic Dermatology | |||
| 13 June 2026 | Source | New source added to Palmitoyl Tripeptide-5Role of topical peptides in preventing or treating aged skin · pubmed.ncbi.nlm.nih.gov/19570099/ | Palmitoyl Tripeptide-5 |
| International Journal of Cosmetic Science | |||
| 13 June 2026 | Source | New source added to Palmitoyl Tripeptide-5Palmitoyl tripeptide-5 — Compound Summary (CID 11950477) · pubchem.ncbi.nlm.nih.gov/compound/Palmitoyl-Tripeptide-5 | Palmitoyl Tripeptide-5 |
| National Center for Biotechnology Information (NCBI) | |||
| 13 June 2026 | Source | New source added to P21 (Adamax)Diffusion MRI measures detect brain microstructure changes due to early treatment with neurotrophic peptide mimetic P021 in the 3xTg-AD mouse model of Alzheimer's disease · pmc.ncbi.nlm.nih.gov/articles/PMC12993872/ | P21 (Adamax) |
| Magnetic Resonance Imaging / Elsevier | |||
| 13 June 2026 | Source | New source added to P21 (Adamax)Effects of a ciliary neurotrophic factor (CNTF) small-molecule peptide mimetic in an in vitro and in vivo model of CDKL5 deficiency disorder · pmc.ncbi.nlm.nih.gov/articles/PMC11590213/ | P21 (Adamax) |
| Journal of Neurodevelopmental Disorders | |||
| 13 June 2026 | Source | New source added to P21 (Adamax)Early neurotrophic pharmacotherapy rescues developmental delay and Alzheimer's-like memory deficits in the Ts65Dn mouse model of Down syndrome · pmc.ncbi.nlm.nih.gov/articles/PMC5377379/ | P21 (Adamax) |
| Scientific Reports / Nature Publishing Group | |||
| 13 June 2026 | Source | New source added to P21 (Adamax)Prevention of dendritic and synaptic deficits and cognitive impairment with a neurotrophic compound · pmc.ncbi.nlm.nih.gov/articles/PMC5488423/ | P21 (Adamax) |
| Alzheimer's Research & Therapy / BioMed Central | |||
| 13 June 2026 | Source | New source added to P21 (Adamax)Neurotrophic factor small-molecule mimetics mediated neuroregeneration and synaptic repair: emerging therapeutic modality for Alzheimer's disease · pmc.ncbi.nlm.nih.gov/articles/PMC4940708/ | P21 (Adamax) |
| Molecular Neurodegeneration / BioMed Central | |||
| 13 June 2026 | Source | New source added to P21 (Adamax)Beneficial Effect of a CNTF Tetrapeptide on Adult Hippocampal Neurogenesis, Neuronal Plasticity, and Spatial Memory in Mice · pubmed.ncbi.nlm.nih.gov/20952820/ | P21 (Adamax) |
| Journal of Alzheimer's Disease / IOS Press | |||
| 13 June 2026 | Source | New source added to P21 (Adamax)Neurotrophic peptides incorporating adamantane improve learning and memory, promote neurogenesis and synaptic plasticity in mice · febs.onlinelibrary.wiley.com/doi/10.1016/j.febslet.2010.06.02… | P21 (Adamax) |
| FEBS Letters / Wiley | |||
| 13 June 2026 | Source | New source added to Semax Low Dose[Semax in prevention of disease progress and development of exacerbations in patients with cerebrovascular insufficiency] · pubmed.ncbi.nlm.nih.gov/15792140/ | Semax Low Dose |
| Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova | |||
| 13 June 2026 | Source | New source added to Semax Low Dose[Effectiveness of semax in acute period of hemispheric ischemic stroke] · pubmed.ncbi.nlm.nih.gov/11517472/ | Semax Low Dose |
| Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova | |||
| 13 June 2026 | Source | New source added to Semax Low DoseAntidepressant-like and antistress effects of the ACTH(4-10) synthetic analogs Semax and Melanotan II on male rats in a model of chronic unpredictable stress · pubmed.ncbi.nlm.nih.gov/39442746/ | Semax Low Dose |
| European Journal of Pharmacology | |||
| 13 June 2026 | Source | New source added to Semax Low DoseThe Potential of the Peptide Drug Semax and Its Derivative for Correcting Pathological Impairments in the Animal Model of Alzheimer's Disease · pmc.ncbi.nlm.nih.gov/articles/PMC12755871/ | Semax Low Dose |
| Acta Naturae | |||
| 13 June 2026 | Source | New source added to Semax Low DoseBrain Protein Expression Profile Confirms the Protective Effect of the ACTH(4-7)PGP Peptide (Semax) in a Rat Model of Cerebral Ischemia-Reperfusion · pmc.ncbi.nlm.nih.gov/articles/PMC8226508/ | Semax Low Dose |
| International Journal of Molecular Sciences | |||
| 13 June 2026 | Source | New source added to Semax Low DoseNovel Insights into the Protective Properties of ACTH(4-7)PGP (Semax) Peptide at the Transcriptome Level Following Cerebral Ischaemia-Reperfusion in Rats · pmc.ncbi.nlm.nih.gov/articles/PMC7350263/ | Semax Low Dose |
| Genes (MDPI) | |||
| 13 June 2026 | Source | New source added to Semax Low DoseSemax, An ACTH(4-10) Analogue with Nootropic Properties, Activates Dopaminergic and Serotoninergic Brain Systems in Rodents · pubmed.ncbi.nlm.nih.gov/16362768/ | Semax Low Dose |
| Neurochemical Research | |||
| 13 June 2026 | Source | New source added to SemaxSemax — Cognitive Vitality For Researchers · alzdiscovery.org/uploads/cognitive_vitality_media… | Semax |
| Alzheimer's Drug Discovery Foundation | |||
| 13 June 2026 | Source | New source added to SemaxNovel Insights into the Protective Properties of ACTH(4-7)PGP (Semax) Peptide at the Transcriptome Level Following Cerebral Ischaemia-Reperfusion in Rats · pmc.ncbi.nlm.nih.gov/articles/PMC7350263/ | Semax |
| International Journal of Molecular Sciences | |||
| 13 June 2026 | Source | New source added to SemaxThe efficacy of semax in the treatment of patients at different stages of ischemic stroke · pubmed.ncbi.nlm.nih.gov/29798983/ | Semax |
| 13 June 2026 | Source | New source added to SemaxSemax and Pro-Gly-Pro Activate the Transcription of Neurotrophins and Their Receptor Genes after Cerebral Ischemia · pmc.ncbi.nlm.nih.gov/articles/PMC11498467/ | Semax |
| Cellular and Molecular Neurobiology | |||
| 13 June 2026 | Source | New source added to SemaxBrain Protein Expression Profile Confirms the Protective Effect of the ACTH(4-7)PGP Peptide (Semax) in a Rat Model of Cerebral Ischemia-Reperfusion · pmc.ncbi.nlm.nih.gov/articles/PMC8226508/ | Semax |
| International Journal of Molecular Sciences | |||
| 13 June 2026 | Source | New source added to SemaxSemax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents · pubmed.ncbi.nlm.nih.gov/16362768/ | Semax |
| Neurochemical Research | |||
| 13 June 2026 | Source | New source added to SemaxEffects of Semax on the Default Mode Network of the Brain · pubmed.ncbi.nlm.nih.gov/30225715/ | Semax |
| Bulletin of Experimental Biology and Medicine | |||
| 13 June 2026 | Source | New source added to SemaxSemax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus · pubmed.ncbi.nlm.nih.gov/16996037/ | Semax |
| Brain Research | |||
| 13 June 2026 | Source | New source added to Selank-AmidateGABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cells · frontiersin.org/journals/pharmacology/articles/1… | Selank-Amidate |
| Frontiers in Pharmacology | |||
| 13 June 2026 | Source | New source added to Selank-AmidateImmunomodulatory effects of selank in patients with anxiety-asthenic disorders · pubmed.ncbi.nlm.nih.gov/18577961/ | Selank-Amidate |
| Zh Nevrol Psikhiatr Im S S Korsakova | |||
| 13 June 2026 | Source | New source added to Selank-AmidateThe inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity · pubmed.ncbi.nlm.nih.gov/11550013/ | Selank-Amidate |
| Bulletin of Experimental Biology and Medicine | |||
| 13 June 2026 | Source | New source added to Selank-AmidatePeptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats · pmc.ncbi.nlm.nih.gov/articles/PMC5322660/ | Selank-Amidate |
| Behavioural Neurology | |||
| 13 June 2026 | Source | New source added to Selank-AmidateSelank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission · pmc.ncbi.nlm.nih.gov/articles/PMC4757669/ | Selank-Amidate |
| Frontiers in Pharmacology | |||
| 13 June 2026 | Source | New source added to SelankPeptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity · pubmed.ncbi.nlm.nih.gov/30255741/ | Selank |
| 13 June 2026 | Source | New source added to SelankGABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cells · pmc.ncbi.nlm.nih.gov/articles/PMC5328971/ | Selank |
| 13 June 2026 | Source | New source added to SelankSelank, Peptide Analogue of Tuftsin, Protects Against Ethanol-Induced Memory Impairment in Rodents · pubmed.ncbi.nlm.nih.gov/31625062/ | Selank |
| 13 June 2026 | Source | New source added to SelankSelank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission · pmc.ncbi.nlm.nih.gov/articles/PMC4757669/ | Selank |
| 13 June 2026 | Source | New source added to Selank[Immunomodulatory effects of selank in patients with anxiety-asthenic disorders] · pubmed.ncbi.nlm.nih.gov/18577961/ | Selank |
| Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova | |||
| 13 June 2026 | Source | New source added to SelankThe inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity · pubmed.ncbi.nlm.nih.gov/11550013/ | Selank |
| 13 June 2026 | Source | New source added to SelankPeptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats · pmc.ncbi.nlm.nih.gov/articles/PMC5322660/ | Selank |
| Behavioural Neurology (Wiley) | |||
| 13 June 2026 | Source | New source added to Selank[Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia] · pubmed.ncbi.nlm.nih.gov/18454096/ | Selank |
| Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova | |||
| 13 June 2026 | Source | New source added to RG3 (Rhodiola)The protective role of ginsenoside Rg3 in heart diseases and mental disorders · frontiersin.org/journals/pharmacology/articles/1… | RG3 (Rhodiola) |
| Frontiers in Pharmacology | |||
| 13 June 2026 | Source | New source added to RG3 (Rhodiola)The Efficacy of Ginsenoside Rg3 Combined with First-line Chemotherapy in the Treatment of Advanced Non-Small Cell Lung Cancer in China: A Systematic Review and Meta-Analysis of Randomized Clinical Trials · pmc.ncbi.nlm.nih.gov/articles/PMC8012535/ | RG3 (Rhodiola) |
| Frontiers in Pharmacology | |||
| 13 June 2026 | Source | New source added to RG3 (Rhodiola)Acute and repeated dose 26-week oral toxicity study of 20(S)-ginsenoside Rg3 in Kunming mice and Sprague-Dawley rats · pmc.ncbi.nlm.nih.gov/articles/PMC7031733/ | RG3 (Rhodiola) |
| 13 June 2026 | Source | New source added to RG3 (Rhodiola)Ginsenoside Rg3 Prevents Cognitive Impairment by Improving Mitochondrial Dysfunction in the Rat Model of Alzheimer's Disease · pubmed.ncbi.nlm.nih.gov/31422666/ | RG3 (Rhodiola) |
| Journal of Agricultural and Food Chemistry | |||
| 13 June 2026 | Source | New source added to RG3 (Rhodiola)Active ginseng components in cognitive impairment: Therapeutic potential and prospects for delivery and clinical study · pmc.ncbi.nlm.nih.gov/articles/PMC6173364/ | RG3 (Rhodiola) |
| Oncotarget | |||
| 13 June 2026 | Source | New source added to RG3 (Rhodiola)Rg3-enriched ginseng extract ameliorates scopolamine-induced learning deficits in mice · pmc.ncbi.nlm.nih.gov/articles/PMC4758096/ | RG3 (Rhodiola) |
| BMC Complementary and Alternative Medicine | |||
| 13 June 2026 | Source | New source added to RG3 (Rhodiola)Ginseng ginsenoside pharmacology in the nervous system: involvement in the regulation of ion channels and receptors · pmc.ncbi.nlm.nih.gov/articles/PMC3958645/ | RG3 (Rhodiola) |
| Frontiers in Physiology | |||
| 13 June 2026 | Source | New source added to RG3 (Rhodiola)Ginsenoside Rg3 antagonizes NMDA receptors through a glycine modulatory site in rat cultured hippocampal neurons · pubmed.ncbi.nlm.nih.gov/15369768/ | RG3 (Rhodiola) |
| Biochemical and Biophysical Research Communications | |||
| 13 June 2026 | Source | New source added to PT-141FDA Approves New Drug Application for Vyleesi (bremelanotide injection) · palatin.com/press_releases/fda-approves-new-… | PT-141 |
| Palatin Technologies | |||
| 13 June 2026 | Source | New source added to PT-141Bremelanotide for Treatment of Female Hypoactive Sexual Desire · pmc.ncbi.nlm.nih.gov/articles/PMC8788464/ | PT-141 |
| 13 June 2026 | Source | New source added to PT-141Bremelanotide - LiverTox: Clinical and Research Information on Drug-Induced Liver Injury · ncbi.nlm.nih.gov/books/NBK573221/ | PT-141 |
| National Library of Medicine (NIH NCBI Bookshelf) | |||
| 13 June 2026 | Source | New source added to PT-141The Patient Experience of Premenopausal Women Treated with Bremelanotide for Hypoactive Sexual Desire Disorder: RECONNECT Exit Study Results · pubmed.ncbi.nlm.nih.gov/33538638/ | PT-141 |
| 13 June 2026 | Source | New source added to PT-141Responder Analyses from a Phase 2b Dose-Ranging Study of Bremelanotide · pubmed.ncbi.nlm.nih.gov/31277966/ | PT-141 |
| 13 June 2026 | Source | New source added to PT-141Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide · pubmed.ncbi.nlm.nih.gov/35230162/ | PT-141 |
| 13 June 2026 | Source | New source added to PT-141Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials · pubmed.ncbi.nlm.nih.gov/31599840/ | PT-141 |
| Obstetrics & Gynecology | |||
| 13 June 2026 | Source | New source added to ProstatilenProstatilen (Prostate Extract - Prostatilenum) 50 mg, 10 suppositories — product listing · rxeli.com/product/prostatilen-prostate-ext… | Prostatilen |
| 13 June 2026 | Source | New source added to ProstatilenOur experience in the use of prostatilen in urology · pubmed.ncbi.nlm.nih.gov/14708243/ | Prostatilen |
| 13 June 2026 | Source | New source added to ProstatilenThe use of prostatilen in treating patients with prostatic adenoma · pubmed.ncbi.nlm.nih.gov/1823683/ | Prostatilen |
| 13 June 2026 | Source | New source added to ProstatilenPolypeptide prostatilen in the treatment of patients with complicated prostatitis · pubmed.ncbi.nlm.nih.gov/15605829/ | Prostatilen |
| 13 June 2026 | Source | New source added to ProstatilenEffect of prostatilen AC suppositories on course of experimental prostatitis · pubmed.ncbi.nlm.nih.gov/23116023/ | Prostatilen |
| 13 June 2026 | Source | New source added to ProstatilenInfluence of adding zinc arginyle-glycinate to improve efficacy of bioregulatory peptides of the prostate gland in treatment of patients with impaired sperm parameters · pubmed.ncbi.nlm.nih.gov/36318852/ | Prostatilen |
| 13 June 2026 | Source | New source added to ProstatilenBioregulatory therapy for chronic abacterial prostatitis · journals.eco-vector.com/uroved/article/view/111581 | Prostatilen |
| Urology Reports (St. Petersburg), Eco-Vector | |||
| 13 June 2026 | Source | New source added to ProstatilenProstatic bioregulatory polypeptide prostatilen: pharmacological properties and 30-year experience of clinical application in urology · journals.eco-vector.com/uroved/article/view/42472 | Prostatilen |
| Urology Reports (St. Petersburg), Eco-Vector | |||
| 13 June 2026 | Source | New source added to PramlintidePramlintide - Wikidoc · wikidoc.org/index.php/Pramlintide | Pramlintide |
| 13 June 2026 | Source | New source added to PramlintideCombined GLP-1 Receptor Agonist and Amylin Analogue Pharmacotherapy to Treat Obesity Comorbid With Type 1 Diabetes · academic.oup.com/jcemcr/article/1/2/luad040/71355… | Pramlintide |
| JCEM Case Reports / The Endocrine Society | |||
| 13 June 2026 | Source | New source added to PramlintidePrimer on pramlintide, an amylin analog · pubmed.ncbi.nlm.nih.gov/21471470/ | Pramlintide |
| 13 June 2026 | Source | New source added to PramlintideEffect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients · pubmed.ncbi.nlm.nih.gov/15090634/ | Pramlintide |
| Obesity Research | |||
| 13 June 2026 | Source | New source added to PramlintideAddition of pramlintide to insulin therapy lowers HbA1c in conjunction with weight loss in patients with type 2 diabetes approaching glycaemic targets · pubmed.ncbi.nlm.nih.gov/14617226/ | Pramlintide |
| 13 June 2026 | Source | New source added to PramlintideThe effect of pramlintide acetate on glycemic control and weight in patients with type 2 diabetes mellitus and in obese patients without diabetes: a systematic review and meta-analysis · pubmed.ncbi.nlm.nih.gov/21199269/ | Pramlintide |
| Diabetes, Obesity and Metabolism | |||
| 13 June 2026 | Source | New source added to PramlintideEfficacy and safety of pramlintide injection adjunct to insulin therapy in patients with type 1 diabetes mellitus: a systematic review and meta-analysis · pmc.ncbi.nlm.nih.gov/articles/PMC5630431/ | Pramlintide |
| 13 June 2026 | Source | New source added to PinealonTripeptides Restore the Number of Neuronal Spines under Conditions of In Vitro Modeled Alzheimer's Disease · pubmed.ncbi.nlm.nih.gov/28853087/ | Pinealon |
| Bulletin of Experimental Biology and Medicine | |||
| 13 June 2026 | Source | New source added to PinealonPinealon protects the rat offspring from prenatal hyperhomocysteinemia · pubmed.ncbi.nlm.nih.gov/22567179/ | Pinealon |
| International Journal of Clinical and Experimental Medicine | |||
| 13 June 2026 | Source | New source added to PinealonNeuroprotective Effects of Tripeptides — Epigenetic Regulators in Mouse Model of Alzheimer's Disease · pmc.ncbi.nlm.nih.gov/articles/PMC8227791/ | Pinealon |
| MDPI Pharmaceuticals | |||
| 13 June 2026 | Source | New source added to PinealonEDR Peptide: Possible Mechanism of Gene Expression and Protein Synthesis Regulation Involved in the Pathogenesis of Alzheimer's Disease · pmc.ncbi.nlm.nih.gov/articles/PMC7795577/ | Pinealon |
| MDPI Molecules | |||
| 13 June 2026 | Source | New source added to Semax-AmidateSemax, a Synthetic Regulatory Peptide, Affects Copper-Induced Abeta Aggregation and Amyloid Formation in Artificial Membrane Models · pmc.ncbi.nlm.nih.gov/articles/PMC8855339/ | Semax-Amidate |
| ACS Chemical Neuroscience | |||
| 13 June 2026 | Source | New source added to Semax-AmidateEffects of Semax on the Default Mode Network of the Brain · pubmed.ncbi.nlm.nih.gov/30225715/ | Semax-Amidate |
| Bulletin of Experimental Biology and Medicine | |||
| 13 June 2026 | Source | New source added to Semax-AmidateSemax and Pro-Gly-Pro Activate the Transcription of Neurotrophins and Their Receptor Genes after Cerebral Ischemia · pmc.ncbi.nlm.nih.gov/articles/PMC11498467/ | Semax-Amidate |
| Cellular and Molecular Neurobiology | |||
| 13 June 2026 | Source | New source added to Semax-AmidateEffects of behaviorally active ACTH(4-10) analogue Semax on rat basal forebrain cholinergic neurons · pubmed.ncbi.nlm.nih.gov/18431004/ | Semax-Amidate |
| Restorative Neurology and Neuroscience | |||
| 13 June 2026 | Source | New source added to Semax-AmidateSemax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents · pubmed.ncbi.nlm.nih.gov/16362768/ | Semax-Amidate |
| Neurochemical Research | |||
| 13 June 2026 | Source | New source added to Semax-AmidateSemax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus · pubmed.ncbi.nlm.nih.gov/16996037/ | Semax-Amidate |
| Brain Research | |||
| 12 June 2026 | Source | New source added to LeptinMetreleptin (Myalept) - Medical Clinical Policy Bulletin · aetna.com/cpb/medical/data/800_899/0882.ht… | Leptin |
| Aetna | |||
| 12 June 2026 | Source | New source added to LeptinLeptin responsiveness restored by amylin agonism in diet-induced obesity: Evidence from nonclinical and clinical studies · pnas.org/doi/10.1073/pnas.0706473105 | Leptin |
| Proceedings of the National Academy of Sciences | |||
| 12 June 2026 | Source | New source added to LeptinMetreleptin for injection to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy · pubmed.ncbi.nlm.nih.gov/26465174/ | Leptin |
| 12 June 2026 | Source | New source added to LeptinBeneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency · jci.org/articles/view/15693 | Leptin |
| Journal of Clinical Investigation | |||
| 12 June 2026 | Source | New source added to LeptinStructural insights into the mechanism of leptin receptor activation · pmc.ncbi.nlm.nih.gov/articles/PMC10066393/ | Leptin |
| Nature Communications | |||
| 12 June 2026 | Source | New source added to LeptinNew advances in the treatment of generalized lipodystrophy: role of metreleptin · pmc.ncbi.nlm.nih.gov/articles/PMC4577254/ | Leptin |
| 12 June 2026 | Source | New source added to LeptinRecent advances in understanding leptin signaling and leptin resistance · pmc.ncbi.nlm.nih.gov/articles/PMC2793049/ | Leptin |
| American Journal of Physiology | |||
| 12 June 2026 | Source | New source added to LarazotideStudy to Evaluate the Efficacy and Safety of Larazotide Acetate for the Relief of CeD Symptoms (CedLara) · clinicaltrials.gov/study/NCT03569007 | Larazotide |
| ClinicalTrials.gov | |||
| 12 June 2026 | Source | New source added to LarazotideClinical Trial Finds Safe, Effective Treatment for Children with Severe Post-COVID Syndrome · massgeneralbrigham.org/en/about/newsroom/press-releases… | Larazotide |
| Mass General Brigham | |||
| 12 June 2026 | Source | New source added to LarazotideA systematic review and meta-analysis of randomized controlled trials: Efficacy and safety of larazotide acetate in celiac disease patients undergoing a gluten challenge · symbiosisonlinepublishing.com/gastroenterology-pancreatology-l… | Larazotide |
| 12 June 2026 | Source | New source added to LarazotideLarazotide acetate: a pharmacological peptide approach to tight junction regulation · pmc.ncbi.nlm.nih.gov/articles/PMC11735010/ | Larazotide |
| American Journal of Physiology-Gastrointestinal and Liver Physiology | |||
| 12 June 2026 | Source | New source added to LarazotideThe potential utility of tight junction regulation in celiac disease: focus on larazotide acetate · pubmed.ncbi.nlm.nih.gov/26770266/ | Larazotide |
| Therapeutic Advances in Gastroenterology | |||
| 12 June 2026 | Source | New source added to LarazotideA randomized, double-blind study of larazotide acetate to prevent the activation of celiac disease during gluten challenge · pubmed.ncbi.nlm.nih.gov/22825365/ | Larazotide |
| 12 June 2026 | Source | New source added to LarazotideLarazotide acetate in patients with coeliac disease undergoing a gluten challenge: a randomised placebo-controlled study · pubmed.ncbi.nlm.nih.gov/23163616/ | Larazotide |
| Gut | |||
| 12 June 2026 | Source | New source added to LarazotideLarazotide Acetate for Persistent Symptoms of Celiac Disease Despite a Gluten-Free Diet: A Randomized Controlled Trial · pubmed.ncbi.nlm.nih.gov/25683116/ | Larazotide |
| Gastroenterology | |||
| 12 June 2026 | Source | New source added to KPVLysine-Proline-Valine peptide mitigates fine dust-induced keratinocyte apoptosis and inflammation by regulating oxidative stress and modulating the MAPK/NF-kB pathway · pubmed.ncbi.nlm.nih.gov/40073467/ | KPV |
| Tissue and Cell (Elsevier) | |||
| 12 June 2026 | Source | New source added to KPVThe Melanocortin System in Inflammatory Bowel Diseases: Insights into Its Mechanisms and Therapeutic Potentials · pubmed.ncbi.nlm.nih.gov/37508552/ | KPV |
| Cells (MDPI) | |||
| 12 June 2026 | Source | New source added to KPVInhibition of cellular and systemic inflammation cues in human bronchial epithelial cells by melanocortin-related peptides: mechanism of KPV action and a role for MC3R agonists · discovery.dundee.ac.uk/en/publications/inhibition-of-ce… | KPV |
| International Journal of Physiology, Pathophysiology and Pharmacology | |||
| 12 June 2026 | Source | New source added to KPVTerminal signal: anti-inflammatory effects of alpha-melanocyte-stimulating hormone related peptides beyond the pharmacophore · pubmed.ncbi.nlm.nih.gov/21222263/ | KPV |
| Advances in Experimental Medicine and Biology (Springer) | |||
| 12 June 2026 | Source | New source added to KPVAntimicrobial effects of alpha-MSH peptides · pubmed.ncbi.nlm.nih.gov/10670585/ | KPV |
| Journal of Leukocyte Biology | |||
| 12 June 2026 | Source | New source added to KPVPepT1-mediated tripeptide KPV uptake reduces intestinal inflammation · pubmed.ncbi.nlm.nih.gov/18061177/ | KPV |
| Gastroenterology (Elsevier) | |||
| 12 June 2026 | Source | New source added to KisspeptinEmerging Therapeutic Potential of Kisspeptin and Neurokinin B · academic.oup.com/edrv/article/45/1/30/7226658 | Kisspeptin |
| Endocrine Reviews | |||
| 12 June 2026 | Source | New source added to KisspeptinIntranasal kisspeptin administration rapidly stimulates gonadotropin release in humans · pmc.ncbi.nlm.nih.gov/articles/PMC12018048/ | Kisspeptin |
| 12 June 2026 | Source | New source added to KisspeptinIncreasing LH Pulsatility in Women With Hypothalamic Amenorrhoea Using Intravenous Infusion of Kisspeptin-54 · pmc.ncbi.nlm.nih.gov/articles/PMC4207927/ | Kisspeptin |
| 12 June 2026 | Source | New source added to KisspeptinEfficacy of Kisspeptin-54 to Trigger Oocyte Maturation in Women at High Risk of Ovarian Hyperstimulation Syndrome (OHSS) During In Vitro Fertilization (IVF) Therapy · pmc.ncbi.nlm.nih.gov/articles/PMC4570165/ | Kisspeptin |
| Journal of Clinical Endocrinology and Metabolism | |||
| 12 June 2026 | Source | New source added to KisspeptinKisspeptin-54 triggers egg maturation in women undergoing in vitro fertilization · jci.org/articles/view/75730 | Kisspeptin |
| Journal of Clinical Investigation | |||
| 12 June 2026 | Source | New source added to KisspeptinThe Role of Kisspeptin in the Control of the Hypothalamic-Pituitary-Gonadal Axis and Reproduction · pmc.ncbi.nlm.nih.gov/articles/PMC9273750/ | Kisspeptin |
| 12 June 2026 | Source | New source added to ImunofanIMUNOFAN — Official Manufacturer Information (NPP BIONOX) · imunofan.ru/en/main/ | Imunofan |
| NPP BIONOX, Russia | |||
| 12 June 2026 | Source | New source added to Imunofan[The immunocorrective action of the new synthetic hexapeptide imunofan in pharmacologically induced and ecological immunodeficiency] · pubmed.ncbi.nlm.nih.gov/8664598/ | Imunofan |
| Vestnik Rossiiskoi Akademii Meditsinskikh Nauk | |||
| 12 June 2026 | Source | New source added to ImunofanP20 - The use of regulatory hexapeptide on frequently ill children · pmc.ncbi.nlm.nih.gov/articles/PMC4081846/ | Imunofan |
| BMC Infectious Diseases (conference supplement) | |||
| 12 June 2026 | Source | New source added to ImunofanRole of immunotherapy in complex treatment of acute optic neuritis associated with herpesvirus infection · actabiomedica.ru/jour/article/view/3439/0?locale=… | Imunofan |
| Acta Biomedica Scientifica | |||
| 12 June 2026 | Source | New source added to Imunofan[Experimental study of the effectiveness of the use of imunofan in the treatment of viral diseases of the eye] · pubmed.ncbi.nlm.nih.gov/11765469/ | Imunofan |
| 12 June 2026 | Source | New source added to ImunofanHydrophilic hexapeptide Imunofan as a hyperactive regulator of transport proteins for multiple drug resistance · pubmed.ncbi.nlm.nih.gov/17603672/ | Imunofan |
| Bulletin of Experimental Biology and Medicine | |||
| 12 June 2026 | Source | New source added to Imunofan[A trial of the use of the immunocorrective preparation Imunofan for treating diphtheria] · pubmed.ncbi.nlm.nih.gov/8771665/ | Imunofan |
| Terapevticheskii Arkhiv | |||
| 12 June 2026 | Source | New source added to ImunofanImunofan—RDKVYR Peptide—Stimulates Skin Cell Proliferation and Promotes Tissue Repair · pmc.ncbi.nlm.nih.gov/articles/PMC7355430/ | Imunofan |
| MDPI Molecules | |||
| 12 June 2026 | Source | New source added to OvagenBuy OVAGEN (liver peptides) - product page · cosmicnootropic.com/products/ovagen-bioregulator/ | Ovagen |
| CosmicNootropic | |||
| 12 June 2026 | Source | New source added to OvagenThe influence of polypeptide liver complex and tetrapeptide KEDA on organism physiological function in norm and age-related pathology · pubmed.ncbi.nlm.nih.gov/32362099/ | Ovagen |
| Advances in Gerontology | |||
| 12 June 2026 | Source | New source added to OvagenTripeptides slow down aging process in renal cell culture · pubmed.ncbi.nlm.nih.gov/25946838/ | Ovagen |
| Advances in Gerontology | |||
| 12 June 2026 | Source | New source added to OvagenShort Peptides Regulate Gene Expression · pubmed.ncbi.nlm.nih.gov/27909961/ | Ovagen |
| Bulletin of Experimental Biology and Medicine | |||
| 12 June 2026 | Source | New source added to OrforglipronATTAIN-Outcomes: Cardiovascular Outcomes Study of Orforglipron (NCT07241390) · clinicaltrials.gov/study/NCT07241390 | Orforglipron |
| ClinicalTrials.gov / Eli Lilly | |||
| 12 June 2026 | Source | New source added to OrforglipronOrforglipron: A Comprehensive Review of an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity and Type 2 Diabetes — PMC · pmc.ncbi.nlm.nih.gov/articles/PMC12898445/ | Orforglipron |
| International Journal of Molecular Sciences / PMC | |||
| 12 June 2026 | Source | New source added to OrforglipronOrforglipron (LY3502970): Phase 1b Multiple-Ascending-Dose Study in Type 2 Diabetes · pubmed.ncbi.nlm.nih.gov/37264711/ | Orforglipron |
| 12 June 2026 | Source | New source added to OrforglipronOrforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes — ACHIEVE-1 Phase 3 · nejm.org/doi/full/10.1056/NEJMoa2505669 | Orforglipron |
| New England Journal of Medicine | |||
| 12 June 2026 | Source | New source added to OrforglipronOrforglipron, an oral small-molecule GLP-1 receptor agonist, for obesity in people with type 2 diabetes (ATTAIN-2) — The Lancet · thelancet.com/journals/lancet/article/PIIS0140… | Orforglipron |
| The Lancet | |||
| 12 June 2026 | Source | New source added to OrforglipronOrforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, for Obesity Treatment — ATTAIN-1 Phase 3 · nejm.org/doi/full/10.1056/NEJMoa2511774 | Orforglipron |
| New England Journal of Medicine | |||
| 12 June 2026 | Source | New source added to OrforglipronDaily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity (Phase 2) · nejm.org/doi/full/10.1056/NEJMoa2302392 | Orforglipron |
| New England Journal of Medicine | |||
| 12 June 2026 | Source | New source added to OrforglipronFOUNDAYO (orforglipron) tablets — DailyMed FDA Prescribing Information (NDA 220934) · dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8ac4… | Orforglipron |
| U.S. National Library of Medicine / FDA | |||
| 12 June 2026 | Source | New source added to NSI-189Antidepressant with novel action appears safe and effective in phase 1b clinical trial · eurekalert.org/news-releases/628798 | NSI-189 |
| EurekAlert / AAAS | |||
| 12 June 2026 | Source | New source added to NSI-189Study of NSI-189 Phosphate for Major Depressive Disorder (NCT02695472) · clinicaltrials.gov/study/NCT02695472 | NSI-189 |
| 12 June 2026 | Source | New source added to NSI-189Neuralstem Announces Top-line Phase 2 Data of NSI-189 for Major Depressive Disorder · globenewswire.com/news-release/2017/07/25/1057673/… | NSI-189 |
| 12 June 2026 | Source | New source added to NSI-189Amelioration of Both Central and Peripheral Neuropathy in Mouse Models of Type 1 and Type 2 Diabetes by the Neurogenic Molecule NSI-189 · pmc.ncbi.nlm.nih.gov/articles/PMC6804627/ | NSI-189 |
| Diabetes (American Diabetes Association) | |||
| 12 June 2026 | Source | New source added to NSI-189Enhancement of synaptic plasticity and reversal of impairments in motor and cognitive functions in a mouse model of Angelman Syndrome by a small neurogenic molecule, NSI-189 · pubmed.ncbi.nlm.nih.gov/30408487/ | NSI-189 |
| Neuropharmacology | |||
| 12 June 2026 | Source | New source added to NSI-189A Phase 1B, randomized, double blind, placebo controlled, multiple-dose escalation study of NSI-189 phosphate, a neurogenic compound, in depressed patients · pubmed.ncbi.nlm.nih.gov/27528461/ | NSI-189 |
| Molecular Psychiatry | |||
| 12 June 2026 | Source | New source added to NSI-189A phase 2, double-blind, placebo-controlled study of NSI-189 phosphate, a neurogenic compound, among outpatients with major depressive disorder · pmc.ncbi.nlm.nih.gov/articles/PMC7303010/ | NSI-189 |
| Molecular Psychiatry | |||
| 12 June 2026 | Source | New source added to NavepegritideNavepegritide: Uses, Interactions, Mechanism of Action — DrugBank · go.drugbank.com/drugs/DB17824 | Navepegritide |
| 12 June 2026 | Source | New source added to NavepegritideFDA Approves Once-Weekly YUVIWEL (navepegritide) for Children with Achondroplasia Aged 2 Years and Older — Ascendis Pharma Press Release · investors.ascendispharma.com/news-releases/news-release-detai… | Navepegritide |
| Ascendis Pharma | |||
| 12 June 2026 | Source | New source added to NavepegritideNew Data from Week 52 of the Ongoing COACH Trial Showed that TransCon hGH Accelerated TransCon CNP's Benefits Beyond Linear Growth in Children with Achondroplasia · globenewswire.com/news-release/2026/04/08/3270080/… | Navepegritide |
| Ascendis Pharma / GlobeNewswire | |||
| 12 June 2026 | Source | New source added to NavepegritideMolecular Mechanism of Induction of Bone Growth by the C-Type Natriuretic Peptide · pmc.ncbi.nlm.nih.gov/articles/PMC9180634/ | Navepegritide |
| 12 June 2026 | Source | New source added to NavepegritideNavepegritide (Yuviwel) for Children with Achondroplasia: New Drugs and Therapeutics — Pediatric Endocrine Society · pedsendo.org/new-meds-and-tech/navepegritide-… | Navepegritide |
| 12 June 2026 | Source | New source added to NavepegritideYUVIWEL (navepegritide) Prescribing Information — DailyMed · dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e01c… | Navepegritide |
| 12 June 2026 | Source | New source added to NavepegritideOnce-Weekly Navepegritide in Children With Achondroplasia: The APPROACH Randomized Clinical Trial · pmc.ncbi.nlm.nih.gov/articles/PMC12624480/ | Navepegritide |
| JAMA Pediatrics / PubMed Central | |||
| 12 June 2026 | Source | New source added to GonadorelinGonadotropin Releasing Hormone (GnRH) Analogues — LiverTox: Clinical and Research Information on Drug-Induced Liver Injury · ncbi.nlm.nih.gov/books/NBK547863/ | Gonadorelin |
| National Institute of Diabetes and Digestive and Kidney Diseases / NCBI Bookshelf | |||
| 12 June 2026 | Source | New source added to GonadorelinFactrel (Gonadorelin Hydrochloride): Full Prescribing Information — RxList · rxlist.com/factrel-drug.htm | Gonadorelin |
| RxList / WebMD | |||
| 12 June 2026 | Source | New source added to GonadorelinTherapeutic effects of a pulsatile GnRH pump on adult male patients with congenital hypogonadotropic hypogonadism (CHH): a retrospective study · pmc.ncbi.nlm.nih.gov/articles/PMC12336735/ | Gonadorelin |
| Translational Andrology and Urology | |||
| 12 June 2026 | Source | New source added to GonadorelinSpermatogenesis of Male Patients with Congenital Hypogonadotropic Hypogonadism Receiving Pulsatile Gonadotropin-Releasing Hormone Therapy Versus Gonadotropin Therapy: A Systematic Review and Meta-Analysis · pmc.ncbi.nlm.nih.gov/articles/PMC8443979/ | Gonadorelin |
| World Journal of Men's Health | |||
| 12 June 2026 | Source | New source added to GonadorelinUse of pulsatile gonadotropin-releasing hormone (GnRH) in patients with functional hypothalamic amenorrhea (FHA) results in monofollicular ovulation and high cumulative live birth rates: a 25-year cohort · pmc.ncbi.nlm.nih.gov/articles/PMC9790838/ | Gonadorelin |
| Journal of Assisted Reproduction and Genetics | |||
| 12 June 2026 | Source | New source added to Glycine PeptideGlycine's Role In Sleep Enhancement: Clinical Evidence, Mechanisms, and Therapeutic Applications · globalrph.com/2025/10/glycines-role-in-sleep-e… | Glycine Peptide |
| GlobalRPH | |||
| 12 June 2026 | Source | New source added to Glycine PeptideGlycine: Health Benefits, Side Effects, Uses, Dose & Precautions · rxlist.com/supplements/glycine.htm | Glycine Peptide |
| RxList | |||
| 12 June 2026 | Source | New source added to Glycine PeptideGlycine for Sleep · sleepfoundation.org/sleep-aids/glycine-for-sleep | Glycine Peptide |
| Sleep Foundation | |||
| 12 June 2026 | Source | New source added to Glycine PeptideGlycine ingestion improves subjective sleep quality in human volunteers, correlating with polysomnographic changes · onlinelibrary.wiley.com/doi/10.1111/j.1479-8425.2007.002… | Glycine Peptide |
| Sleep and Biological Rhythms (Wiley) | |||
| 12 June 2026 | Source | New source added to Glycine PeptideCollagen peptide supplementation before bedtime reduces sleep fragmentation and improves cognitive function in physically active males with sleep complaints · pmc.ncbi.nlm.nih.gov/articles/PMC10799148/ | Glycine Peptide |
| British Journal of Nutrition | |||
| 12 June 2026 | Source | New source added to Glycine PeptideThe sleep-promoting and hypothermic effects of glycine are mediated by NMDA receptors in the suprachiasmatic nucleus · pubmed.ncbi.nlm.nih.gov/25533534/ | Glycine Peptide |
| Neuropsychopharmacology | |||
| 12 June 2026 | Source | New source added to Glycine PeptideThe effects of glycine on subjective daytime performance in partially sleep-restricted healthy volunteers · pubmed.ncbi.nlm.nih.gov/22529837/ | Glycine Peptide |
| Frontiers in Neurology | |||
| 12 June 2026 | Source | New source added to Fragment 176-191Human Growth Hormone Fragment 176-191 Peptide Enhances the Toxicity of Doxorubicin-Loaded Chitosan Nanoparticles Against MCF-7 Breast Cancer Cells · pubmed.ncbi.nlm.nih.gov/35783198/ | Fragment 176-191 |
| Drug Design, Development and Therapy | |||
| 12 June 2026 | Source | New source added to Fragment 176-191Metabolic Pharmaceuticals AOD9604 Phase 2B Trial Update · biospace.com/metabolic-pharmaceuticals-s-obes… | Fragment 176-191 |
| BioSpace | |||
| 12 June 2026 | Source | New source added to Fragment 176-191Obesity drug codenamed AOD9604 highly successful in trials (Phase IIa results) · news-medical.net/news/2004/12/16/6878.aspx | Fragment 176-191 |
| News-Medical.Net | |||
| 12 June 2026 | Source | New source added to Fragment 176-191Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans · jofem.org/index.php/jofem/article/view/157… | Fragment 176-191 |
| Journal of Endocrinology and Metabolism | |||
| 12 June 2026 | Source | New source added to Fragment 176-191The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice · pubmed.ncbi.nlm.nih.gov/11713213/ | Fragment 176-191 |
| Endocrinology (Oxford Academic) | |||
| 12 June 2026 | Source | New source added to DulaglutideLiraglutide and Dulaglutide therapy in addition to SGLT-2 inhibitor and metformin treatment in Indian type 2 diabetics: a real world retrospective observational study · pmc.ncbi.nlm.nih.gov/articles/PMC5941332/ | Dulaglutide |
| 12 June 2026 | Source | New source added to DulaglutideEffect of once-weekly dulaglutide on renal function in patients with chronic kidney disease · pubmed.ncbi.nlm.nih.gov/35960776/ | Dulaglutide |
| 12 June 2026 | Source | New source added to DulaglutideExploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND · pmc.ncbi.nlm.nih.gov/articles/PMC8466679/ | Dulaglutide |
| 12 June 2026 | Source | New source added to DulaglutideDulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial · sciencedirect.com/science/article/abs/pii/S0140673… | Dulaglutide |
| The Lancet | |||
| 12 June 2026 | Source | New source added to DulaglutideEffect of dulaglutide 3.0 and 4.5 mg on weight in patients with type 2 diabetes: Exploratory analyses of AWARD-11 · pubmed.ncbi.nlm.nih.gov/34189841/ | Dulaglutide |
| 12 June 2026 | Source | New source added to DulaglutideEfficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11) · diabetesjournals.org/care/article/44/3/765/138650/Eff… | Dulaglutide |
| Diabetes Care / American Diabetes Association | |||
| 12 June 2026 | Source | New source added to DulaglutideEfficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program · pubmed.ncbi.nlm.nih.gov/27102969/ | Dulaglutide |
| 12 June 2026 | Source | New source added to DulaglutideTRULICITY (dulaglutide) Prescribing Information - DailyMed · dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=af4e… | Dulaglutide |
| U.S. National Library of Medicine / Eli Lilly and Company | |||
| 12 June 2026 | Source | New source added to NA-Semax-AmidateNeuroprotective Effects of ACTH4-10PRO8-GLY9-PRO10 (NCT05648526) · clinicaltrials.gov/study/NCT05648526 | NA-Semax-Amidate |
| ClinicalTrials.gov | |||
| 12 June 2026 | Source | New source added to NA-Semax-AmidateBrain Protein Expression Profile Confirms the Protective Effect of the ACTH(4-7)PGP Peptide (Semax) in a Rat Model of Cerebral Ischemia-Reperfusion · pmc.ncbi.nlm.nih.gov/articles/PMC8226508/ | NA-Semax-Amidate |
| International Journal of Molecular Sciences | |||
| 12 June 2026 | Source | New source added to NA-Semax-AmidateThe efficacy of semax in the treatment of patients at different stages of ischemic stroke · pubmed.ncbi.nlm.nih.gov/29798983/ | NA-Semax-Amidate |
| Zh Nevrol Psikhiatr Im S S Korsakova | |||
| 12 June 2026 | Source | New source added to NA-Semax-AmidateSemax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus · pubmed.ncbi.nlm.nih.gov/16996037/ | NA-Semax-Amidate |
| Brain Research | |||
| 12 June 2026 | Source | New source added to MOTS-cMOTS-c improves intrinsic muscle mitochondrial bioenergetic health and efficiency in a PGC-1alpha/AMPK-dependent manner · pubmed.ncbi.nlm.nih.gov/41520850/ | MOTS-c |
| Free Radical Biology and Medicine | |||
| 12 June 2026 | Source | New source added to MOTS-cCohBar Announces Positive Topline Results from the Phase 1a/1b Study of CB4211 Under Development for NASH and Obesity · globenewswire.com/news-release/2021/08/10/2278324/… | MOTS-c |
| GlobeNewswire / CohBar Inc. | |||
| 12 June 2026 | Source | New source added to MOTS-cMOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation · pubmed.ncbi.nlm.nih.gov/36761202/ | MOTS-c |
| Frontiers in Endocrinology | |||
| 12 June 2026 | Source | New source added to MOTS-cMitochondrial-Encoded Peptide MOTS-c, Diabetes, and Aging-Related Diseases · e-dmj.org/journal/view.php?number=2725 | MOTS-c |
| Diabetes and Metabolism Journal | |||
| 12 June 2026 | Source | New source added to MOTS-cMOTS-c, the Most Recent Mitochondrial Derived Peptide in Human Aging and Age-Related Diseases · pmc.ncbi.nlm.nih.gov/articles/PMC9570330/ | MOTS-c |
| International Journal of Molecular Sciences | |||
| 12 June 2026 | Source | New source added to MOTS-cMOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis · nature.com/articles/s41467-020-20790-0 | MOTS-c |
| Nature Communications | |||
| 12 June 2026 | Source | New source added to MOTS-cThe Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress · pubmed.ncbi.nlm.nih.gov/29983246/ | MOTS-c |
| Cell Metabolism | |||
| 12 June 2026 | Source | New source added to MOTS-cThe mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance · pubmed.ncbi.nlm.nih.gov/25738459/ | MOTS-c |
| Cell Metabolism | |||
| 12 June 2026 | Source | New source added to MK-677 (Ibutamoren)Growth Hormone Secretagogues as Potential Therapeutic Agents to Restore Growth Hormone Secretion in Older Subjects to Those Observed in Young Adults · pmc.ncbi.nlm.nih.gov/articles/PMC10272984/ | MK-677 (Ibutamoren) |
| Journals of Gerontology: Series A | |||
| 12 June 2026 | Source | New source added to MK-677 (Ibutamoren)Hepatotoxicity induced by MK-677 · pubmed.ncbi.nlm.nih.gov/40675653/ | MK-677 (Ibutamoren) |
| 12 June 2026 | Source | New source added to MK-677 (Ibutamoren)Could Overt Diabetes Be Triggered by Abuse of Selective Androgen Receptor Modulators and Growth Hormone Secretagogues? A Case Report and Review · pmc.ncbi.nlm.nih.gov/articles/PMC9331610/ | MK-677 (Ibutamoren) |
| Frontiers in Endocrinology | |||
| 12 June 2026 | Source | New source added to MK-677 (Ibutamoren)Effects of oral administration of ibutamoren mesylate on the GH-IGF-I axis in GH-deficient children (Codner et al., 2001) · pubmed.ncbi.nlm.nih.gov/11452249/ | MK-677 (Ibutamoren) |
| Clinical Pharmacology and Therapeutics | |||
| 12 June 2026 | Source | New source added to MK-677 (Ibutamoren)Structural basis of human ghrelin receptor signaling by ghrelin and the synthetic agonist ibutamoren · pmc.ncbi.nlm.nih.gov/articles/PMC8568970/ | MK-677 (Ibutamoren) |
| Nature Communications | |||
| 12 June 2026 | Source | New source added to MK-677 (Ibutamoren)MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism (Murphy et al., 1998) · pubmed.ncbi.nlm.nih.gov/9467534/ | MK-677 (Ibutamoren) |
| Journal of Clinical Endocrinology and Metabolism | |||
| 12 June 2026 | Source | New source added to MK-677 (Ibutamoren)Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial · pubmed.ncbi.nlm.nih.gov/19015485/ | MK-677 (Ibutamoren) |
| Neurology | |||
| 12 June 2026 | Source | New source added to MK-677 (Ibutamoren)Effects of an Oral Ghrelin Mimetic on Body Composition and Clinical Outcomes in Healthy Older Adults: A Randomized, Controlled Trial (Nass et al., 2008) · pmc.ncbi.nlm.nih.gov/articles/PMC2757071/ | MK-677 (Ibutamoren) |
| Annals of Internal Medicine | |||
| 12 June 2026 | Source | New source added to MemantineDonepezil and memantine for moderate-to-severe Alzheimer's disease · pubmed.ncbi.nlm.nih.gov/22397651/ | Memantine |
| New England Journal of Medicine | |||
| 12 June 2026 | Source | New source added to MemantineDailyMed - MEMANTINE tablet - Full Prescribing Information · dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a5dc… | Memantine |
| National Library of Medicine / DailyMed | |||
| 12 June 2026 | Source | New source added to MemantineMemantine in Psychiatry: An Underutilized Therapeutic Breakthrough? · pmc.ncbi.nlm.nih.gov/articles/PMC12260883/ | Memantine |
| 12 June 2026 | Source | New source added to MemantineMemantine and Cholinesterase Inhibitors: Complementary Mechanisms in the Treatment of Alzheimer's Disease · pmc.ncbi.nlm.nih.gov/articles/PMC3753463/ | Memantine |
| Neurotoxicity Research / Springer | |||
| 12 June 2026 | Source | New source added to MemantineMemantine Monotherapy for Alzheimer's Disease: A Systematic Review and Meta-Analysis · journals.plos.org/plosone/article?id=10.1371%2Fjou… | Memantine |
| PLOS ONE | |||
| 12 June 2026 | Source | New source added to MemantineBasic information about memantine and its treatment of Alzheimer's disease and other clinical applications · pmc.ncbi.nlm.nih.gov/articles/PMC10527776/ | Memantine |
| iBrain / Wiley Online Library | |||
| 12 June 2026 | Source | New source added to MemantineUpdate on the use of memantine in Alzheimer's disease · pmc.ncbi.nlm.nih.gov/articles/PMC2695219/ | Memantine |
| Neuropsychiatric Disease and Treatment | |||
| 12 June 2026 | Source | New source added to MemantineMemantine - StatPearls - NCBI Bookshelf · ncbi.nlm.nih.gov/books/NBK500025/ | Memantine |
| StatPearls Publishing / NCBI | |||
| 12 June 2026 | Source | New source added to Melatonin Peptide ComplexSafety of higher doses of melatonin in adults: A systematic review and meta-analysis · pmc.ncbi.nlm.nih.gov/articles/PMC10109390/ | Melatonin Peptide Complex |
| Journal of Pineal Research / PMC | |||
| 12 June 2026 | Source | New source added to Melatonin Peptide ComplexA clinical trial with DSIP · pubmed.ncbi.nlm.nih.gov/6391926/ | Melatonin Peptide Complex |
| European Neurology | |||
| 12 June 2026 | Source | New source added to Melatonin Peptide ComplexThe influence of synthetic DSIP (delta-sleep-inducing-peptide) on disturbed human sleep · pubmed.ncbi.nlm.nih.gov/7028502/ | Melatonin Peptide Complex |
| Experientia | |||
| 12 June 2026 | Source | New source added to Melatonin Peptide ComplexDelta-sleep-inducing peptide stimulates melatonin, 5-methoxytryptophol and serotonin release from perifused rat pineal glands · pubmed.ncbi.nlm.nih.gov/1339175/ | Melatonin Peptide Complex |
| Biological Signals | |||
| 12 June 2026 | Source | New source added to Melatonin Peptide ComplexDifferential Function of Melatonin MT1 and MT2 Receptors in REM and NREM Sleep · pmc.ncbi.nlm.nih.gov/articles/PMC6407453/ | Melatonin Peptide Complex |
| Frontiers in Endocrinology | |||
| 12 June 2026 | Source | New source added to Melatonin Peptide ComplexEffect of melatonin supplementation on sleep quality: a systematic review and meta-analysis of randomized controlled trials · pubmed.ncbi.nlm.nih.gov/33417003/ | Melatonin Peptide Complex |
| Journal of Sleep Research | |||
| 12 June 2026 | Source | New source added to Melatonin Peptide ComplexMeta-Analysis: Melatonin for the Treatment of Primary Sleep Disorders · pmc.ncbi.nlm.nih.gov/articles/PMC3656905/ | Melatonin Peptide Complex |
| PLOS ONE | |||
| 12 June 2026 | Source | New source added to Melatonin Peptide ComplexOverview of Epitalon — Highly Bioactive Pineal Tetrapeptide with Promising Properties · pmc.ncbi.nlm.nih.gov/articles/PMC11943447/ | Melatonin Peptide Complex |
| MDPI / PMC | |||
| 12 June 2026 | Source | New source added to HumaninMitochondrial-derived peptides MOTS-c and humanin attenuate dexamethasone-induced atrophy in human skeletal muscle cells · pmc.ncbi.nlm.nih.gov/articles/PMC12930096/ | Humanin |
| 12 June 2026 | Source | New source added to HumaninThe emerging role of the mitochondrial-derived peptide humanin in stress resistance · pubmed.ncbi.nlm.nih.gov/23239898/ | Humanin |
| Journal of Molecular Endocrinology | |||
| 12 June 2026 | Source | New source added to HumaninChronic treatment with the mitochondrial peptide humanin prevents age-related myocardial fibrosis in mice · pubmed.ncbi.nlm.nih.gov/30004252/ | Humanin |
| 12 June 2026 | Source | New source added to HumaninNew Role for the Mitochondrial Peptide Humanin: Protective Agent Against Chemotherapy-Induced Side Effects · pmc.ncbi.nlm.nih.gov/articles/PMC3982780/ | Humanin |
| Journal of the National Cancer Institute | |||
| 12 June 2026 | Source | New source added to HumaninNeuroprotective Action of Humanin and Humanin Analogues: Research Findings and Perspectives · pmc.ncbi.nlm.nih.gov/articles/PMC10740898/ | Humanin |
| International Journal of Molecular Sciences | |||
| 12 June 2026 | Source | New source added to HumaninThe mitochondrial derived peptide humanin is a regulator of lifespan and healthspan · aging-us.com/article/103534/text | Humanin |
| Aging (Albany NY) | |||
| 12 June 2026 | Source | New source added to HumaninHumanin Prevents Age-Related Cognitive Decline in Mice and is Associated with Improved Cognitive Age in Humans · pmc.ncbi.nlm.nih.gov/articles/PMC6154958/ | Humanin |
| Scientific Reports (Nature) | |||
| 12 June 2026 | Source | New source added to HexarelinHexarelin Modulation of MAPK and PI3K/Akt Pathways in Neuro-2A Cells Inhibits Hydrogen Peroxide-Induced Apoptotic Toxicity · pmc.ncbi.nlm.nih.gov/articles/PMC8150489/ | Hexarelin |
| Pharmaceuticals (MDPI) | |||
| 12 June 2026 | Source | New source added to HexarelinModulation of PTEN by hexarelin attenuates coronary artery ligation-induced heart failure in rats · pmc.ncbi.nlm.nih.gov/articles/PMC7018219/ | Hexarelin |
| 12 June 2026 | Source | New source added to HexarelinHexarelin treatment preserves myocardial function and reduces cardiac fibrosis in a mouse model of acute myocardial infarction · pmc.ncbi.nlm.nih.gov/articles/PMC5949285/ | Hexarelin |
| 12 June 2026 | Source | New source added to HexarelinEffects of acute hexarelin administration on cardiac performance in patients with coronary artery disease during by-pass surgery · pubmed.ncbi.nlm.nih.gov/12144941/ | Hexarelin |
| European Journal of Pharmacology | |||
| 12 June 2026 | Source | New source added to HexarelinGrowth Hormone Status during Long-Term Hexarelin Therapy · academic.oup.com/jcem/article/83/5/1644/2865542 | Hexarelin |
| Oxford Academic / Endocrine Society | |||
| 12 June 2026 | Source | New source added to HexarelinHexarelin-induced growth hormone, cortisol, and prolactin release: a dose-response study · academic.oup.com/jcem/article-abstract/81/12/4338… | Hexarelin |
| Oxford Academic / Endocrine Society | |||
| 12 June 2026 | Source | New source added to HexarelinGrowth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal, and oral administration in man · academic.oup.com/jcem/article-abstract/78/3/693/2… | Hexarelin |
| Oxford Academic / Endocrine Society | |||
| 12 June 2026 | Source | New source added to Hexapeptide-11What does Hexapeptide-11 do for skin and hair? — ChemicalBook · chemicalbook.com/article/what-does-hexapeptide-11… | Hexapeptide-11 |
| 12 June 2026 | Source | New source added to Hexapeptide-11Hexapeptide-11 ingredient listing — INCIDecoder · incidecoder.com/ingredients/hexapeptide-11 | Hexapeptide-11 |
| 12 June 2026 | Source | New source added to Hexapeptide-11Peptamide 6 (Hexapeptide-11) — Cosmetic Ingredients Guide · ci.guide/peptides/peptamidetm-6 | Hexapeptide-11 |
| 12 June 2026 | Source | New source added to Hexapeptide-11Hexapeptide-11 in Skin Care: What It Is and Is It Safe? — Paula's Choice · paulaschoice.de/en/hexapeptide-11/ingredient-hex… | Hexapeptide-11 |
| 12 June 2026 | Source | New source added to Hexapeptide-11Hexapeptide-11 (CID 24998056) — PubChem Compound · pubchem.ncbi.nlm.nih.gov/compound/Hexapeptide-11 | Hexapeptide-11 |
| National Library of Medicine / NIH | |||
| 12 June 2026 | Source | New source added to Hexapeptide-11Hexapeptide-11 is a novel modulator of the proteostasis network in human diploid fibroblasts (PMC full text) · pmc.ncbi.nlm.nih.gov/articles/PMC4434199/ | Hexapeptide-11 |
| Redox Biology (Elsevier) | |||
| 12 June 2026 | Source | New source added to Hexapeptide-11Modulation of cellular senescence in fibroblasts and dermal papillae cells in vitro · pubmed.ncbi.nlm.nih.gov/23578831/ | Hexapeptide-11 |
| Journal of Cosmetic Science | |||
| 12 June 2026 | Source | New source added to Hexapeptide-11Hexapeptide-11 is a novel modulator of the proteostasis network in human diploid fibroblasts · pubmed.ncbi.nlm.nih.gov/25974626/ | Hexapeptide-11 |
| Redox Biology (Elsevier) | |||
| 12 June 2026 | Source | New source added to HCG (Human Chorionic Gonadotropin)Pregnyl (chorionic gonadotropin for injection, USP) Prescribing Information — NDA 017692 · accessdata.fda.gov/drugsatfda_docs/label/2011/01769… | HCG (Human Chorionic Gonadotropin) |
| U.S. Food and Drug Administration | |||
| 12 June 2026 | Source | New source added to HCG (Human Chorionic Gonadotropin)Preserving fertility in the hypogonadal patient: an update · pmc.ncbi.nlm.nih.gov/articles/PMC4378070/ | HCG (Human Chorionic Gonadotropin) |
| Asian Journal of Andrology / PMC | |||
| 12 June 2026 | Source | New source added to HCG (Human Chorionic Gonadotropin)The effect of human chorionic gonadotropin (hCG) in the treatment of obesity by means of the Simeons therapy: a criteria-based meta-analysis (DARE review) · ncbi.nlm.nih.gov/books/NBK66355/ | HCG (Human Chorionic Gonadotropin) |
| NCBI Bookshelf / Database of Abstracts of Reviews of Effects | |||
| 12 June 2026 | Source | New source added to HCG (Human Chorionic Gonadotropin)The Safety of Human Chorionic Gonadotropin Monotherapy Among Men With Previous Exogenous Testosterone Use · pmc.ncbi.nlm.nih.gov/articles/PMC9271319/ | HCG (Human Chorionic Gonadotropin) |
| Cureus | |||
| 12 June 2026 | Source | New source added to HCG (Human Chorionic Gonadotropin)Management Outcomes in Males With Hypogonadotropic Hypogonadism Treated With Gonadotropins · pmc.ncbi.nlm.nih.gov/articles/PMC10063211/ | HCG (Human Chorionic Gonadotropin) |
| Cureus | |||
| 12 June 2026 | Source | New source added to HCG (Human Chorionic Gonadotropin)Testosterone versus hCG in Hypogonadotropic Hypogonadism: Comparing Clinical Effects and Evaluating Current Practice · pubmed.ncbi.nlm.nih.gov/35187206/ | HCG (Human Chorionic Gonadotropin) |
| Global Pediatric Health | |||
| 12 June 2026 | Source | New source added to HCG (Human Chorionic Gonadotropin)Dose-dependent increase in intratesticular testosterone by very low-dose human chorionic gonadotropin in normal men with experimental gonadotropin deficiency · pubmed.ncbi.nlm.nih.gov/20484472/ | HCG (Human Chorionic Gonadotropin) |
| Journal of Clinical Endocrinology and Metabolism | |||
| 12 June 2026 | Source | New source added to HCG (Human Chorionic Gonadotropin)Human LH and hCG stimulate differently the early signalling pathways but result in equal testosterone synthesis in mouse Leydig cells in vitro · pmc.ncbi.nlm.nih.gov/articles/PMC5217336/ | HCG (Human Chorionic Gonadotropin) |
| Reproductive Biology and Endocrinology / BioMed Central | |||
| 12 June 2026 | Source | New source added to GroprinosinImunovir 500mg Tablets — Summary of Product Characteristics (SmPC) · medicines.org.uk/emc/product/2824/smpc | Groprinosin |
| Electronic Medicines Compendium (UK) | |||
| 12 June 2026 | Source | New source added to GroprinosinA Review on Inosine Pranobex Immunotherapy for Cervical HPV-Positive Patients · pubmed.ncbi.nlm.nih.gov/34103950/ | Groprinosin |
| Dove Medical Press | |||
| 12 June 2026 | Source | New source added to GroprinosinInosine Pranobex Deserves Attention as a Potential Immunomodulator to Achieve Early Alteration of the COVID-19 Disease Course · pmc.ncbi.nlm.nih.gov/articles/PMC8619495/ | Groprinosin |
| Viruses (MDPI) | |||
| 12 June 2026 | Source | New source added to GroprinosinEfficacy of inosine pranobex oral therapy in subclinical human papillomavirus infection of the vulva: a randomized double-blinded placebo controlled study · pubmed.ncbi.nlm.nih.gov/8876359/ | Groprinosin |
| International Journal of STD and AIDS | |||
| 12 June 2026 | Source | New source added to GroprinosinThe Efficacy of Inosine Pranobex in Preventing the Acquired Immunodeficiency Syndrome in Patients with Human Immunodeficiency Virus Infection (Scandinavian Isoprinosine Study Group) · pubmed.ncbi.nlm.nih.gov/1693173/ | Groprinosin |
| New England Journal of Medicine | |||
| 12 June 2026 | Source | New source added to GroprinosinEfficacy and Safety of Inosine Pranobex in COVID-19 Patients: A Multicenter Phase 3 Randomized Double-Blind, Placebo-Controlled Trial · pubmed.ncbi.nlm.nih.gov/36246300/ | Groprinosin |
| Advanced Therapeutics (Wiley) | |||
| 12 June 2026 | Source | New source added to GroprinosinInosine pranobex is safe and effective for the treatment of subjects with confirmed acute respiratory viral infections: Phase 4, randomised, placebo-controlled, double-blind study · pmc.ncbi.nlm.nih.gov/articles/PMC5100179/ | Groprinosin |
| BMC Infectious Diseases | |||
| 12 June 2026 | Source | New source added to Melanotan IISCENESSE (afamelanotide) Prescribing Information · accessdata.fda.gov/drugsatfda_docs/label/2019/21079… | Melanotan II |
| U.S. Food and Drug Administration | |||
| 12 June 2026 | Source | New source added to Melanotan IIMelanotan II · dermnetnz.org/topics/melanotan-ii | Melanotan II |
| DermNet New Zealand | |||
| 12 June 2026 | Source | New source added to Melanotan IIEruptive dysplastic nevi following melanotan use · pubmed.ncbi.nlm.nih.gov/22425244/ | Melanotan II |
| Actas Dermosifiliograficas | |||
| 12 June 2026 | Source | New source added to Melanotan IIMelanotan-associated melanoma in situ · pubmed.ncbi.nlm.nih.gov/22724573/ | Melanotan II |
| Australasian Journal of Dermatology | |||
| 12 June 2026 | Source | New source added to Melanotan IIMelanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II · pubmed.ncbi.nlm.nih.gov/11035391/ | Melanotan II |
| International Journal of Impotence Research | |||
| 12 June 2026 | Source | New source added to Melanotan IIEffect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction · pubmed.ncbi.nlm.nih.gov/11018622/ | Melanotan II |
| Urology | |||
| 12 June 2026 | Source | New source added to Melanotan IIEvaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study · sciencedirect.com/science/article/pii/002432059600… | Melanotan II |
| Life Sciences (Elsevier) | |||
| 12 June 2026 | Source | New source added to Matrixyl 3000Safety Assessment of Tripeptide-1, Hexapeptide-12, Their Metal Salts and Fatty Acyl Derivatives, and Palmitoyl Tetrapeptide-7 as Used in Cosmetics · journals.sagepub.com/doi/10.1177/1091581818807863 | Matrixyl 3000 |
| International Journal of Toxicology (Cosmetic Ingredient Review) | |||
| 12 June 2026 | Source | New source added to Matrixyl 3000Topical Peptide Treatments with Effective Anti-Aging Results · mdpi.com/2079-9284/4/2/16 | Matrixyl 3000 |
| MDPI Cosmetics | |||
| 12 June 2026 | Source | New source added to Matrixyl 3000Clinical evidence of the efficacy and safety of a new multi-peptide anti-aging topical eye serum · pubmed.ncbi.nlm.nih.gov/37335808/ | Matrixyl 3000 |
| Journal of Cosmetic Dermatology | |||
| 12 June 2026 | Source | New source added to Matrixyl (Palmitoyl Pentapeptide)Safety Assessment of Myristoyl Pentapeptide-4, Palmitoyl Pentapeptide-4, and Pentapeptide-4 as Used in Cosmetics · cir-safety.org/supplementaldoc/safety-assessmen… | Matrixyl (Palmitoyl Pentapeptide) |
| Cosmetic Ingredient Review | |||
| 12 June 2026 | Source | New source added to Matrixyl (Palmitoyl Pentapeptide)The pentapeptide KTTKS promoting the expressions of type I collagen and transforming growth factor-beta of tendon cells · onlinelibrary.wiley.com/doi/abs/10.1002/jor.20455 | Matrixyl (Palmitoyl Pentapeptide) |
| Journal of Orthopaedic Research | |||
| 12 June 2026 | Source | New source added to Matrixyl (Palmitoyl Pentapeptide)The Effects of a Novel Series of KTTKS Analogues on Cytotoxicity and Proteolytic Activity · pmc.ncbi.nlm.nih.gov/articles/PMC6832239/ | Matrixyl (Palmitoyl Pentapeptide) |
| Molecules | |||
| 12 June 2026 | Source | New source added to Matrixyl (Palmitoyl Pentapeptide)Dermal Stability and In Vitro Skin Permeation of Collagen Pentapeptides (KTTKS and palmitoyl-KTTKS) · pmc.ncbi.nlm.nih.gov/articles/PMC4131521/ | Matrixyl (Palmitoyl Pentapeptide) |
| Biomolecules and Therapeutics | |||
| 12 June 2026 | Source | New source added to Matrixyl (Palmitoyl Pentapeptide)Topically applied KTTKS: a review · pubmed.ncbi.nlm.nih.gov/21535443/ | Matrixyl (Palmitoyl Pentapeptide) |
| International Journal of Cosmetic Science | |||
| 12 June 2026 | Source | New source added to Matrixyl (Palmitoyl Pentapeptide)Topical palmitoyl pentapeptide provides improvement in photoaged human facial skin · pubmed.ncbi.nlm.nih.gov/18492182/ | Matrixyl (Palmitoyl Pentapeptide) |
| International Journal of Cosmetic Science | |||
| 12 June 2026 | Source | New source added to Matrixyl (Palmitoyl Pentapeptide)A pentapeptide from type I procollagen promotes extracellular matrix production · pubmed.ncbi.nlm.nih.gov/8486721/ | Matrixyl (Palmitoyl Pentapeptide) |
| Journal of Biological Chemistry | |||
| 12 June 2026 | Source | New source added to LL-37LL-37: Cathelicidin-related antimicrobial peptide with pleiotropic activity · pubmed.ncbi.nlm.nih.gov/27117377/ | LL-37 |
| Pharmacological Reports | |||
| 12 June 2026 | Source | New source added to LL-37LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells · pubmed.ncbi.nlm.nih.gov/11015447/ | LL-37 |
| Journal of Experimental Medicine | |||
| 12 June 2026 | Source | New source added to LL-37Oral intake of phenylbutyrate with or without vitamin D3 upregulates the cathelicidin LL-37 in human macrophages: a dose finding study for treatment of tuberculosis · pmc.ncbi.nlm.nih.gov/articles/PMC3637063/ | LL-37 |
| PLOS ONE | |||
| 12 June 2026 | Source | New source added to LL-37Immunomodulatory Role of the Antimicrobial LL-37 Peptide in Autoimmune Diseases and Viral Infections · pmc.ncbi.nlm.nih.gov/articles/PMC7565865/ | LL-37 |
| Frontiers in Immunology | |||
| 12 June 2026 | Source | New source added to LL-37The Human Cathelicidin Antimicrobial Peptide LL-37 as a Potential Treatment for Polymicrobial Infected Wounds · frontiersin.org/journals/immunology/articles/10.… | LL-37 |
| Frontiers in Immunology | |||
| 12 June 2026 | Source | New source added to LL-37In vitro and in vivo wound healing-promoting activities of human cathelicidin LL-37 · pubmed.ncbi.nlm.nih.gov/17805349/ | LL-37 |
| Journal of Investigative Dermatology | |||
| 12 June 2026 | Source | New source added to LL-37Treatment with LL-37 is safe and effective in enhancing healing of hard-to-heal venous leg ulcers: a randomized, placebo-controlled clinical trial · pubmed.ncbi.nlm.nih.gov/24888447/ | LL-37 |
| Wound Repair and Regeneration / Wiley | |||
| 12 June 2026 | Source | New source added to LL-37Evaluation of LL-37 in healing of hard-to-heal venous leg ulcers: A multicentric prospective randomized placebo-controlled clinical trial · pmc.ncbi.nlm.nih.gov/articles/PMC9298190/ | LL-37 |
| Wound Repair and Regeneration / Wiley | |||
| 12 June 2026 | Source | New source added to LiraglutideSCALE Trial Summary - Wiki Journal Club · wikijournalclub.org/wiki/SCALE | Liraglutide |
| 12 June 2026 | Source | New source added to LiraglutideHigh-Dose Liraglutide and SGLT2 Inhibitor: A Promising Combination (case series) · pmc.ncbi.nlm.nih.gov/articles/PMC8788265/ | Liraglutide |
| MDPI / Endocrines | |||
| 12 June 2026 | Source | New source added to LiraglutideEffects of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes With or Without Heart Failure (LEADER sub-analysis) · jacc.org/doi/10.1016/j.jacc.2019.12.063 | Liraglutide |
| Journal of the American College of Cardiology | |||
| 12 June 2026 | Source | New source added to LiraglutideSAXENDA (liraglutide) injection - FDA Prescribing Information · accessdata.fda.gov/drugsatfda_docs/label/2023/20632… | Liraglutide |
| U.S. Food and Drug Administration / Novo Nordisk | |||
| 12 June 2026 | Source | New source added to LiraglutideLiraglutide and Renal Outcomes in Type 2 Diabetes (LEADER renal sub-analysis) · pubmed.ncbi.nlm.nih.gov/28854085/ | Liraglutide |
| New England Journal of Medicine | |||
| 12 June 2026 | Source | New source added to LiraglutideLiraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER trial) · pubmed.ncbi.nlm.nih.gov/27295427/ | Liraglutide |
| New England Journal of Medicine | |||
| 12 June 2026 | Source | New source added to LiraglutideA Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE trial) · nejm.org/doi/full/10.1056/NEJMoa1411892 | Liraglutide |
| New England Journal of Medicine | |||
| 12 June 2026 | Source | New source added to LiraglutideLiraglutide - StatPearls - NCBI Bookshelf · ncbi.nlm.nih.gov/books/NBK608007/ | Liraglutide |
| NCBI Bookshelf / StatPearls | |||
| 12 June 2026 | Source | New source added to OxytocinOxytocin functions: an overview · medcraveonline.com/MOJAP/oxytocin-functions-an-over… | Oxytocin |
| MedCrave Online | |||
| 12 June 2026 | Source | New source added to OxytocinOxytocin: its mechanism of action and receptor signalling in the myometrium · pubmed.ncbi.nlm.nih.gov/24888645/ | Oxytocin |
| PubMed / National Library of Medicine | |||
| 12 June 2026 | Source | New source added to OxytocinOxytocin and Women Postpartum Depression: A Systematic Review of Randomized Controlled Trials · pmc.ncbi.nlm.nih.gov/articles/PMC10122502/ | Oxytocin |
| PMC / National Library of Medicine | |||
| 12 June 2026 | Source | New source added to OxytocinOxytocin and postpartum depression: A systematic review · pubmed.ncbi.nlm.nih.gov/32683141/ | Oxytocin |
| PubMed / National Library of Medicine | |||
| 12 June 2026 | Source | New source added to OxytocinEffects of multiple-dose intranasal oxytocin administration on social responsiveness in children with autism: a randomized, placebo-controlled trial · pmc.ncbi.nlm.nih.gov/articles/PMC10117268/ | Oxytocin |
| PMC / National Library of Medicine | |||
| 12 June 2026 | Source | New source added to OxytocinThe neurobiological impact of oxytocin in mental health disorders: a comprehensive review · pmc.ncbi.nlm.nih.gov/articles/PMC11981257/ | Oxytocin |
| PMC / National Library of Medicine | |||
| 12 June 2026 | Source | New source added to OxytocinOxytocin - StatPearls · ncbi.nlm.nih.gov/books/NBK507848/ | Oxytocin |
| StatPearls Publishing / NCBI Bookshelf | |||
| 12 June 2026 | Source | New source added to IcotrokinraA Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naive Participants With Active Psoriatic Arthritis — ClinicalTrials.gov NCT06878404 · clinicaltrials.gov/study/NCT06878404 | Icotrokinra |
| ClinicalTrials.gov / NIH | |||
| 12 June 2026 | Source | New source added to IcotrokinraOnce-daily oral icotrokinra versus placebo and deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2) — ScienceDirect abstract · sciencedirect.com/science/article/abs/pii/S0140673… | Icotrokinra |
| The Lancet | |||
| 12 June 2026 | Source | New source added to IcotrokinraICONIC-LEAD Phase 3: Icotrokinra for Moderate-to-Severe Plaque Psoriasis — Results Through Week 24 (ScienceDirect abstract) · sciencedirect.com/science/article/abs/pii/S0003496… | Icotrokinra |
| 12 June 2026 | Source | New source added to IcotrokinraFDA approval of ICOTYDE (icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide — Johnson & Johnson press release · prnewswire.com/news-releases/fda-approval-of-ic… | Icotrokinra |
| Johnson & Johnson / PR Newswire | |||
| 12 June 2026 | Source | New source added to IcotrokinraSafety and efficacy of oral icotrokinra for moderate-to-severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials · frontiersin.org/journals/immunology/articles/10.… | Icotrokinra |
| Frontiers in Immunology | |||
| 12 June 2026 | Source | New source added to IcotrokinraIcotrokinra induces early and sustained pharmacodynamic responses in phase IIb study of patients with moderate-to-severe psoriasis · pmc.ncbi.nlm.nih.gov/articles/PMC12890502/ | Icotrokinra |
| PubMed Central / NCBI | |||
| 12 June 2026 | Source | New source added to IcotrokinraTranslational Pharmacokinetics of Icotrokinra, a Targeted Oral Peptide that Selectively Blocks Interleukin-23 Receptor and Inhibits Signaling · pmc.ncbi.nlm.nih.gov/articles/PMC12354395/ | Icotrokinra |
| PubMed Central / NCBI | |||
| 12 June 2026 | Source | New source added to IcotrokinraLabel: ICOTYDE (icotrokinra) tablet, film coated — DailyMed, NIH · dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aee3… | Icotrokinra |
| U.S. National Library of Medicine / Janssen Biotech Inc. | |||
| 12 June 2026 | Source | New source added to GHRP-4Pralmorelin — History and Discovery (Peptide Initiative) · peptideinitiative.com/peptide-chronicles/pralmorelin | GHRP-4 |
| Peptide Initiative | |||
| 12 June 2026 | Source | New source added to GHRP-4Growth hormone-releasing peptides: clinical and basic aspects · pubmed.ncbi.nlm.nih.gov/8950613/ | GHRP-4 |
| 12 June 2026 | Source | New source added to GHRP-4Growth hormone-releasing peptides and their analogs — Camanni F, Ghigo E, Arvat E · pubmed.ncbi.nlm.nih.gov/9465289/ | GHRP-4 |
| Frontiers in Neuroendocrinology | |||
| 12 June 2026 | Source | New source added to GHRP-4Growth hormone-releasing peptide (GHRP) — Bowers CY · pubmed.ncbi.nlm.nih.gov/9893708/ | GHRP-4 |
| Cell Mol Life Sci | |||
| 12 June 2026 | Source | New source added to GHRP-4The Safety and Efficacy of Growth Hormone Secretagogues · pmc.ncbi.nlm.nih.gov/articles/PMC5632578/ | GHRP-4 |
| Sexual Medicine Reviews | |||
| 12 June 2026 | Source | New source added to GHRP-4Synthetic Growth Hormone-Releasing Peptides (GHRPs): A Historical Appraisal of the Evidences Supporting Their Cytoprotective Effects · pmc.ncbi.nlm.nih.gov/articles/PMC5392015/ | GHRP-4 |
| SAGE Open Medicine | |||
| 12 June 2026 | Source | New source added to GHRP-4Growth Hormone-Releasing Peptides: Investigation of Their Secondary Structure, Thermal Stability, and Model Membrane Interactions · pmc.ncbi.nlm.nih.gov/articles/PMC12869127/ | GHRP-4 |
| PMC / NCBI | |||
| 12 June 2026 | Source | New source added to GhrelinomimeticGhrelin accelerates wound healing through GHS-R1a-mediated MAPK-NF-kappaB/GR signaling pathways in combined radiation and burn injury in rats · pubmed.ncbi.nlm.nih.gov/27271793/ | Ghrelinomimetic |
| Scientific Reports | |||
| 12 June 2026 | Source | New source added to GhrelinomimeticThe regulatory approval of anamorelin for treatment of cachexia in patients with non-small cell lung cancer, gastric cancer, pancreatic cancer, and colorectal cancer in Japan: facts and numbers · pmc.ncbi.nlm.nih.gov/articles/PMC7890143/ | Ghrelinomimetic |
| Journal of Cachexia, Sarcopenia and Muscle | |||
| 12 June 2026 | Source | New source added to GhrelinomimeticROMANA 3: a phase 3 safety extension study of anamorelin in advanced non-small-cell lung cancer (NSCLC) patients with cachexia · pmc.ncbi.nlm.nih.gov/articles/PMC5834076/ | Ghrelinomimetic |
| Annals of Oncology | |||
| 12 June 2026 | Source | New source added to GhrelinomimeticAnamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials · pubmed.ncbi.nlm.nih.gov/26906526/ | Ghrelinomimetic |
| Lancet Oncology | |||
| 12 June 2026 | Source | New source added to GhrelinomimeticEffects of an Oral Ghrelin Mimetic on Body Composition and Clinical Outcomes in Healthy Older Adults: A Randomized Trial · acpjournals.org/doi/10.7326/0003-4819-149-9-2008… | Ghrelinomimetic |
| Annals of Internal Medicine | |||
| 12 June 2026 | Source | New source added to GhrelinomimeticStimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjects · pubmed.ncbi.nlm.nih.gov/8954023/ | Ghrelinomimetic |
| Journal of Clinical Endocrinology and Metabolism | |||
| 12 June 2026 | Source | New source added to GhrelinomimeticIpamorelin, the first selective growth hormone secretagogue · pubmed.ncbi.nlm.nih.gov/9849822/ | Ghrelinomimetic |
| European Journal of Endocrinology | |||
| 12 June 2026 | Source | New source added to GhrelinomimeticThe Growth Hormone Secretagogue Receptor: Its Intracellular Signaling and Regulation · pmc.ncbi.nlm.nih.gov/articles/PMC3975427/ | Ghrelinomimetic |
| Frontiers in Endocrinology | |||
| 12 June 2026 | Source | New source added to GHK-CuEpigenetic mechanisms activated by GHK-Cu increase skin collagen density in clinical trial (EurekAlert press release, McGill University / Wayne Carey MD) · eurekalert.org/news-releases/990464 | GHK-Cu |
| 12 June 2026 | Source | New source added to GHK-CuExploring the Role of Tripeptides in Wound Healing and Skin Regeneration: A Comprehensive Review · pmc.ncbi.nlm.nih.gov/articles/PMC12595317/ | GHK-Cu |
| Medical Sciences | |||
| 12 June 2026 | Source | New source added to GHK-CuThe potential of GHK as an anti-aging peptide · pmc.ncbi.nlm.nih.gov/articles/PMC8789089/ | GHK-Cu |
| Aging Pathobiology and Therapeutics | |||
| 12 June 2026 | Source | New source added to GHK-CuGlycyl-L-histidyl-L-lysine-Cu2+ attenuates cigarette smoke-induced pulmonary emphysema and inflammation by reducing oxidative stress pathway · pmc.ncbi.nlm.nih.gov/articles/PMC9354777/ | GHK-Cu |
| Frontiers in Molecular Biosciences | |||
| 12 June 2026 | Source | New source added to GHK-CuA gene expression signature of emphysema-related lung destruction and its reversal by the tripeptide GHK · pubmed.ncbi.nlm.nih.gov/22937864/ | GHK-Cu |
| Genome Medicine | |||
| 12 June 2026 | Source | New source added to GHK-CuGHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration · pmc.ncbi.nlm.nih.gov/articles/PMC4508379/ | GHK-Cu |
| BioMed Research International | |||
| 12 June 2026 | Source | New source added to GHK-CuRegenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data · pmc.ncbi.nlm.nih.gov/articles/PMC6073405/ | GHK-Cu |
| International Journal of Molecular Sciences | |||
| 12 June 2026 | Source | New source added to Collagen PeptidesEfficacy of collagen peptide supplementation on bone and muscle health: a meta-analysis · frontiersin.org/journals/nutrition/articles/10.3… | Collagen Peptides |
| Frontiers in Nutrition | |||
| 12 June 2026 | Source | New source added to Collagen PeptidesCollagen supplementation in skin and orthopedic diseases: A review of the literature · pmc.ncbi.nlm.nih.gov/articles/PMC10102402/ | Collagen Peptides |
| Heliyon | |||
| 12 June 2026 | Source | New source added to Collagen PeptidesEvaluation of the Efficacy and Safety of CollaSel PRO Type I and Type III Hydrolyzed Collagen Peptides in the Treatment of Osteoarthritis: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial · pmc.ncbi.nlm.nih.gov/articles/PMC12156922/ | Collagen Peptides |
| Journal of Clinical Medicine | |||
| 12 June 2026 | Source | New source added to Collagen PeptidesEffect of calcium and vitamin D supplementation with and without collagen peptides on bone turnover in postmenopausal women with osteopenia · pubmed.ncbi.nlm.nih.gov/32131366/ | Collagen Peptides |
| Journal of Musculoskeletal and Neuronal Interactions | |||
| 12 June 2026 | Source | New source added to Collagen PeptidesOral administration of hydrolyzed collagen alleviates pain and enhances functionality in knee osteoarthritis: Results from a randomized, double-blind, placebo-controlled study · pmc.ncbi.nlm.nih.gov/articles/PMC11745964/ | Collagen Peptides |
| Contemporary Clinical Trials Communications | |||
| 12 June 2026 | Source | New source added to Collagen PeptidesThe Effects of Type I Collagen Hydrolysate Supplementation on Bones, Muscles, and Joints: A Systematic Review · orthopedicreviews.openmedicalpublishing.org/article/129086-the-effects-of-ty… | Collagen Peptides |
| Orthopedic Reviews | |||
| 12 June 2026 | Source | New source added to Collagen PeptidesAnalgesic efficacy of collagen peptide in knee osteoarthritis: a meta-analysis of randomized controlled trials · pmc.ncbi.nlm.nih.gov/articles/PMC10505327/ | Collagen Peptides |
| Journal of Orthopaedic Surgery and Research | |||
| 12 June 2026 | Source | New source added to Collagen PeptidesSpecific Collagen Peptides Improve Bone Mineral Density and Bone Markers in Postmenopausal Women — A Randomized Controlled Study · pmc.ncbi.nlm.nih.gov/articles/PMC5793325/ | Collagen Peptides |
| Nutrients | |||
| 12 June 2026 | Source | New source added to CerebrolysinCerebrolysin: Cognitive Vitality Rating · alzdiscovery.org/cognitive-vitality/ratings/cereb… | Cerebrolysin |
| Alzheimer's Drug Discovery Foundation | |||
| 12 June 2026 | Source | New source added to CerebrolysinEfficacy and safety of Cerebrolysin in moderate to moderately severe Alzheimer's disease: results of a randomized, double-blind, controlled trial investigating three dosages of Cerebrolysin · pubmed.ncbi.nlm.nih.gov/20500802/ | Cerebrolysin |
| European Journal of Neurology | |||
| 12 June 2026 | Source | New source added to CerebrolysinCerebrolysin in Alzheimer's disease: a randomized, double-blind, placebo-controlled trial with a neurotrophic agent · pubmed.ncbi.nlm.nih.gov/12111446/ | Cerebrolysin |
| Journal of Neural Transmission | |||
| 12 June 2026 | Source | New source added to CerebrolysinCombined citicoline and Cerebrolysin for neuroprotection in traumatic brain injury: a retrospective cohort analysis · pmc.ncbi.nlm.nih.gov/articles/PMC12705382/ | Cerebrolysin |
| Frontiers in Neurology | |||
| 12 June 2026 | Source | New source added to CerebrolysinCerebrolysin in Patients with TBI: Systematic Review and Meta-Analysis · pmc.ncbi.nlm.nih.gov/articles/PMC10046100/ | Cerebrolysin |
| Brain Sciences, MDPI | |||
| 12 June 2026 | Source | New source added to CerebrolysinCerebrolysin in Mild-to-Moderate Alzheimer's Disease: A Meta-Analysis of Randomized Controlled Clinical Trials · karger.com/dem/article/39/5-6/332/98339/Cer… | Cerebrolysin |
| Dementia and Geriatric Cognitive Disorders, Karger | |||
| 12 June 2026 | Source | New source added to CerebrolysinCerebrolysin for acute ischaemic stroke (Cochrane Review, 7th edition) · cochrane.org/evidence/CD007026_cerebrolysin-a… | Cerebrolysin |
| Cochrane | |||
| 12 June 2026 | Source | New source added to CalcitoninCalcitonin Salmon Injection — Full Prescribing Information (DailyMed) · dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?seti… | Calcitonin |
| U.S. National Library of Medicine / FDA | |||
| 12 June 2026 | Source | New source added to CalcitoninCalcitonin (FORTICAL, MIACALCIN) for the treatment of vertebral compression fractures · pmc.ncbi.nlm.nih.gov/articles/PMC8567816/ | Calcitonin |
| Orthopedic Reviews | |||
| 12 June 2026 | Source | New source added to CalcitoninThe safety and efficacy of long-term use of calcitonin analogs in the treatment of osteoporosis in the elderly: a pharmacovigilance and RCT meta-analysis · pmc.ncbi.nlm.nih.gov/articles/PMC12515915/ | Calcitonin |
| Frontiers in Pharmacology | |||
| 12 June 2026 | Source | New source added to CalcitoninEfficacy of calcitonin for treating acute pain associated with osteoporotic vertebral compression fracture: an updated systematic review · pubmed.ncbi.nlm.nih.gov/32188529/ | Calcitonin |
| Canadian Journal of Emergency Medicine | |||
| 12 June 2026 | Source | New source added to CalcitoninCalcitonin — StatPearls · ncbi.nlm.nih.gov/books/NBK537269/ | Calcitonin |
| StatPearls / NCBI Bookshelf (NIH) | |||
| 12 June 2026 | Source | New source added to CalcitoninA randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study (PROOF) · pubmed.ncbi.nlm.nih.gov/10996576/ | Calcitonin |
| American Journal of Medicine | |||
| 12 June 2026 | Source | New source added to CagriSemaCagrilintide-semaglutide as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3) · pubmed.ncbi.nlm.nih.gov/42251856/ | CagriSema |
| The Lancet | |||
| 12 June 2026 | Source | New source added to CagriSemaSafety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management (phase 1b trial) · thelancet.com/journals/lancet/article/PIIS0140… | CagriSema |
| The Lancet | |||
| 12 June 2026 | Source | New source added to CagriSemaThe next frontier in metabolic health: Cagrilintide-Semaglutide and the evolving landscape of therapies · the-innovation.org/article/doi/10.59717/j.xinn-med.… | CagriSema |
| The Innovation Medicine | |||
| 12 June 2026 | Source | New source added to CagriSemaREDEFINE 1 and REDEFINE 2: Greater Weight Loss With Combined Cagrilintide-Semaglutide vs. Either Drug Alone or Placebo · acc.org/Latest-in-Cardiology/Journal-Sca… | CagriSema |
| American College of Cardiology | |||
| 12 June 2026 | Source | New source added to CagriSemaNovo Nordisk files for FDA approval of CagriSema, the first once-weekly combination of GLP-1 and amylin analogues for weight management · prnewswire.com/news-releases/novo-nordisk-files… | CagriSema |
| Novo Nordisk / PR Newswire | |||
| 12 June 2026 | Source | New source added to CagriSemaStructural and dynamic features of cagrilintide binding to calcitonin and amylin receptors · pmc.ncbi.nlm.nih.gov/articles/PMC11982234/ | CagriSema |
| Nature Communications | |||
| 12 June 2026 | Source | New source added to CagriSemaEfficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in type 2 diabetes (phase 2 trial) · pubmed.ncbi.nlm.nih.gov/37364590/ | CagriSema |
| The Lancet | |||
| 12 June 2026 | Source | New source added to CagriSemaCoadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity (REDEFINE 1) · pubmed.ncbi.nlm.nih.gov/40544433/ | CagriSema |
| New England Journal of Medicine | |||
| 12 June 2026 | Source | New source added to FGL (Fibroblast Growth Loop)NeuroFGL: Development of a novel FGL therapy and translational tests for regenerative treatment of neurological disorders (EU CORDIS FP7 project 278006) · cordis.europa.eu/project/id/278006/reporting | FGL (Fibroblast Growth Loop) |
| 12 June 2026 | Source | New source added to FGL (Fibroblast Growth Loop)The neural cell adhesion molecule-derived peptide, FGL, attenuates lipopolysaccharide-induced changes in glia in a CD200-dependent manner · pubmed.ncbi.nlm.nih.gov/23337536/ | FGL (Fibroblast Growth Loop) |
| 12 June 2026 | Source | New source added to FGL (Fibroblast Growth Loop)Impact of the Neural Cell Adhesion Molecule-Derived Peptide FGL on Seizure Progression and Cellular Alterations in the Mouse Kindling Model (PMC) · pmc.ncbi.nlm.nih.gov/articles/PMC3963124/ | FGL (Fibroblast Growth Loop) |
| 12 June 2026 | Source | New source added to FGL (Fibroblast Growth Loop)The synthetic NCAM mimetic peptide FGL mobilizes neural stem cells in vitro and in vivo · pubmed.ncbi.nlm.nih.gov/24817672/ | FGL (Fibroblast Growth Loop) |
| 12 June 2026 | Source | New source added to FGL (Fibroblast Growth Loop)A neural cell adhesion molecule-derived peptide reduces neuropathological signs and cognitive impairment induced by Abeta25-35 · pubmed.ncbi.nlm.nih.gov/17223274/ | FGL (Fibroblast Growth Loop) |
| 12 June 2026 | Source | New source added to FGL (Fibroblast Growth Loop)Peptide Sparks Synaptic Plasticity, Improves Memory in Rodents (ALZFORUM, covering Esteban et al. PLoS Biology 2012) · alzforum.org/news/research-news/peptide-spark… | FGL (Fibroblast Growth Loop) |
| 12 June 2026 | Source | New source added to FGL (Fibroblast Growth Loop)Tolerability, Safety and Pharmacokinetics of the FGLL Peptide, a Novel Mimetic of Neural Cell Adhesion Molecule, Following Intranasal Administration in Healthy Volunteers (Clinical Pharmacokinetics, 2007) · link.springer.com/article/10.2165/00003088-2007460… | FGL (Fibroblast Growth Loop) |
| Clinical Pharmacokinetics / Springer | |||
| 12 June 2026 | Source | New source added to FGL (Fibroblast Growth Loop)A synthetic NCAM-derived peptide, FGL, protects hippocampal neurons from ischemic insult both in vitro and in vivo · pubmed.ncbi.nlm.nih.gov/16197499/ | FGL (Fibroblast Growth Loop) |
| 12 June 2026 | Source | New source added to Epithalon + Follistatin StackPeptide Epitalon activates chromatin at the old age · pubmed.ncbi.nlm.nih.gov/14647006/ | Epithalon + Follistatin Stack |
| Neuro Endocrinology Letters | |||
| 12 June 2026 | Source | New source added to Epithalon + Follistatin StackSynthetic tetrapeptide epitalon restores disturbed neuroendocrine regulation in senescent monkeys · pubmed.ncbi.nlm.nih.gov/11524632/ | Epithalon + Follistatin Stack |
| Neuro Endocrinology Letters | |||
| 12 June 2026 | Source | New source added to Epithalon + Follistatin StackStructural basis for the inhibition of activin signalling by follistatin · pmc.ncbi.nlm.nih.gov/articles/PMC1409725/ | Epithalon + Follistatin Stack |
| The EMBO Journal | |||
| 12 June 2026 | Source | New source added to Epithalon + Follistatin StackA Phase 1/2a Follistatin Gene Therapy Trial for Becker Muscular Dystrophy · pubmed.ncbi.nlm.nih.gov/25322757/ | Epithalon + Follistatin Stack |
| Molecular Therapy | |||
| 12 June 2026 | Source | New source added to Epithalon + Follistatin StackOverview of Epitalon — Highly Bioactive Pineal Tetrapeptide with Promising Properties · pmc.ncbi.nlm.nih.gov/articles/PMC11943447/ | Epithalon + Follistatin Stack |
| International Journal of Molecular Sciences | |||
| 12 June 2026 | Source | New source added to Epithalon + Follistatin StackEpithalon peptide induces telomerase activity and telomere elongation in human somatic cells · pubmed.ncbi.nlm.nih.gov/12937682/ | Epithalon + Follistatin Stack |
| Bulletin of Experimental Biology and Medicine | |||
| 12 June 2026 | Source | New source added to EpitalonEpitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity · link.springer.com/article/10.1007/s10522-025-10315… | Epitalon |
| Biogerontology (Springer Nature) | |||
| 12 June 2026 | Source | New source added to EpitalonPineal-regulating tetrapeptide epitalon improves eye retina condition in retinitis pigmentosa · pubmed.ncbi.nlm.nih.gov/12195242/ | Epitalon |
| Neuroendocrinology Letters | |||
| 12 June 2026 | Source | New source added to EpitalonPeptide geroprotector from the pituitary gland inhibits rapid aging of elderly people: results of 15-year follow-up · pubmed.ncbi.nlm.nih.gov/22451889/ | Epitalon |
| Bulletin of Experimental Biology and Medicine | |||
| 12 June 2026 | Source | New source added to EpitalonGeroprotective effect of epithalamine (pineal gland peptide preparation) in elderly subjects with accelerated aging · pubmed.ncbi.nlm.nih.gov/17426848/ | Epitalon |
| Bulletin of Experimental Biology and Medicine | |||
| 12 June 2026 | Source | New source added to EpitalonEpithalon peptide induces telomerase activity and telomere elongation in human somatic cells · pubmed.ncbi.nlm.nih.gov/12937682/ | Epitalon |
| Bulletin of Experimental Biology and Medicine | |||
| 12 June 2026 | Source | New source added to EpitalonOverview of Epitalon — Highly Bioactive Pineal Tetrapeptide with Promising Properties · pmc.ncbi.nlm.nih.gov/articles/PMC11943447/ | Epitalon |
| International Journal of Molecular Sciences (MDPI) | |||
| 12 June 2026 | Source | New source added to DSIPMechanism of delta-sleep inducing peptide geroprotective activity · pubmed.ncbi.nlm.nih.gov/21809625/ | DSIP |
| 12 June 2026 | Source | New source added to DSIPSynthetic delta-sleep-inducing peptide improves sleep in insomniacs · pubmed.ncbi.nlm.nih.gov/6112579/ | DSIP |
| Lancet | |||
| 12 June 2026 | Source | New source added to DSIPSaturable mechanism for delta sleep-inducing peptide (DSIP) at the blood-brain barrier of the vascularly perfused guinea pig brain · pubmed.ncbi.nlm.nih.gov/2547200/ | DSIP |
| 12 June 2026 | Source | New source added to DSIPSuccessful treatment of withdrawal symptoms with delta sleep-inducing peptide, a neuropeptide with potential agonistic activity on opiate receptors · pubmed.ncbi.nlm.nih.gov/6328354/ | DSIP |
| Neuropsychobiology | |||
| 12 June 2026 | Source | New source added to DSIPCharacterization, properties and multivariate functions of delta-sleep-inducing peptide (DSIP) · pubmed.ncbi.nlm.nih.gov/6548966/ | DSIP |
| European Neurology | |||
| 12 June 2026 | Source | New source added to DSIPTherapeutic effects of delta-sleep-inducing peptide (DSIP) in patients with chronic, pronounced pain episodes. A clinical pilot study · pubmed.ncbi.nlm.nih.gov/6548970/ | DSIP |
| European Neurology | |||
| 12 June 2026 | Source | New source added to DSIPEffects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study · pubmed.ncbi.nlm.nih.gov/1299794/ | DSIP |
| 12 June 2026 | Source | New source added to DSIPDelta sleep-inducing peptide (DSIP): a still unresolved riddle · pubmed.ncbi.nlm.nih.gov/16539679/ | DSIP |
| Journal of Neurochemistry | |||
| 12 June 2026 | Source | New source added to DihexaFosgonimeton — Alzforum Therapeutics Database · alzforum.org/therapeutics/fosgonimeton | Dihexa |
| 12 June 2026 | Source | New source added to DihexaFour papers by Athira CEO earn expressions of concern · retractionwatch.com/2021/09/24/four-papers-by-athira… | Dihexa |
| 12 June 2026 | Source | New source added to DihexaAngIV-Analog Dihexa Rescues Cognitive Impairment and Recovers Memory in the APP/PS1 Mouse via the PI3K/AKT Signaling Pathway · pmc.ncbi.nlm.nih.gov/articles/PMC8615599/ | Dihexa |
| Brain Sciences | |||
| 12 June 2026 | Source | New source added to DihexaRetraction: The Procognitive and Synaptogenic Effects of Angiotensin IV-Derived Peptides Are Dependent on Activation of the Hepatocyte Growth Factor/c-Met System · pmc.ncbi.nlm.nih.gov/articles/PMC13095468/ | Dihexa |
| Journal of Pharmacology and Experimental Therapeutics | |||
| 12 June 2026 | Source | New source added to DihexaThe Procognitive and Synaptogenic Effects of Angiotensin IV-Derived Peptides Are Dependent on Activation of the Hepatocyte Growth Factor/c-Met System (RETRACTED April 2025) · pmc.ncbi.nlm.nih.gov/articles/PMC4201273/ | Dihexa |
| Journal of Pharmacology and Experimental Therapeutics | |||
| 12 June 2026 | Source | New source added to DihexaEvaluation of Metabolically Stabilized Angiotensin IV Analogs as Procognitive/Antidementia Agents (Notice of Concern, 2021) · pmc.ncbi.nlm.nih.gov/articles/PMC3533412/ | Dihexa |
| Journal of Pharmacology and Experimental Therapeutics | |||
| 12 June 2026 | Source | New source added to DHEA PeptideINTRAROSA (prasterone) Prescribing Information · us.intrarosa.com/what-is-intrarosa | DHEA Peptide |
| Endoceutics Inc. | |||
| 12 June 2026 | Source | New source added to DHEA PeptideShould Dehydroepiandrosterone Be Administered to Women? · pmc.ncbi.nlm.nih.gov/articles/PMC9113789/ | DHEA Peptide |
| PubMed Central | |||
| 12 June 2026 | Source | New source added to DHEA PeptideDehydroepiandrosterone improves follicular fluid bone morphogenetic protein-15 and accumulated embryo score of infertility patients with diminished ovarian reserve undergoing IVF: a randomized controlled trial · pmc.ncbi.nlm.nih.gov/articles/PMC4210503/ | DHEA Peptide |
| PubMed Central | |||
| 12 June 2026 | Source | New source added to DHEA PeptideThe Utilization of Dehydroepiandrosterone as a Sexual Hormone Precursor in Premenopausal and Postmenopausal Women: An Overview · pmc.ncbi.nlm.nih.gov/articles/PMC8781653/ | DHEA Peptide |
| PubMed Central | |||
| 12 June 2026 | Source | New source added to DHEA PeptideThe effect of dehydroepiandrosterone (DHEA) supplementation on estradiol levels in women: A dose-response and meta-analysis of randomized clinical trials · pubmed.ncbi.nlm.nih.gov/34246664/ | DHEA Peptide |
| PubMed | |||
| 12 June 2026 | Source | New source added to DHEA PeptideEffects of Dehydroepiandrosterone Supplementation on Cognitive Function and Quality of Life: The DHEA and Well-Ness (DAWN) Trial · pmc.ncbi.nlm.nih.gov/articles/PMC2574781/ | DHEA Peptide |
| PubMed Central | |||
| 12 June 2026 | Source | New source added to DHEA PeptideThe Sex Hormone Precursors Dehydroepiandrosterone (DHEA) and Its Sulfate Ester Form (DHEAS): Molecular Mechanisms and Actions on Human Body · pmc.ncbi.nlm.nih.gov/articles/PMC12429729/ | DHEA Peptide |
| PubMed Central | |||
| 12 June 2026 | Source | New source added to CortexinNeurotropic Effects of Cortexin on Models of Mental and Physical Developmental Delay · pmc.ncbi.nlm.nih.gov/articles/PMC12024793/ | Cortexin |
| Biomedicines (MDPI) | |||
| 12 June 2026 | Source | New source added to CortexinAn open clinical trial of cortexin in treatment of brain ischemia · pubmed.ncbi.nlm.nih.gov/25403301/ | Cortexin |
| 12 June 2026 | Source | New source added to CortexinThe efficacy and safety of animal-derived nootropics in cognitive disorders: Systematic review and meta-analysis · pmc.ncbi.nlm.nih.gov/articles/PMC9616232/ | Cortexin |
| ScienceDirect / PMC | |||
| 12 June 2026 | Source | New source added to CortexinResults of a multicenter study on the efficacy of cortexin in treatment of cognitive dysfunction in children · medcraveonline.com/JNSK/results-of-a-multicenter-st… | Cortexin |
| MedCrave Journal of Neurology and Stroke | |||
| 12 June 2026 | Source | New source added to CortexinClinical efficacy and pharmacoeconomic characteristics of the neuroprotection with low doses of cortexin in the treatment of acute ischemic stroke · pubmed.ncbi.nlm.nih.gov/24874316/ | Cortexin |
| 12 June 2026 | Source | New source added to CortexinDose-dependent effects of cortexin in chronic cerebral ischemia (results of a multicenter randomized controlled study) · pubmed.ncbi.nlm.nih.gov/30335070/ | Cortexin |
| 12 June 2026 | Source | New source added to CortexinMolecular Mechanisms of the Actions of Brain Peptide-Containing Drugs: Cortexin · pubmed.ncbi.nlm.nih.gov/30499504/ | Cortexin |
| Neuroscience and Behavioral Physiology (Springer) | |||
| 12 June 2026 | Source | New source added to CortexinNeuroprotective action of Cortexin, Cerebrolysin and Actovegin in acute or chronic brain ischemia in rats · pmc.ncbi.nlm.nih.gov/articles/PMC8279368/ | Cortexin |
| PLOS ONE | |||
| 12 June 2026 | Source | New source added to CortagenEpigenetic Regulation of Aged Heterochromatin by Peptide Bioregulator Cortagen · link.springer.com/article/10.1007/s10989-014-9443-… | Cortagen |
| International Journal of Peptide Research and Therapeutics | |||
| 12 June 2026 | Source | New source added to CortagenNeuroprotective Effects of Peptides during Ischemic Preconditioning (Zarubina and Shabanov 2016) · pubmed.ncbi.nlm.nih.gov/26902350/ | Cortagen |
| Bulletin of Experimental Biology and Medicine | |||
| 12 June 2026 | Source | New source added to CortagenModulatory Effects of Cortexin and Cortagen on Locomotor Activity and Anxiety-Related Behavior in Mice (Adriani et al.) · benthamopenarchives.com/abstract.php?ArticleCode=TONEURO… | Cortagen |
| The Open Neuropsychopharmacology Journal | |||
| 12 June 2026 | Source | New source added to CortagenCortexin and cortagen as correcting agents in functional and metabolic disorders in the brain in chronic ischemia · pubmed.ncbi.nlm.nih.gov/21476278/ | Cortagen |
| Eksperimental'naia i Klinicheskaia Farmakologiia | |||
| 12 June 2026 | Source | New source added to CortagenElucidation of the effect of brain cortex tetrapeptide Cortagen on gene expression in mouse heart by microarray · semanticscholar.org/paper/Elucidation-of-the-effect-… | Cortagen |
| Neuroendocrinology Letters | |||
| 12 June 2026 | Source | New source added to CortagenTissue-specific effects of peptides (Khavinson VK; organotypic culture with Cortagen, Epithalon, Livagen, Vilon) · pubmed.ncbi.nlm.nih.gov/11713572/ | Cortagen |
| Bulletin of Experimental Biology and Medicine | |||
| 12 June 2026 | Source | New source added to CortagenEffect of tetrapeptide cortagen on regeneration of sciatic nerve · pubmed.ncbi.nlm.nih.gov/11276314/ | Cortagen |
| Bulletin of Experimental Biology and Medicine | |||
| 12 June 2026 | Source | New source added to BulevirtideStudy to Assess Efficacy and Safety of Bulevirtide in Participants With Chronic Hepatitis Delta (MYR301) – NCT03852719 · clinicaltrials.gov/study/NCT03852719 | Bulevirtide |
| 12 June 2026 | Source | New source added to BulevirtideFDA Grants Accelerated Approval to Gilead's Hepcludex (bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus · gilead.com/news/news-details/2026/fda-grant… | Bulevirtide |
| Gilead Sciences | |||
| 12 June 2026 | Source | New source added to BulevirtideComparative Efficacy of Bulevirtide, Interferons, and Nucleos(t)ide Analogs for Chronic Hepatitis Delta: A Systematic Review and Network Meta-Analysis · pmc.ncbi.nlm.nih.gov/articles/PMC13122728/ | Bulevirtide |
| 12 June 2026 | Source | New source added to BulevirtideTreating hepatitis D with bulevirtide – Real-world experience from 114 patients · pmc.ncbi.nlm.nih.gov/articles/PMC10071092/ | Bulevirtide |
| 12 June 2026 | Source | New source added to BulevirtideBulevirtide Monotherapy Is Safe and Well Tolerated in Chronic Hepatitis Delta: An Integrated Safety Analysis of Bulevirtide Clinical Trials at Week 48 · pmc.ncbi.nlm.nih.gov/articles/PMC11907224/ | Bulevirtide |
| 12 June 2026 | Source | New source added to BulevirtideBulevirtide Monotherapy or in Combination for Chronic Hepatitis Delta: 2025 Update · pmc.ncbi.nlm.nih.gov/articles/PMC12644311/ | Bulevirtide |
| 12 June 2026 | Source | New source added to BulevirtideStructure of antiviral drug bulevirtide bound to hepatitis B and D virus receptor protein NTCP · pmc.ncbi.nlm.nih.gov/articles/PMC10954734/ | Bulevirtide |
| Nature Communications | |||
| 12 June 2026 | Source | New source added to Beta-Glucan PeptidePotent induction of trained immunity by Saccharomyces cerevisiae beta-glucans · pmc.ncbi.nlm.nih.gov/articles/PMC10896952/ | Beta-Glucan Peptide |
| Frontiers in Immunology | |||
| 12 June 2026 | Source | New source added to Beta-Glucan PeptideEffects of a β-Glucan-Rich Blend of Medicinal Mushrooms and Botanicals on Innate Immune Cell Activation and Function Are Enhanced by a Very Low Dose of Bovine Colostrum Peptides · pmc.ncbi.nlm.nih.gov/articles/PMC11207084/ | Beta-Glucan Peptide |
| Nutrients (MDPI) | |||
| 12 June 2026 | Source | New source added to Beta-Glucan PeptideRole of beta-(1→3)(1→6)-D-glucan derived from yeast on natural killer (NK) cells and breast cancer cell lines in 2D and 3D cultures · pmc.ncbi.nlm.nih.gov/articles/PMC10938759/ | Beta-Glucan Peptide |
| BMC Cancer | |||
| 12 June 2026 | Source | New source added to Beta-Glucan PeptideEffect and Tolerability of ABB C1 Beta-Glucan/Selenium/Zinc with Influenza or COVID-19 Vaccine: A Randomized, Double-Blind, Placebo-Controlled Study · pmc.ncbi.nlm.nih.gov/articles/PMC8708701/ | Beta-Glucan Peptide |
| Nutrients (MDPI) | |||
| 12 June 2026 | Source | New source added to Beta-Glucan PeptideThe Effects of Orally Administered Beta-Glucan on Innate Immune Responses in Humans, a Randomized Open-Label Intervention Pilot-Study · pmc.ncbi.nlm.nih.gov/articles/PMC4182605/ | Beta-Glucan Peptide |
| PLOS ONE | |||
| 12 June 2026 | Source | New source added to Beta-Glucan Peptideβ-Glucan Metabolic and Immunomodulatory Properties and Potential for Clinical Application · pmc.ncbi.nlm.nih.gov/articles/PMC7770584/ | Beta-Glucan Peptide |
| Journal of Fungi (MDPI) | |||
| 12 June 2026 | Source | New source added to Beta-Glucan PeptideBeta-Glucan Recognition by the Innate Immune System (PMC6618291) · pmc.ncbi.nlm.nih.gov/articles/PMC6618291/ | Beta-Glucan Peptide |
| Nature Reviews Immunology | |||
| 12 June 2026 | Source | New source added to Beta-Glucan PeptideBeta Glucan: Supplement or Drug? From Laboratory to Clinical Trials · pmc.ncbi.nlm.nih.gov/articles/PMC6479769/ | Beta-Glucan Peptide |
| Molecules (MDPI) | |||
| 12 June 2026 | Source | New source added to Argireline (Acetyl Hexapeptide-8)The Peptide Argireline: The Importance of Local Application on the Skin, in the Light of Current Knowledge · eurekaselect.com/article/82902 | Argireline (Acetyl Hexapeptide-8) |
| Letters in Drug Design and Discovery | |||
| 12 June 2026 | Source | New source added to Argireline (Acetyl Hexapeptide-8)Safety Assessment of Acetyl Hexapeptide-8 and Acetyl Hexapeptide-8 Amide as Used in Cosmetics · cir-safety.org/sites/default/files/AcetylHexape… | Argireline (Acetyl Hexapeptide-8) |
| Cosmetic Ingredient Review | |||
| 12 June 2026 | Source | New source added to Argireline (Acetyl Hexapeptide-8)Enhanced Skin Permeation of Anti-wrinkle Peptides via Molecular Modification · pmc.ncbi.nlm.nih.gov/articles/PMC5785486/ | Argireline (Acetyl Hexapeptide-8) |
| Scientific Reports | |||
| 12 June 2026 | Source | New source added to Argireline (Acetyl Hexapeptide-8)Investigating the effects of Argireline in a skin serum containing hyaluronic acids on skin surface wrinkles using the Visia Complexion Analysis camera system for objective skin analysis · pmc.ncbi.nlm.nih.gov/articles/PMC10665711/ | Argireline (Acetyl Hexapeptide-8) |
| GMS Interdisciplinary Plastic and Reconstructive Surgery DGPW | |||
| 12 June 2026 | Source | New source added to Argireline (Acetyl Hexapeptide-8)Pilot Study of Topical Acetyl Hexapeptide-8 in Treatment of Blepharospasm in Patients Receiving Botulinum Neurotoxin Therapy · pmc.ncbi.nlm.nih.gov/articles/PMC4747634/ | Argireline (Acetyl Hexapeptide-8) |
| European Journal of Neurology | |||
| 12 June 2026 | Source | New source added to Argireline (Acetyl Hexapeptide-8)The anti-wrinkle efficacy of Argireline · pubmed.ncbi.nlm.nih.gov/23464592/ | Argireline (Acetyl Hexapeptide-8) |
| Journal of Cosmetic and Laser Therapy | |||
| 12 June 2026 | Source | New source added to Argireline (Acetyl Hexapeptide-8)The Anti-Wrinkle Efficacy of Argireline, a Synthetic Hexapeptide, in Chinese Subjects: A Randomized, Placebo-Controlled Study · pubmed.ncbi.nlm.nih.gov/23417317/ | Argireline (Acetyl Hexapeptide-8) |
| American Journal of Clinical Dermatology | |||
| 12 June 2026 | Source | New source added to Argireline (Acetyl Hexapeptide-8)A synthetic hexapeptide (Argireline) with antiwrinkle activity · pubmed.ncbi.nlm.nih.gov/18498523/ | Argireline (Acetyl Hexapeptide-8) |
| International Journal of Cosmetic Science | |||
| 12 June 2026 | Source | New source added to ARA-290Study of Efficacy of ARA 290 on Corneal Nerve Fiber Density and Neuropathic Symptoms of Subjects With Sarcoidosis (NCT02039687) · clinicaltrials.gov/study/NCT02039687 | ARA-290 |
| ClinicalTrials.gov | |||
| 12 June 2026 | Source | New source added to ARA-290Araim Pharmaceuticals Receives Orphan Drug Designation from the US FDA for ARA 290 for the Treatment of Sarcoidosis · prnewswire.com/news-releases/araim-pharmaceutic… | ARA-290 |
| PR Newswire | |||
| 12 June 2026 | Source | New source added to ARA-290Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain · iovs.arvojournals.org/article.aspx?articleid=2625918 | ARA-290 |
| Investigative Ophthalmology and Visual Science | |||
| 12 June 2026 | Source | New source added to ARA-290ARA 290, a Nonerythropoietic Peptide Engineered from Erythropoietin, Improves Metabolic Control and Neuropathic Symptoms in Patients with Type 2 Diabetes · pmc.ncbi.nlm.nih.gov/articles/PMC4365069/ | ARA-290 |
| 12 June 2026 | Source | New source added to ARA-290ARA 290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain coupled with suppression of the spinal microglia response · pubmed.ncbi.nlm.nih.gov/24529189/ | ARA-290 |
| Molecular Pain | |||
| 12 June 2026 | Source | New source added to ARA-290ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density · pubmed.ncbi.nlm.nih.gov/24136731/ | ARA-290 |
| Molecular Medicine | |||
| 12 June 2026 | Source | New source added to ARA-290Safety and Efficacy of ARA 290 in Sarcoidosis Patients with Symptoms of Small Fiber Neuropathy: A Randomized, Double-Blind Pilot Study · pubmed.ncbi.nlm.nih.gov/23168581/ | ARA-290 |
| Molecular Medicine | |||
| 12 June 2026 | Source | New source added to AOD-9604Central and Peripheral Molecular Targets for Anti-Obesity Pharmacotherapy (PMC3136748 — cites AOD9604 trial data) · pmc.ncbi.nlm.nih.gov/articles/PMC3136748/ | AOD-9604 |
| Clinical Pharmacology and Therapeutics / PMC | |||
| 12 June 2026 | Source | New source added to AOD-9604Obesity Pharmacotherapy: Current Perspectives and Future Directions (PMC3584306 — includes AOD9604 Phase IIb failure summary) · pmc.ncbi.nlm.nih.gov/articles/PMC3584306/ | AOD-9604 |
| Current Hypertension Reports / PMC | |||
| 12 June 2026 | Source | New source added to AOD-9604Obesity drug codenamed AOD9604 highly successful in trials (Phase IIa 12-week trial report) · news-medical.net/news/2004/12/16/6878.aspx | AOD-9604 |
| News-Medical.net | |||
| 12 June 2026 | Source | New source added to AOD-9604Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model · pubmed.ncbi.nlm.nih.gov/26275694/ | AOD-9604 |
| Annals of Clinical and Laboratory Science | |||
| 12 June 2026 | Source | New source added to AOD-9604Detection and in vitro metabolism of AOD9604 · pubmed.ncbi.nlm.nih.gov/25208511/ | AOD-9604 |
| Drug Testing and Analysis | |||
| 12 June 2026 | Source | New source added to AOD-9604Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone · pubmed.ncbi.nlm.nih.gov/11146367/ | AOD-9604 |
| Hormone Research | |||
| 12 June 2026 | Source | New source added to AOD-9604Effects of Human GH and Its Lipolytic Fragment (AOD9604) on Lipid Metabolism Following Chronic Treatment in Obese Mice and β3-AR Knock-Out Mice · academic.oup.com/endo/article/142/12/5182/2988749 | AOD-9604 |
| Endocrinology (Oxford Academic) | |||
| 12 June 2026 | Source | New source added to AOD-9604Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment · pubmed.ncbi.nlm.nih.gov/11673763/ | AOD-9604 |
| International Journal of Obesity and Related Metabolic Disorders | |||
| 12 June 2026 | Source | New source added to AMP-KThe role of AMPK in macrophage metabolism, function and polarisation · pmc.ncbi.nlm.nih.gov/articles/PMC10709986/ | AMP-K |
| Journal of Translational Medicine | |||
| 12 June 2026 | Source | New source added to AMP-KAMPK activates Parkin independent autophagy and improves post sepsis immune defense against secondary bacterial lung infections · pmc.ncbi.nlm.nih.gov/articles/PMC8196038/ | AMP-K |
| Scientific Reports | |||
| 12 June 2026 | Source | New source added to AMP-KAICAr, a Widely Used AMPK Activator with Important AMPK-Independent Effects: A Systematic Review · pmc.ncbi.nlm.nih.gov/articles/PMC8147799/ | AMP-K |
| Cells (MDPI) | |||
| 12 June 2026 | Source | New source added to AMP-KAMPK-dependent and independent effects of AICAR and compound C on T-cell responses · pmc.ncbi.nlm.nih.gov/articles/PMC5085118/ | AMP-K |
| Oncotarget | |||
| 12 June 2026 | Source | New source added to AMP-KAMPK integrates metabolite and kinase-based immunometabolic control in macrophages · pmc.ncbi.nlm.nih.gov/articles/PMC9842865/ | AMP-K |
| Molecular Metabolism | |||
| 12 June 2026 | Source | New source added to AMP-KAMP-activated protein kinase promotes macrophage polarization to an anti-inflammatory functional phenotype · pmc.ncbi.nlm.nih.gov/articles/PMC2756051/ | AMP-K |
| Journal of Immunology | |||
| 12 June 2026 | Source | New source added to AMP-KAMPK-derived peptides reduce blood glucose levels but lead to fat retention in the liver of obese mice · pubmed.ncbi.nlm.nih.gov/24478381/ | AMP-K |
| Journal of Endocrinology | |||
| 12 June 2026 | Source | New source added to ActoveginCurrent Synthesis and Systematic Review of Main Effects of Calf Blood Deproteinized Medicine (Actovegin) in Ischemic Stroke · pubmed.ncbi.nlm.nih.gov/32365943/ | Actovegin |
| MDPI / International Journal of Molecular Sciences | |||
| 12 June 2026 | Source | New source added to ActoveginActovegin in the management of patients after ischemic stroke: A systematic review · journals.plos.org/plosone/article?id=10.1371%2Fjou… | Actovegin |
| PLOS ONE | |||
| 12 June 2026 | Source | New source added to ActoveginEfficacy and safety of Actovegin in the treatment of intermittent claudication: results of an international, multicenter, placebo-controlled, randomized, phase IIIb clinical trial (APOLLO) · pubmed.ncbi.nlm.nih.gov/36264097/ | Actovegin |
| Minerva Medica / International Angiology | |||
| 12 June 2026 | Source | New source added to ActoveginARTEMIDA Trial: A Randomized Controlled Trial to Assess the Efficacy of Actovegin in Poststroke Cognitive Impairment · pmc.ncbi.nlm.nih.gov/articles/PMC5404405/ | Actovegin |
| American Heart Association / Stroke | |||
| 12 June 2026 | Source | New source added to ActoveginTreatment of Symptomatic Polyneuropathy With Actovegin in Type 2 Diabetic Patients · pubmed.ncbi.nlm.nih.gov/19470838/ | Actovegin |
| American Diabetes Association / Diabetes Care | |||
| 12 June 2026 | Source | New source added to ACE-031ACE-031 0.5 mg/kg q4wk and ACE-031 1.0 mg/kg q2wk in Duchenne Muscular Dystrophy (NCT01099761) · ichgcp.net/clinical-trials-registry/NCT0109… | ACE-031 |
| 12 June 2026 | Source | New source added to ACE-031UPDATE: ACE-031 Clinical Trials in Duchenne MD · mda.org/quest/article/update-ace-031-cli… | ACE-031 |
| Muscular Dystrophy Association | |||
| 12 June 2026 | Source | New source added to ACE-031Challenges and Future Prospects of Targeting Myostatin/Activin A Signaling to Treat Diseases of Muscle Loss and Metabolic Dysfunction · pmc.ncbi.nlm.nih.gov/articles/PMC10272974/ | ACE-031 |
| 12 June 2026 | Source | New source added to ACE-031Myostatin Inhibitors: Panacea or Predicament for Musculoskeletal Disorders? · pmc.ncbi.nlm.nih.gov/articles/PMC7571243/ | ACE-031 |
| 12 June 2026 | Source | New source added to ACE-031ACE-031, a Soluble Activin Type IIB Receptor, Increases Muscle Mass and Strength in the Common Marmoset (Callithrix jacchus) · pmc.ncbi.nlm.nih.gov/articles/PMC12904423/ | ACE-031 |
| PLOS ONE | |||
| 12 June 2026 | Source | New source added to ACE-031Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial · pubmed.ncbi.nlm.nih.gov/27462804/ | ACE-031 |
| Muscle & Nerve | |||
| 12 June 2026 | Source | New source added to ACE-031A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers · pubmed.ncbi.nlm.nih.gov/23169607/ | ACE-031 |
| Muscle & Nerve | |||
| 12 June 2026 | Source | New source added to AbaloparatideThe Why and How of Sequential and Combination Therapy in Osteoporosis: A Review of the Current Evidence · pmc.ncbi.nlm.nih.gov/articles/PMC10118820/ | Abaloparatide |
| 12 June 2026 | Source | New source added to AbaloparatideTYMLOS (abaloparatide) Injection — Full Prescribing Information, Initial U.S. Approval 2017 · nctr-crs.fda.gov/fdalabel/services/spl/set-ids/71… | Abaloparatide |
| 12 June 2026 | Source | New source added to AbaloparatideAbaloparatide - StatPearls (NCBI Bookshelf) · ncbi.nlm.nih.gov/books/NBK587447/ | Abaloparatide |
| StatPearls / NCBI | |||
| 12 June 2026 | Source | New source added to AbaloparatideEffect of Abaloparatide on Vertebral, Nonvertebral, Major Osteoporotic, and Clinical Fractures in a Subset of Postmenopausal Women at Increased Risk of Fracture by FRAX Probability · pmc.ncbi.nlm.nih.gov/articles/PMC6373333/ | Abaloparatide |
| 12 June 2026 | Source | New source added to AbaloparatideThe Efficacy and Safety of Abaloparatide-SC in Men With Osteoporosis: A Randomized Clinical Trial (ATOM) · pmc.ncbi.nlm.nih.gov/articles/PMC10091818/ | Abaloparatide |
| Journal of Bone and Mineral Research | |||
| 12 June 2026 | Source | New source added to AbaloparatideBinding Selectivity of Abaloparatide for PTH-Type-1-Receptor Conformations and Effects on Downstream Signaling · pmc.ncbi.nlm.nih.gov/articles/PMC4701881/ | Abaloparatide |
| Endocrinology | |||
| 12 June 2026 | Source | New source added to AbaloparatideACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis · pmc.ncbi.nlm.nih.gov/articles/PMC6097601/ | Abaloparatide |
| Journal of Clinical Endocrinology and Metabolism | |||
| 12 June 2026 | Source | New source added to AbaloparatideEffect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial (ACTIVE) · pubmed.ncbi.nlm.nih.gov/27533157/ | Abaloparatide |
| JAMA | |||
| 12 June 2026 | Peptide | Peptide updated: NMN (Nicotinamide Mononucleotide) | NMN (Nicotinamide Mononucleotide) |
| NAD+ direct precursor nucleotide; key longevity compound. | |||
| 12 June 2026 | Peptide | Peptide updated: Thymosin Alpha-1 | Thymosin Alpha-1 |
| Immune system support | |||
| 11 June 2026 | Source | New source added to TesamorelinSpotlight on tesamorelin in HIV-associated lipodystrophy · pubmed.ncbi.nlm.nih.gov/22050344/ | Tesamorelin |
| BioDrugs | |||
| 11 June 2026 | Source | New source added to TesamorelinEffects of Tesamorelin on Nonalcoholic Fatty Liver Disease in HIV: A Randomized, Double-Blind, Multicenter Trial · pmc.ncbi.nlm.nih.gov/articles/PMC6981288/ | Tesamorelin |
| Lancet HIV | |||
| 11 June 2026 | Source | New source added to TesamorelinEfficacy and Safety of Tesamorelin in People with HIV on Integrase Inhibitors · pmc.ncbi.nlm.nih.gov/articles/PMC11365754/ | Tesamorelin |
| 11 June 2026 | Source | New source added to TesamorelinEffect of tesamorelin in people with HIV with and without dorsocervical fat: Post hoc analysis of phase III double-blind placebo-controlled trial · pmc.ncbi.nlm.nih.gov/articles/PMC9947601/ | Tesamorelin |
| 11 June 2026 | Source | New source added to TesamorelinEffects of Growth Hormone-Releasing Hormone on Cognitive Function in Adults With Mild Cognitive Impairment and Healthy Older Adults: Results of a Controlled Trial · pmc.ncbi.nlm.nih.gov/articles/PMC3764914/ | Tesamorelin |
| 11 June 2026 | Source | New source added to TesamorelinClinical Review Report: Tesamorelin (Egrifta) - NCBI Bookshelf · ncbi.nlm.nih.gov/books/NBK539127/ | Tesamorelin |
| CADTH | |||
| 11 June 2026 | Source | New source added to TesamorelinGrowth hormone and tesamorelin in the management of HIV-associated lipodystrophy · pmc.ncbi.nlm.nih.gov/articles/PMC3218714/ | Tesamorelin |
| 11 June 2026 | Source | New source added to TesamorelinLabel: EGRIFTA SV - tesamorelin kit - DailyMed · dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d78… | Tesamorelin |
| U.S. National Library of Medicine / FDA | |||
| 11 June 2026 | Source | New source added to IpamorelinSafety and Efficacy of Ipamorelin for Management of Post-Operative Ileus (NCT00672074) · clinicaltrials.gov/study/NCT00672074 | Ipamorelin |
| 11 June 2026 | Source | New source added to IpamorelinThe GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats · pubmed.ncbi.nlm.nih.gov/10828840/ | Ipamorelin |
| Journal of Endocrinology | |||
| 11 June 2026 | Source | New source added to IpamorelinIpamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats · pubmed.ncbi.nlm.nih.gov/10373343/ | Ipamorelin |
| Growth Hormone and IGF Research | |||
| 11 June 2026 | Source | New source added to IpamorelinProspective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients · pubmed.ncbi.nlm.nih.gov/25331030/ | Ipamorelin |
| International Journal of Colorectal Disease | |||
| 11 June 2026 | Source | New source added to IpamorelinPharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers · pubmed.ncbi.nlm.nih.gov/10496658/ | Ipamorelin |
| Pharmaceutical Research | |||
| 11 June 2026 | Source | New source added to IpamorelinIpamorelin, the first selective growth hormone secretagogue · pubmed.ncbi.nlm.nih.gov/9849822/ | Ipamorelin |
| European Journal of Endocrinology | |||
| 11 June 2026 | Source | New source added to CJC-1295Pharmacy Compounding Advisory Committee (PCAC) Meeting — Federal Register Notice, Bulk Drug Substances Including CJC-1295 · federalregister.gov/documents/2024/10/25/2024-24828/… | CJC-1295 |
| U.S. Food and Drug Administration / Federal Register | |||
| 11 June 2026 | Source | New source added to CJC-1295CJC-1295 Use in Sports and Military Rules Explained · bscg.org/blogs/single/cjc-1295-use-in-spo… | CJC-1295 |
| Banned Substances Control Group (BSCG) | |||
| 11 June 2026 | Source | New source added to CJC-1295Pulsatile Secretion of Growth Hormone (GH) Persists during Continuous Stimulation by CJC-1295 — Oxford Academic abstract · academic.oup.com/jcem/article-abstract/91/12/4792… | CJC-1295 |
| Oxford University Press / JCEM | |||
| 11 June 2026 | Source | New source added to CJC-1295Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295 — Oxford Academic abstract · academic.oup.com/jcem/article-abstract/91/3/799/2… | CJC-1295 |
| Oxford University Press / JCEM | |||
| 11 June 2026 | Source | New source added to CJC-1295Lipodystrophy study halted after patient death · aidsmap.com/news/jul-2006/lipodystrophy-stud… | CJC-1295 |
| aidsmap | |||
| 11 June 2026 | Source | New source added to CJC-1295Pulsatile Secretion of Growth Hormone (GH) Persists during Continuous Stimulation by CJC-1295, a Long-Acting GH-Releasing Hormone Analog · pubmed.ncbi.nlm.nih.gov/17018654/ | CJC-1295 |
| Journal of Clinical Endocrinology & Metabolism | |||
| 11 June 2026 | Source | New source added to CJC-1295Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults · pubmed.ncbi.nlm.nih.gov/16352683/ | CJC-1295 |
| Journal of Clinical Endocrinology & Metabolism | |||
| 11 June 2026 | Source | New source added to TirzepatideTirzepatide for the treatment of adults with type 2 diabetes: An endocrine perspective · pmc.ncbi.nlm.nih.gov/articles/PMC10087310/ | Tirzepatide |
| Diabetes, Obesity and Metabolism | |||
| 11 June 2026 | Source | New source added to TirzepatideTirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5) · nejm.org/doi/abs/10.1056/NEJMoa2416394 | Tirzepatide |
| New England Journal of Medicine | |||
| 11 June 2026 | Source | New source added to TirzepatideOnce-weekly tirzepatide versus once-daily insulin degludec in patients with type 2 diabetes (SURPASS-3) · pubmed.ncbi.nlm.nih.gov/34370970/ | Tirzepatide |
| The Lancet | |||
| 11 June 2026 | Source | New source added to TirzepatideEfficacy and safety of tirzepatide versus placebo in overweight or obese adults without diabetes: a systematic review and meta-analysis of randomized controlled trials · pmc.ncbi.nlm.nih.gov/articles/PMC11576767/ | Tirzepatide |
| International Journal of Clinical Pharmacy | |||
| 11 June 2026 | Source | New source added to TirzepatideTirzepatide - StatPearls · ncbi.nlm.nih.gov/books/NBK585056/ | Tirzepatide |
| NCBI Bookshelf / StatPearls | |||
| 11 June 2026 | Source | New source added to TirzepatideTirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist · pmc.ncbi.nlm.nih.gov/articles/PMC7526454/ | Tirzepatide |
| JCI Insight | |||
| 11 June 2026 | Source | New source added to TirzepatideTirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) · nejm.org/doi/full/10.1056/NEJMoa2206038 | Tirzepatide |
| New England Journal of Medicine | |||
| 11 June 2026 | Source | New source added to SemaglutideSemaglutide - StatPearls · ncbi.nlm.nih.gov/books/NBK603723/ | Semaglutide |
| StatPearls Publishing / NCBI Bookshelf | |||
| 11 June 2026 | Source | New source added to SemaglutideMolecular mechanisms of semaglutide and liraglutide as a therapeutic option for obesity · pmc.ncbi.nlm.nih.gov/articles/PMC11090168/ | Semaglutide |
| Frontiers in Endocrinology | |||
| 11 June 2026 | Source | New source added to SemaglutideA Review on Semaglutide: An Oral Glucagon-Like Peptide 1 Receptor Agonist in Management of Type 2 Diabetes Mellitus · pmc.ncbi.nlm.nih.gov/articles/PMC7434819/ | Semaglutide |
| International Journal of Molecular Sciences | |||
| 11 June 2026 | Source | New source added to SemaglutideSemaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes · pmc.ncbi.nlm.nih.gov/articles/PMC8736331/ | Semaglutide |
| Cardiovascular Diabetology | |||
| 11 June 2026 | Source | New source added to SemaglutideSemaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials · pmc.ncbi.nlm.nih.gov/articles/PMC6099440/ | Semaglutide |
| Diabetes, Obesity and Metabolism | |||
| 11 June 2026 | Source | New source added to SemaglutideOnce-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1 trial) · nejm.org/doi/full/10.1056/NEJMoa2032183 | Semaglutide |
| New England Journal of Medicine | |||
| 11 June 2026 | Source | New source added to SemaglutideWEGOVY (semaglutide) injection prescribing information · accessdata.fda.gov/drugsatfda_docs/label/2023/21525… | Semaglutide |
| U.S. Food and Drug Administration | |||
| 11 June 2026 | Source | New source added to SemaglutideOZEMPIC (semaglutide) injection prescribing information · accessdata.fda.gov/drugsatfda_docs/label/2023/20963… | Semaglutide |
| U.S. Food and Drug Administration | |||
| 10 June 2026 | Source | New source added to GLOW StackRegenerative and Protective Actions of the GHK-Cu Peptide · mdpi.com/1422-0067/19/7/1987 | GLOW Stack |
| Int. J. Mol. Sci. (Pickart & Margolina, 2018) | |||
| 10 June 2026 | Source | New source added to GLOW StackInterim Policy on Compounding Using Bulk Drug Substances Under Section 503A — 503A Bulks List (Category 1 & 2) · fda.gov/drugs/human-drug-compounding/503… | GLOW Stack |
| U.S. Food and Drug Administration | |||
| 10 June 2026 | Source | New source added to GLOW StackThymosin beta-4 activates ILK and promotes cardiac cell migration, survival and cardiac repair · nature.com/articles/nature03000 | GLOW Stack |
| Nature (Bock-Marquette et al., 2004) | |||
| 10 June 2026 | Source | New source added to GLOW StackWADA Prohibited List — S2 Peptide Hormones, Growth Factors, Related Substances and Mimetics · wada-ama.org/en/prohibited-list | GLOW Stack |
| World Anti-Doping Agency | |||
| 10 June 2026 | Source | New source added to GLOW StackMultifunctionality and Possible Medical Application of the BPC 157 Peptide — Literature and Patent Review · ncbi.nlm.nih.gov/pmc/articles/PMC11859134/ | GLOW Stack |
| Pharmaceuticals (Jozwiak et al., 2025) | |||
| 5 June 2026 | Research | New research: Retatrutide TRANSCEND-T2D-1 Phase 3: A1C Lowered up to ~2.0% and Weight up to 16.8% at 40 Weeks in Type 2 Diabetes (Eli Lilly, ADA 2026)investor.lilly.com/news-releases/news-release-details/lillys-triple… | Retatrutide |
| Phase 3 TRANSCEND-T2D-1 (manufacturer-reported topline; Eli Lilly press release dated May 28, 2026 ahead of the ADA 86th Scientific Sessions; full results scheduled for presentation at the ADA retatrutide symposium on June 6, 2026): in adults with type 2 diabetes, retatrutide — a | |||
| 5 June 2026 | Research | New research: ADA 2026 Scientific Sessions (June 5-8, New Orleans): First-Time CagriSema REIMAGINE Phase 3 and Oral GLP-1 Readouts Scheduledmedscape.com/viewarticle/latest-glp-1-based-therapy-be-featur… | CagriSema, Cagrilintide, Semaglutide, Elecoglipron |
| The American Diabetes Association's 86th Scientific Sessions run June 5-8, 2026 in New Orleans, with GLP-1-based therapies featured in seven of eight major clinical-trial result sessions. Phase 3 REIMAGINE 1, 2 and 3 data for CagriSema (cagrilintide + semaglutide, Novo Nordisk) a | |||
| 4 June 2026 | Research | New research: FDA Confirms 7-Peptide Agenda for July 23–24, 2026 PCAC 503A Bulks-List Review (BPC-157, KPV, TB-500, MOTS-C, DSIP/Emideltide, Semax, Epitalon)fda.gov/advisory-committees/advisory-committee-calendar/… | BPC-157, KPV, TB-500, MOTS-C, DSIP (Emideltide), Semax, Epitalon |
| FDA primary source (Pharmacy Compounding Advisory Committee meeting notice; page content current as of 2026-04-15). The PCAC will meet July 23–24, 2026 at FDA White Oak Campus to discuss bulk drug substances nominated for inclusion on the Section 503A Bulks List. The confirmed ag | |||
| 4 June 2026 | Research | New research: Enlicitide Decanoate (Oral Macrocyclic Peptide PCSK9 Inhibitor) Reduced LDL-C 55.8% in Phase 3 CORALreef Lipids (Merck, AHA 2025)merck.com/news/mercks-enlicitide-decanoate-an-investigatio… | Enlicitide decanoate (MK-0616) |
| Investigational once-daily ORAL macrocyclic peptide PCSK9 inhibitor (Merck/MSD; MK-0616). Late-breaking Phase 3 CORALreef Lipids results presented at AHA Scientific Sessions 2025 (announced 8 Nov 2025): in adults with or at risk for atherosclerotic cardiovascular disease on backg | |||
| 3 June 2026 | Research | New research: Health Canada Public Advisory (RA-81874): Unauthorized Injectable Peptide Drugs Sold Online May Cause Serious Harmrecalls-rappels.canada.ca/en/alert-recall/think-twice-injecting-peptides-b… | BPC-157, TB-500, Retatrutide, CJC-1295, DSIP, Epitalon, GHK-Cu, Ipamorelin, KPV, Melanotan I/II, MOTS-C, NAD+, SS-31, HCG |
| Health Canada public advisory (RA-81874, published 2026-04-09) warning consumers about serious health risks of unauthorized injectable peptide drugs sold online and marketed for anti-aging, weight loss, bodybuilding, athletic performance, injury recovery, sleep, mental focus, or | |||
| 3 June 2026 | Research | New research: Unimolecular Quintuple Agonist GLP-1–GIP–Lanifibranor Corrects Obesity and Diabetes in Mice (Nature, 2026)nature.com/articles/s41586-026-10427-5 | GLP-1–GIP–lanifibranor, Semaglutide, Tirzepatide |
| Peer-reviewed preclinical study (Nature, published 29 April 2026; DOI 10.1038/s41586-026-10427-5; Helmholtz Munich with Indiana Biosciences Research Institute and the Novo Nordisk Research Center Indianapolis). Reports a unimolecular quintuple agonist, GLP-1–GIP–lanifibranor, a p | |||
| 1 June 2026 | Peptide | New peptide added: Bulevirtide | Bulevirtide |
| First/only FDA-approved treatment for chronic hepatitis delta virus (HDV). FDA accelerated approval May 22, 2026. Brand: Hepcludex (Gilead). | |||
| 29 May 2026 | Peptide | New peptide added: Pegzilarginase-nbln | Pegzilarginase-nbln |
| PEGylated recombinant arginase enzyme for Arginase 1 Deficiency. FDA approved February 23, 2026. | |||
| 29 May 2026 | Peptide | New peptide added: Navepegritide | Navepegritide |
| PEGylated CNP analog for achondroplasia. FDA approved February 27, 2026. | |||
| 29 May 2026 | Peptide | New peptide added: Icotrokinra | Icotrokinra |
| Oral macrocyclic peptide. First-in-class IL-23 receptor antagonist. FDA approved March 17, 2026 for plaque psoriasis. | |||
| 28 May 2026 | FDA approval | New FDA-approved peptide: Metreleptinaccessdata.fda.gov/drugsatfda_docs/label/2014/125390s000lbl.pdf | Metreleptin |
| Myalept — Leptin deficiency in generalized lipodystrophy | |||
| 28 May 2026 | Peptide | New peptide added: NMN (Nicotinamide Mononucleotide) | NMN (Nicotinamide Mononucleotide) |
| NAD+ direct precursor nucleotide; key longevity compound. | |||
| 23 May 2026 | Research | New research: Self-Reported Side Effects of Semaglutide and Tirzepatide in Online Communities (Nature Health, 2026)nature.com/articles/s44360-026-00108-y | Semaglutide, Tirzepatide |
| Peer-reviewed pharmacovigilance study (Nature Health, 2026; DOI 10.1038/s44360-026-00108-y) applying large-scale natural-language analysis to 410,198 Reddit posts (May 2019-June 2025) mentioning semaglutide or tirzepatide. Of 67,008 users who self-reported use, 43.5% described at | |||
| 22 May 2026 | Research | New research: FDA Approves First Treatment for Chronic Hepatitis Delta Virus (HDV): Hepcludex (Bulevirtide-gmod)fda.gov/news-events/press-announcements/fda-approves-fir… | Bulevirtide |
| On May 22, 2026 the FDA granted accelerated approval to Hepcludex (bulevirtide-gmod), the first and only approved US treatment for chronic hepatitis delta virus (HDV) infection in adults without cirrhosis or with compensated cirrhosis. Bulevirtide is an HBV/HDV entry inhibitor (N | |||
| 22 May 2026 | FDA approval | New FDA-approved peptide: Bulevirtidefda.gov/news-events/press-announcements/fda-approves-fir… | Bulevirtide |
| Hepcludex — Chronic hepatitis delta virus (HDV) infection in adults without cirrhosis or with compensated cirrhosis. Granted accelerated approval based on reduction in HDV RNA and ALT normalization (Phase 3 MYR301, Week 48); clinical-outcome benefit not yet established and contin | |||
| 21 May 2026 | Research | New research: Retatrutide TRIUMPH-1 Phase 3: 28.3% Weight Loss at 80 Weeks (Eli Lilly, May 2026)investor.lilly.com/news-releases/news-release-details/lillys-triple… | Retatrutide, Tirzepatide, CagriSema |
| Phase 3 TRIUMPH-1 (Eli Lilly press release May 21, 2026): Retatrutide 12 mg produced 28.3% body weight loss (70.3 lb) over 80 weeks in adults with obesity without T2D. 9 mg: 25.9% (64.4 lb). 4 mg: 19.0% (47.2 lb). All doses met primary and key secondary endpoints. 45.3% of 12 mg | |||
| 19 May 2026 | Research | New research: Safety Risks in the GLP-1 Market: May 2026 Update on Compounded & Counterfeit Semaglutide/Tirzepatidesafemedicines.org/2026/05/glp-1-safety-risks-may-2026.html | Semaglutide, Tirzepatide, Retatrutide |
| Partnership for Safe Medicines May 2026 roundup documenting safety risks across the GLP-1 weight-loss market: counterfeit Ozempic/Mounjaro seizures (US, Canada, Australia, India, UK), illicit online sales of unregistered semaglutide, tirzepatide and "research-use-only" retatrutid | |||
| 18 May 2026 | Research | New research: FDA Warns 503B Outsourcing Facility for Compounding Tirzepatide After Shortage Endedsafemedicines.org/2026/05/may-18-2026.html | Tirzepatide |
| FDA issued a warning to a 503B compounding pharmacy for producing tirzepatide after the official shortage ended, consistent with the agency's April 30, 2026 proposal to exclude GLP-1 drugs from the 503B bulks list. | |||
| 30 April 2026 | Research | New research: FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide from the 503B Bulks Listfda.gov/news-events/press-announcements/fda-proposes-exc… | Semaglutide, Tirzepatide, Liraglutide |
| FDA proposed (Apr 30, 2026; Federal Register May 1, 2026) to leave semaglutide, tirzepatide, and liraglutide OFF the 503B Bulk Drug Substances List, finding no clinical need for outsourcing-facility bulk compounding now that shortages have ended. Comment period closes June 29, 20 | |||
| 16 April 2026 | Research | New research: FDA Announces Removal of 12 Peptides from Category 2 — April 15, 2026orrick.com/en/Insights/2026/04/FDA-Announces-Removal-of-12-… | BPC-157, TB-500, Semax, Epitalon, DSIP, GHK-Cu, KPV, PEG-MGF, Melanotan II, MOTS-C, LL-37, DiHexa |
| On April 15, 2026, FDA announced removal of 12 peptide bulk drug substances from Category 2 effective April 22, 2026, following withdrawal of nominations. No longer "significant safety risk" designation but not yet on 503A Bulks List. PCAC reviews July 23-24, 2026. | |||
| 1 April 2026 | Research | New research: FDA Novel Drug Approval: Foundayo (Orforglipron) — First Oral GLP-1 Agonistfda.gov/drugs/novel-drug-approvals-fda/novel-drug-approv… | Orforglipron |
| FDA approved Foundayo (orforglipron) April 1, 2026. First oral GLP-1 receptor agonist for weight management in adults with obesity or overweight. Eli Lilly. | |||
| 1 April 2026 | FDA approval | New FDA-approved peptide: Orforglipron | Orforglipron |
| Foundayo — Obesity or overweight with at least one weight-related comorbidity in adults; combined with reduced-calorie diet and increased physical activity | |||
| 17 March 2026 | Research | New research: FDA Novel Drug Approval: Icotyde (Icotrokinra) — First Oral Peptide for Plaque Psoriasisfda.gov/drugs/novel-drug-approvals-fda/novel-drug-approv… | Icotrokinra |
| FDA approved Icotyde (icotrokinra) March 17, 2026. First-in-class oral macrocyclic peptide IL-23R antagonist for moderate-to-severe plaque psoriasis. J&J / Protagonist Therapeutics. | |||
| 17 March 2026 | FDA approval | New FDA-approved peptide: Icotrokinra | Icotrokinra |
| Icotyde — Moderate-to-severe plaque psoriasis in patients 12 years and older weighing at least 40 kg who are candidates for systemic therapy or phototherapy | |||
| 27 February 2026 | Research | New research: FDA Novel Drug Approval: Yuviwel (Navepegritide) — CNP Analog for Achondroplasiafda.gov/drugs/novel-drug-approvals-fda/novel-drug-approv… | Navepegritide |
| FDA approved Yuviwel (navepegritide) Feb 27, 2026 for pediatric achondroplasia. PEGylated CNP analog activating NPR-B to promote bone growth. BioMarin. | |||
| 27 February 2026 | FDA approval | New FDA-approved peptide: Navepegritide | Navepegritide |
| Yuviwel — Increase linear growth in pediatric patients 2 years and older with achondroplasia with open epiphyses | |||
| 23 February 2026 | Research | New research: FDA Novel Drug Approval: Loargys (Pegzilarginase-nbln) — Enzyme for Arginase 1 Deficiencyfda.gov/drugs/novel-drug-approvals-fda/novel-drug-approv… | Pegzilarginase-nbln |
| FDA approved Loargys (pegzilarginase-nbln) Feb 23, 2026. PEGylated arginase enzyme for Arginase 1 Deficiency. IV infusion with dietary protein restriction. | |||
| 23 February 2026 | FDA approval | New FDA-approved peptide: Pegzilarginase-nbln | Pegzilarginase-nbln |
| Loargys — Hyperarginemia in adults and pediatric patients 2 years and older with Arginase 1 Deficiency, in conjunction with dietary protein restriction | |||
| 7 October 2025 | Peptide | New peptide added: TB-500 | TB-500 |
| Connective tissue repair | |||
| 7 October 2025 | Peptide | New peptide added: BPC-157 | BPC-157 |
| Bone and cartilage healing | |||
| 7 October 2025 | Peptide | New peptide added: GHK-Cu | GHK-Cu |
| Bone remodeling support | |||
| 7 October 2025 | Peptide | New peptide added: Collagen Peptides | Collagen Peptides |
| Structural bone and joint support | |||
| 7 October 2025 | Peptide | New peptide added: Calcitonin | Calcitonin |
| FDA-approved bone resorption inhibitor | |||
| 7 October 2025 | Peptide | New peptide added: Pentosan Polysulfate | Pentosan Polysulfate |
| Cartilage and joint protection | |||
| 7 October 2025 | Peptide | New peptide added: Abaloparatide | Abaloparatide |
| Advanced bone anabolic | |||
| 7 October 2025 | Peptide | New peptide added: Teriparatide | Teriparatide |
| FDA-approved bone builder | |||
| 7 October 2025 | Peptide | New peptide added: Melanotan II | Melanotan II |
| Melanocortin system activator | |||
| 7 October 2025 | Peptide | New peptide added: Prostatilen | Prostatilen |
| Prostate and male hormone support | |||
| 7 October 2025 | Peptide | New peptide added: Thyreogen | Thyreogen |
| Thyroid function support | |||
| 7 October 2025 | Peptide | New peptide added: DHEA Peptide | DHEA Peptide |
| Hormone precursor support | |||
| 7 October 2025 | Peptide | New peptide added: Oxytocin | Oxytocin |
| Bonding and relaxation hormone | |||
| 7 October 2025 | Peptide | New peptide added: PT-141 | PT-141 |
| Sexual function peptide | |||
| 7 October 2025 | Peptide | New peptide added: HCG (Human Chorionic Gonadotropin) | HCG (Human Chorionic Gonadotropin) |
| Testosterone production support | |||
| 7 October 2025 | Peptide | New peptide added: Gonadorelin | Gonadorelin |
| GnRH for fertility | |||
| 7 October 2025 | Peptide | New peptide added: Kisspeptin | Kisspeptin |
| Reproductive hormone regulator | |||
| 7 October 2025 | Peptide | New peptide added: DSIP | DSIP |
| Pain perception modulation | |||
| 7 October 2025 | Peptide | New peptide added: Thymosin Beta-4 | Thymosin Beta-4 |
| Comprehensive tissue pain relief | |||
| 7 October 2025 | Peptide | New peptide added: TB-500 | TB-500 |
| Injury and inflammation pain relief | |||
| 7 October 2025 | Peptide | New peptide added: KPV | KPV |
| Anti-inflammatory pain relief | |||
| 7 October 2025 | Peptide | New peptide added: BPC-157 | BPC-157 |
| Multi-purpose healing for pain | |||
| 7 October 2025 | Peptide | New peptide added: LL-37 | LL-37 |
| Inflammatory pain modulation | |||
| 7 October 2025 | Peptide | New peptide added: GHK-Cu | GHK-Cu |
| Anti-inflammatory tissue repair | |||
| 7 October 2025 | Peptide | New peptide added: Actovegin | Actovegin |
| Hypoxic pain and healing | |||
| 7 October 2025 | Peptide | New peptide added: Pentosan Polysulfate | Pentosan Polysulfate |
| Joint and cartilage pain relief | |||
| 7 October 2025 | Peptide | New peptide added: Cerebrolysin | Cerebrolysin |
| Neuropathic pain support | |||
| 7 October 2025 | Peptide | New peptide added: PEA (Palmitoylethanolamide) | PEA (Palmitoylethanolamide) |
| Natural pain modulator | |||
| 7 October 2025 | Peptide | New peptide added: ARA-290 | ARA-290 |
| Neuropathic pain specialist | |||
| 7 October 2025 | Peptide | New peptide added: Epithalon | Epithalon |
| Circadian rhythm regulator | |||
| 7 October 2025 | Peptide | New peptide added: Semax Low Dose | Semax Low Dose |
| Evening cognitive calming | |||
| 7 October 2025 | Peptide | New peptide added: DSIP | DSIP |
| Delta sleep-inducing peptide | |||
| 7 October 2025 | Peptide | New peptide added: GHK-Cu | GHK-Cu |
| Recovery enhancement peptide | |||
| 7 October 2025 | Peptide | New peptide added: Cerebrolysin | Cerebrolysin |
| Neural restoration during sleep | |||
| 7 October 2025 | Peptide | New peptide added: Glycine Peptide | Glycine Peptide |
| Sleep quality amino peptide | |||
| 7 October 2025 | Peptide | New peptide added: Pinealon | Pinealon |
| Pineal gland bioregulator | |||
| 7 October 2025 | Peptide | New peptide added: Cortexin | Cortexin |
| Neuropeptide for rest | |||
| 7 October 2025 | Peptide | New peptide added: Melatonin Peptide Complex | Melatonin Peptide Complex |
| Enhanced melatonin delivery | |||
| 7 October 2025 | Peptide | New peptide added: Selank | Selank |
| Anxiolytic for sleep | |||
| 7 October 2025 | Peptide | New peptide added: KPV | KPV |
| Anti-inflammatory immune peptide | |||
| 7 October 2025 | Peptide | New peptide added: LL-37 | LL-37 |
| Antimicrobial defense peptide | |||
| 7 October 2025 | Peptide | New peptide added: AMP-K | AMP-K |
| Metabolic immune support | |||
| 7 October 2025 | Peptide | New peptide added: Splenopentin | Splenopentin |
| Spleen-derived immune peptide | |||
| 7 October 2025 | Peptide | New peptide added: Beta-Glucan Peptide | Beta-Glucan Peptide |
| Immune activating complex | |||
| 7 October 2025 | Peptide | New peptide added: Groprinosin | Groprinosin |
| Antiviral immune booster | |||
| 7 October 2025 | Peptide | New peptide added: Imunofan | Imunofan |
| Russian immune peptide | |||
| 7 October 2025 | Peptide | New peptide added: Vilon | Vilon |
| Simple immune dipeptide | |||
| 7 October 2025 | Peptide | New peptide added: Vladonix | Vladonix |
| Thymus bioregulator complex | |||
| 7 October 2025 | Peptide | New peptide added: Thymalin | Thymalin |
| Thymus restoration peptide | |||
| 7 October 2025 | Peptide | New peptide added: Thymosin Alpha-1 | Thymosin Alpha-1 |
| Potent immune modulator | |||
| 7 October 2025 | Peptide | New peptide added: Copper Peptide GHK-Cu | Copper Peptide GHK-Cu |
| Multi-functional skin peptide | |||
| 7 October 2025 | Peptide | New peptide added: PT-141 (Bremelanotide) | PT-141 (Bremelanotide) |
| Libido enhancement peptide | |||
| 7 October 2025 | Peptide | New peptide added: Hexapeptide-11 | Hexapeptide-11 |
| Cell renewal peptide | |||
| 7 October 2025 | Peptide | New peptide added: Palmitoyl Tripeptide-5 | Palmitoyl Tripeptide-5 |
| Collagen booster | |||
| 7 October 2025 | Peptide | New peptide added: Snap-8 | Snap-8 |
| Enhanced Argireline | |||
| 7 October 2025 | Peptide | New peptide added: Syn-Coll | Syn-Coll |
| Collagen synthesis peptide | |||
| 7 October 2025 | Peptide | New peptide added: Matrixyl 3000 | Matrixyl 3000 |
| Advanced collagen booster | |||
| 7 October 2025 | Peptide | New peptide added: Argireline (Acetyl Hexapeptide-8) | Argireline (Acetyl Hexapeptide-8) |
| Botox-like peptide | |||
| 7 October 2025 | Peptide | New peptide added: Urolithin A | Urolithin A |
| Mitochondrial health compound | |||
| 7 October 2025 | Peptide | New peptide added: NMN | NMN |
| NAD+ precursor | |||
| 7 October 2025 | Peptide | New peptide added: Vladonix | Vladonix |
| Thymus bioregulator | |||
| 7 October 2025 | Peptide | New peptide added: Ovagen | Ovagen |
| Digestive system bioregulator | |||
| 7 October 2025 | Peptide | New peptide added: Prostatilen | Prostatilen |
| Prostate bioregulator | |||
| 7 October 2025 | Peptide | New peptide added: Thyreogen | Thyreogen |
| Thyroid bioregulator | |||
| 7 October 2025 | Peptide | New peptide added: Cortagen | Cortagen |
| Brain bioregulator | |||
| 7 October 2025 | Peptide | New peptide added: Vilon | Vilon |
| Thymus dipeptide | |||
| 7 October 2025 | Peptide | New peptide added: Thymalin | Thymalin |
| Thymus bioregulator | |||
| 7 October 2025 | Peptide | New peptide added: NA-Semax-Amidate | NA-Semax-Amidate |
| Triple modified Semax | |||
| 7 October 2025 | Peptide | New peptide added: Semax-Amidate | Semax-Amidate |
| Extended release Semax | |||
| 7 October 2025 | Peptide | New peptide added: Memantine | Memantine |
| NMDA antagonist | |||
| 7 October 2025 | Peptide | New peptide added: RG3 (Rhodiola) | RG3 (Rhodiola) |
| Adaptogenic peptide | |||
| 7 October 2025 | Peptide | New peptide added: FGL (Fibroblast Growth Loop) | FGL (Fibroblast Growth Loop) |
| NCAM mimetic | |||
| 7 October 2025 | Peptide | New peptide added: Cortexin | Cortexin |
| Neuropeptide complex | |||
| 7 October 2025 | Peptide | New peptide added: P21 (Adamax) | P21 (Adamax) |
| Neurogenic peptide | |||
| 7 October 2025 | Peptide | New peptide added: Selank-Amidate | Selank-Amidate |
| Extended release Selank | |||
| 7 October 2025 | Peptide | New peptide added: Epithalon + Follistatin Stack | Epithalon + Follistatin Stack |
| Anti-aging performance combo | |||
| 7 October 2025 | Peptide | New peptide added: HGH Fragment 176-191 | HGH Fragment 176-191 |
| Fat loss without GH effects | |||
| 7 October 2025 | Peptide | New peptide added: YK-11 | YK-11 |
| Myostatin inhibitor | |||
| 7 October 2025 | Peptide | New peptide added: ACE-031 | ACE-031 |
| Myostatin inhibitor | |||
| 7 October 2025 | Peptide | New peptide added: TB4-FRAG | TB4-FRAG |
| TB-500 fragment | |||
| 7 October 2025 | Peptide | New peptide added: GHRP-4 | GHRP-4 |
| Fourth generation GHRP | |||
| 7 October 2025 | Peptide | New peptide added: Tesamorelin | Tesamorelin |
| GHRH for visceral fat | |||
| 7 October 2025 | Peptide | New peptide added: Sermorelin | Sermorelin |
| GHRH for natural GH release | |||
| 7 October 2025 | Peptide | New peptide added: Orforglipron | Orforglipron |
| Oral GLP-1 | |||
| 7 October 2025 | Peptide | New peptide added: Liraglutide | Liraglutide |
| FDA-approved GLP-1 for weight loss | |||
| 7 October 2025 | Peptide | New peptide added: Retatrutide | Retatrutide |
| Investigational triple agonist (GIP/GLP-1/glucagon). TRIUMPH-1 Phase 3 (May 2026): 28.3% body weight loss at 80 weeks. FDA submission anticipated Q3–Q4 2026. | |||
| 7 October 2025 | Peptide | New peptide added: Fragment 176-191 | Fragment 176-191 |
| HGH fragment for fat loss | |||
| 7 October 2025 | Peptide | New peptide added: Leptin | Leptin |
| Satiety hormone | |||
| 7 October 2025 | Peptide | New peptide added: Pramlintide | Pramlintide |
| Amylin analog for diabetes | |||
| 7 October 2025 | Peptide | New peptide added: CagriSema | CagriSema |
| Combination therapy | |||
| 7 October 2025 | Peptide | New peptide added: Dulaglutide | Dulaglutide |
| Weekly GLP-1 (Trulicity) | |||
| 7 October 2025 | Peptide | New peptide added: BPC-157 Stable | BPC-157 Stable |
| Stabilized BPC variant | |||
| 7 October 2025 | Peptide | New peptide added: FGL (Fibroblast Growth-Like) | FGL (Fibroblast Growth-Like) |
| Neural repair peptide | |||
| 7 October 2025 | Peptide | New peptide added: Actovegin | Actovegin |
| Tissue regeneration complex | |||
| 7 October 2025 | Peptide | New peptide added: Ghrelinomimetic | Ghrelinomimetic |
| Appetite and healing support | |||
| 7 October 2025 | Peptide | New peptide added: Pentosan Polysulfate | Pentosan Polysulfate |
| Joint and bladder support | |||
| 7 October 2025 | Peptide | New peptide added: Larazotide | Larazotide |
| Gut permeability regulator | |||
| 7 October 2025 | FDA approval | New FDA-approved peptide: Pasireotide | Pasireotide |
| Signifor — Cushing's disease | |||
| 7 October 2025 | FDA approval | New FDA-approved peptide: Lanreotide | Lanreotide |
| Somatuline — Acromegaly, neuroendocrine tumors | |||
| 7 October 2025 | FDA approval | New FDA-approved peptide: Octreotide | Octreotide |
| Sandostatin — Acromegaly, carcinoid syndrome | |||
| 7 October 2025 | FDA approval | New FDA-approved peptide: Desmopressin | Desmopressin |
| DDAVP, Stimate — Diabetes insipidus, hemophilia A | |||
| 7 October 2025 | FDA approval | New FDA-approved peptide: Bivalirudin | Bivalirudin |
| Angiomax — Anticoagulation during cardiac procedures | |||
| 7 October 2025 | FDA approval | New FDA-approved peptide: Pramlintide | Pramlintide |
| Symlin — Diabetes (adjunct to insulin) | |||
| 7 October 2025 | FDA approval | New FDA-approved peptide: Abaloparatide | Abaloparatide |
| Tymlos — Postmenopausal osteoporosis | |||
| 7 October 2025 | FDA approval | New FDA-approved peptide: Teriparatide | Teriparatide |
| Forteo — Osteoporosis | |||
| 7 October 2025 | FDA approval | New FDA-approved peptide: Calcitonin | Calcitonin |
| Miacalcin, Fortical — Osteoporosis, Paget's disease | |||
| 7 October 2025 | FDA approval | New FDA-approved peptide: Insulin | Insulin |
| Humalog, Novolog, Lantus, many others — Diabetes management | |||
| 7 October 2025 | FDA approval | New FDA-approved peptide: Oxytocin | Oxytocin |
| Pitocin — Labor induction, postpartum bleeding | |||
| 7 October 2025 | FDA approval | New FDA-approved peptide: Gonadorelin | Gonadorelin |
| Factrel — Hypogonadotropic hypogonadism | |||
| 7 October 2025 | FDA approval | New FDA-approved peptide: Sermorelin | Sermorelin |
| Sermorelin Acetate — Growth hormone deficiency in children | |||
| 7 October 2025 | FDA approval | New FDA-approved peptide: Tesamorelin | Tesamorelin |
| Egrifta — HIV-associated lipodystrophy | |||
| 7 October 2025 | FDA approval | New FDA-approved peptide: Exenatide | Exenatide |
| Byetta, Bydureon — Type 2 diabetes | |||
| 7 October 2025 | FDA approval | New FDA-approved peptide: Dulaglutide | Dulaglutide |
| Trulicity — Type 2 diabetes | |||
| 7 October 2025 | FDA approval | New FDA-approved peptide: Liraglutide | Liraglutide |
| Victoza, Saxenda — Type 2 diabetes (Victoza), Weight management (Saxenda) | |||
| 7 October 2025 | FDA approval | New FDA-approved peptide: Tirzepatide | Tirzepatide |
| Mounjaro, Zepbound — Type 2 diabetes (Mounjaro), Chronic weight management (Zepbound) | |||
| 7 October 2025 | FDA approval | New FDA-approved peptide: Semaglutide | Semaglutide |
| Ozempic, Wegovy, Rybelsus — Type 2 diabetes (Ozempic), Chronic weight management (Wegovy) | |||
| 7 October 2025 | Peptide | New peptide added: Dihexa | Dihexa |
| Potent cognitive enhancer | |||
| 7 October 2025 | Peptide | New peptide added: Epitalon | Epitalon |
| Longevity, telomere support | |||
| 7 October 2025 | Peptide | New peptide added: MOTS-c | MOTS-c |
| Mitochondrial optimization | |||
| 7 October 2025 | Peptide | New peptide added: TB-500 | TB-500 |
| Tissue repair, flexibility, inflammation | |||
| 7 October 2025 | Peptide | New peptide added: Melanotan II | Melanotan II |
| Tanning, libido | |||
| 7 October 2025 | Peptide | New peptide added: BPC-157 | BPC-157 |
| Healing & recovery, gut health | |||
| 7 October 2025 | Peptide | New peptide added: Copper Peptides | Copper Peptides |
| Skin regeneration | |||
| 7 October 2025 | Peptide | New peptide added: GHK-Cu | GHK-Cu |
| Skin health, anti-aging, wound healing | |||
| 7 October 2025 | Peptide | New peptide added: GHK-Cu | GHK-Cu |
| Wound healing, skin regeneration | |||
| 7 October 2025 | Peptide | New peptide added: Semax | Semax |
| Cognitive enhancement, focus, memory | |||
| 7 October 2025 | Peptide | New peptide added: Matrixyl (Palmitoyl Pentapeptide) | Matrixyl (Palmitoyl Pentapeptide) |
| Anti-aging skincare | |||
| 7 October 2025 | Peptide | New peptide added: Tirzepatide | Tirzepatide |
| Dual GIP/GLP-1 agonist for weight loss | |||
| 7 October 2025 | Peptide | New peptide added: Semaglutide | Semaglutide |
| Weight loss, blood sugar control | |||
| 7 October 2025 | Peptide | New peptide added: SS-31 (Elamipretide) | SS-31 (Elamipretide) |
| Mitochondrial optimization | |||
| 7 October 2025 | Peptide | New peptide added: Humanin | Humanin |
| Mitochondrial protection, longevity | |||
| 7 October 2025 | Peptide | New peptide added: Cerebrolysin | Cerebrolysin |
| Neuroprotection, recovery | |||
| 7 October 2025 | Peptide | New peptide added: NSI-189 | NSI-189 |
| Neurogenesis, depression | |||
| 7 October 2025 | Peptide | New peptide added: Selank | Selank |
| Anxiety reduction, focus | |||
| 7 October 2025 | Peptide | New peptide added: Hexarelin | Hexarelin |
| Potent GH releaser | |||
| 7 October 2025 | Peptide | New peptide added: MK-677 (Ibutamoren) | MK-677 (Ibutamoren) |
| Oral GH secretagogue | |||
| 7 October 2025 | Peptide | New peptide added: Ipamorelin | Ipamorelin |
| GH secretagogue, anti-aging | |||
| 7 October 2025 | Peptide | New peptide added: CJC-1295 | CJC-1295 |
| Growth hormone, muscle mass, fat loss | |||
| 7 October 2025 | Peptide | New peptide added: AOD-9604 | AOD-9604 |
| Fat loss, metabolic enhancement | |||
| 7 October 2025 | Peptide | New peptide added: Thymosin Alpha-1 | Thymosin Alpha-1 |
| Immune system support | |||
| 1 June 2024 | Research | New research: Peptide Therapy in Sports Medicine: Current Evidence and Future Directionspubmed.ncbi.nlm.nih.gov/18462162/ | BPC-157, TB-500, Ipamorelin, CJC-1295 |
| Critical review of peptide use in athletic recovery: available evidence, WADA prohibited status, ethical considerations. | |||
| 15 March 2024 | Research | New research: Growth Hormone Secretagogues: Peptide and Non-Peptide Options in 2024pubmed.ncbi.nlm.nih.gov/9849822/ | Ipamorelin, CJC-1295, Sermorelin, MK-677 |
| Comprehensive comparison of GHRH analogs, GHRPs, and ghrelin mimetics for clinical and off-label applications. | |||
| 1 February 2024 | Research | New research: Oral Peptides and GLP-1 Analogs: Breaking the Injection Barrierpubmed.ncbi.nlm.nih.gov/37399058/ | Orforglipron, Semaglutide (oral) |
| Review of advances in oral peptide bioavailability: Rybelsus SNAC technology, orforglipron, next-generation oral metabolic agents. | |||
| 15 January 2024 | Research | New research: BPC-157: A Comprehensive Overview of the Research Evidenceexamine.com/supplements/bpc-157/ | BPC-157 |
| Comprehensive review of BPC-157 preclinical evidence, proposed mechanisms, dosing, and limitations of available human data. | |||
| 1 September 2023 | Research | New research: The GLP-1 Revolution: How Semaglutide and Tirzepatide Are Reshaping Obesity Medicineendocrine.org/news-and-advocacy/news-room/2023/glp1-revolution | Semaglutide, Tirzepatide |
| Overview of GLP-1/GIP receptor agonist landscape, efficacy comparison, and future directions including oral formulations and triple agonists. | |||
| 1 June 2023 | Research | New research: Russian Nootropic Peptides: Semax and Selank in Clinical Practicepubmed.ncbi.nlm.nih.gov/12647316/ | Semax, Selank, NA-Semax-Amidate |
| Clinical review of Russian peptide nootropics: regulatory approval, mechanism, and comparative analysis. | |||
| 1 May 2023 | Research | New research: Melanocortin Peptides in Sexual Medicine: PT-141 and Melanotan IIpubmed.ncbi.nlm.nih.gov/17085743/ | PT-141, Melanotan II |
| Review of MC-receptor agonists for sexual dysfunction: PT-141 FDA approval for HSDD, off-label erectile use, Melanotan II safety concerns. | |||
| 1 September 2022 | Research | New research: Mitochondrial Peptides and the Future of Aging Researchnature.com/articles/s43587-022-00281-z | MOTS-c, Humanin, SS-31 |
| Comprehensive review of mitochondria-derived peptides as a new class of longevity therapeutics. | |||
| 1 February 2014 | Research | New research: GHK-Cu: More Than a Skin Peptide - Systemic Applications in Agingpubmed.ncbi.nlm.nih.gov/24305429/ | Copper Peptide GHK-Cu |
| Expanding GHK-Cu beyond dermatology: gene expression modulation, anti-cancer effects, wound healing, systemic administration. | |||
| 1 January 2013 | Research | New research: The Thymosin Family: Biological and Clinical Significancepubmed.ncbi.nlm.nih.gov/23537089/ | Thymosin Alpha-1, Thymosin Beta-4 |
| Review of thymosin class peptides: alpha-1 immune modulation and clinical approvals, beta-4 tissue repair. | |||
| 1 November 2012 | Research | New research: Peptide Bioregulators: Khavinsons Life Work on Aging and Longevitypubmed.ncbi.nlm.nih.gov/23517072/ | Epitalon, Thymalin, Vilon |
| Review of 40+ years of Khavinsons peptide bioregulators: mechanism, clinical applications, and longevity data. | |||